These presentations are NOT meant to be taken as recommendations in any manner, but rather are offered to help provide a sense of the growing edge of cancer research as pertaining to pancreatic cancer treatment, diagnosis and care. And also to give attention to some of the more current interesting, unusual or even offbeat studies.
September 2014
The prognostic value of stroma in pancreatic cancer in patients receiving adjuvant therapy.
Bever KM, Sugar EA, Bigelow E, Sharma R, Laheru D, Wolfgang CL, Jaffee EM, Anders RA, De Jesus-Acosta A, Zheng L.
HPB (Oxford). 2014 Sep 23
miRNAs in Pancreatic Cancer: Therapeutic Potential, Delivery Challenges and Strategies.
Chitkara D, Mittal A, Mahato RI.
Adv Drug Deliv Rev. 2014 Sep 20
MicroRNA-216a inhibits pancreatic cancer by directly targeting Janus kinase 2.
Wang S, Chen X, Tang M.
Oncol Rep. 2014 Sep 15
Ablation therapies for pancreatic cancer: an updated review.
Salgado S, Sharaiha R, Gaidhane M, Kahaleh M.
Minerva Gastroenterol Dietol. 2014 Sep 12
August 2014
Zhang JS, Herreros-Villanueva M, Koenig A, Deng Z, de Narvajas AA, Gomez TS, Meng X, Bujanda L, Ellenrieder V, Li XK, Kaufmann SH, Billadeau DD.
Cell Death Dis. 2014 Aug 7
Van Loon K, Owzar K, Jiang C, Kindler HL, Mulcahy MF, Niedzwiecki D, O’Reilly EM, Fuchs C, Innocenti F, Venook AP; Alliance for Clinical Trials in Oncology.
J Natl Cancer Inst. 2014 Aug 6
Interleukin-6: a villain in the drama of pancreatic cancer development and progression.
Holmer R, Goumas FA, Waetzig GH, Rose-John S, Kalthoff H.
Hepatobiliary Pancreat Dis Int. 2014 Aug 1
July 2014
Li J, Lang J, Wang P, Kang S, Lin MH, Chen X, Chen F, Guo M, Chen L, Ma CM.
Med Dosim. 2014 Jul 30.
18F-FDG PET/CT can be used to detect non-functioning pancreatic neuroendocrine tumors.
Luo G, Liu Z, Guo M, Jin K, Xiao Z, Liu L, Xu J, Zhang B, Liu C, Huang D, Hu S, Ni Q, Long J, Yu X.
Int J Oncol. 2014 Jul 29.
Progress in the knowledge and treatment of advanced pancreatic cancer: From benchside to bedside.
Oettle H.
Cancer Treat Rev. 2014 Jul 18.
Neoadjuvant therapy in pancreatic cancer: an emerging strategy.
Bittoni A, Santoni M, Lanese A, Pellei C, Andrikou K, Stefano C.
Gastroenterol Res Pract. 2014 Jul 1.
June 2014
Kumar S, Torres MP, Kaur S, Rachagani S, Joshi S, Johansson SL, Momi N, Baine MJ, Gilling CE, Smith LM, Wyatt TA, Jain M, Joshi SS, Batra SK.
Oncogene 2014 Jun 9. doi: 10.1038/onc.2014.154.
Yu Y, Guo M, Han X.
Cell Biochem Biophys 2014 Jun 8
Aglietta M, Barone C, Sawyer MB, Moore MJ, Miller WH Jr, Bagalà C, Colombi F, Cagnazzo C, Gioeni L, Wang E, Huang B, Fly KD, Leone F.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO”>Ann Oncol. 2014 Jun 6. pii: mdu205.
May 2014
PHLDA3 is a novel tumor suppressor of pancreatic neuroendocrine tumors.
Ohki R, Saito K, Chen Y, Kawase T, Hiraoka N, Saigawa R, Minegishi M, Aita Y, Yanai G, Shimizu H, Yachida S, Sakata N, Doi R, Kosuge T, Shimada K, Tycko B, Tsukada T, Kanai Y, Sumi S, Namiki H, Taya Y, Shibata T, Nakagama H.
Proc Natl Acad Sci U S A. 2014 May 27. pii: 201319962.
Hogendorf P, Durczyński A, Kumor A, Strzelczyk J.
Archives of medical science : AMS”>Arch Med Sci. 2014 May 12;10(2):288-93. doi: 10.5114/aoms.2014.42581. Epub 2014 May 13.
Targeting insulin-like growth factor 1 receptor inhibits pancreatic cancer growth and metastasis.
Subramani R, Lopez-Valdez R, Arumugam A, Nandy S, Boopalan T, Lakshmanaswamy R.
PLoS One. 2014 May 8;9(5):e97016. doi: 10.1371/journal.pone.0097016. eCollection 2014.
April 2014
Han S, Jin G, Wang L, Li M, He C, Guo X, Zhu Q.
J Immunol Res. 2014;2014:268479. Epub 2014 Apr 10. Review.
Xu Q, Ma J, Lei J, Duan W, Sheng L, Chen X, Hu A, Wang Z, Wu Z, Wu E, Ma Q, Li X.
Biomed Res Int. 2014;2014:546353. doi: 10.1155/2014/546353. Epub 2014 Apr 10.
March 2014
Anorexia-cachexia syndrome in pancreatic cancer: Recent advances and new pharmacological approach.
Ronga I, Gallucci F, Riccardi F, Uomo G.
Adv Med Sci. 2014 Mar;59(1):1-6. doi: 10.1016/j.advms.2013.11.001. Epub 2014 Mar 15. Review.
STAT3 down regulates LC3 to inhibit autophagy and pancreatic cancer cell growth.
Gong J, Muñoz AR, Chan D, Ghosh R, Kumar AP.
Oncotarget. 2014 Mar 15.
February 2014
Rembielak AI, Jain P, Jackson AS, Green MM, Santorelli GR, Whitfield GA, Crellin A, Garcia-Alonso A, Radhakrishna G, Cullen J, Taylor MB, Swindell R, West CM, Valle J, Saleem A, Price PM.
Transl Oncol. 2014 Feb 1;7(1):55-64. eCollection 2014 Feb.
Long Y, Sun Q, Wu J, Wang Y, Jiao S.
Oncol Lett. 2014 May;7(5):1594-1598. Epub 2014 Feb 24.
December 2013
Emoto K, Masugi Y, Yamazaki K, Effendi K, Tsujikawa H, Tanabe M, Kitagawa Y, Sakamoto M.
Hum Pathol. 2014 Apr;45(4):817-25. doi: 10.1016/j.humpath.2013.11.017. Epub 2013 Dec 13.
Rebours V, Le Faouder J, Laouirem S, Mebarki M, Albuquerque M, Camadro JM, Léger T, Ruszniewski P, Lévy P, Paradis V, Bedossa P, Couvelard A.
Pancreatology. 2014 Mar-Apr;14(2):117-24. doi: 10.1016/j.pan.2013.12.001. Epub 2013 Dec 17.
November 2013
Shimoda M, Mori S, Kita J, Sawada T, Kubota K.
Hepatogastroenterology. 2013 Nov-Dec;60(128):2094-8.
CD40 expression in pancreatic cancer.
Unek T, Unek IT, Agalar AA, Sagol O, Ellidokuz H, Ertener O, Oztop I, Karademir S, Yilmaz U, Astarcioglu I.
Hepatogastroenterology. 2013 Nov-Dec;60(128):2085-93.
October 2013
Walker AJ, Alcorn SR, Narang AK, Nugent KM, Wild AT, Herman JM, Tran PT.
Curr Probl Cancer. 2013 Sep-Oct;37(5):301-12. doi: 10.1016/j.currproblcancer.2013.10.008. Epub 2013 Oct 5.
The role of endoscopy in the treatment, management, and personalization of pancreatic cancer.
Shin EJ, Khashab M.
Curr Probl Cancer. 2013 Sep-Oct;37(5):293-300. doi: 10.1016/j.currproblcancer.2013.10.007. Epub 2013 Oct 8.
August 2013
Histamine regulation of pancreatitis and pancreatic cancer: a review of recent findings.
Francis T, Graf A, Hodges K, Kennedy L, Hargrove L, Price M, Kearney K, Francis H.
Hepatobiliary Surg Nutr. 2013 Aug;2(4):216-226. Review.
Choi JH, Seo DW, Park do H, Lee SK, Kim MH.
Gut Liver. 2014 Jan;8(1):88-93. doi: 10.5009/gnl.2014.8.1.88. Epub 2013 Aug 14.
July 2013
Tajima H, Kitagawa H, Tsukada T, Okamoto K, Nakanuma SI, Sakai S, Makino I, Furukawa H, Hayashi H, Oyama K, Inokuchi M, Nakagawara H, Miyashita T, Itoh H, Fujita H, Takamura H, Ninomiya I, Fushida S, Fujimura T, Ohta T, Koda W, Minami T, Ryu Y, Sanada J, Gabata T, Matsui O, Sai Y.
Mol Clin Oncol. 2013 Sep;1(5):869-874. Epub 2013 Jul 23.
Barreto SG, Chaudhary A.
Natl Med J India. 2013 Jul-Aug;26(4):219-20. No abstract available.
June 2013
Kessel KA, Habermehl D, Jäger A, Floca RO, Zhang L, Bendl R, Debus J, Combs SE.
Radiat Oncol. 2013 Jun 7;8:138. doi: 10.1186/1748-717X-8-138.
Leon-Takahashi AM, Gomez-Pedraza A, Cruz-Rodriguez A, Ruiz-Molina JM, Padilla-Rosciano A, Herrera-Gomez A.
Indian J Surg. 2013 Jun;75(Suppl 1):247-9. doi: 10.1007/s12262-012-0655-9. Epub 2012 Jul 5.
May 2013
Tajima H, Kitagawa H, Tsukada T, Nakanuma S, Okamoto K, Sakai S, Makino I, Furukawa H, Nakamura K, Hayashi H, Oyama K, Inokuchi M, Nakagawara H, Miyashita T, Fujita H, Itoh H, Takamura H, Ninomiya I, Fushida S, Fujimura T, Ohta T.
Mol Clin Oncol. 2013 Jul;1(4):768-772. Epub 2013 May 27.
Tas F, Sen F, Keskin S, Kilic L, Yildiz I.
Mol Clin Oncol. 2013 Jul;1(4):788-792. Epub 2013 May 23.
April 2013
RAN GTPase and Osteopontin in Pancreatic Cancer.
Saxena S, Gandhi A, Lim PW, Relles D, Sarosiek K, Kang C, Chipitsyna G, Sendecki J, Yeo CJ, Arafat HA.
Pancreat Disord Ther. 2013 Apr 1;3(1):113.
Shi SB, Ma TH, Tang XY, Li CH.
Zhonghua Zhong Liu Za Zhi. 2013 Apr;35(4):301-4. doi: 10.3760/cma.j.issn.0253-3766.2013.04.013. Chinese.
March 2013
The retropancreatic fusion fascia acts as a barrier against infiltration by pancreatic carcinoma.
Kitagawa H, Tajima H, Nakagawara H, Hayashi H, Makino I, Takamura H, Ninomiya I, Fushida S, Kayahara M, Ohta T, Ikeda H.
Mol Clin Oncol. 2013 May;1(3):418-422. Epub 2013 Mar 20.
Expression levels of microRNA-375 in pancreatic cancer.
Song S, Zhou J, He S, Zhu D, Zhang Z, Zhao H, Wang Y, Li D.
Biomed Rep. 2013 May;1(3):393-398. Epub 2013 Mar 27.
February 2013
Moraru IC, Tai A, Erickson B, Li XA.
Pract Radiat Oncol. 2014 Jan-Feb;4(1):13-9. doi: 10.1016/j.prro.2013.01.005. Epub 2013 Feb 26.
Li L, Wu B, Yang L, Yin G, Wei W, Sui S, Liu J.
Oncol Lett. 2013 May;5(5):1731-1735. Epub 2013 Feb 28.
January 2013
Lu QY, Zhang L, Lugea A, Moro A, Edderkaoui M, Eibl G, Pandol SJ, Go VL.
J Chromatogr Sep Tech. 2013 Jan 1;4(1). pii: 100062.
Kras as a key oncogene and therapeutic target in pancreatic cancer.
Collins MA, Pasca di Magliano M.
Front Physiol. 2014 Jan 21;4:407. eCollection 2013. Review.
December 2012
Zhang Y, Satoh K, Li M.
Drugs Context. 2012 Dec 11;2012:212244. doi: 10.7573/dic.212244. eCollection 2012 Dec 11
November 2012
Local drug delivery to a human pancreatic tumor via a newly designed multiple injectable needle.
Ohara K, Kohno M, Horibe T, Kawakami K.
Mol Clin Oncol. 2013 Mar;1(2):231-234. Epub 2012 Nov 29.
Arshad A, Chung WY, Steward W, Metcalfe MS, Dennison AR.
HPB (Oxford). 2013 Jun;15(6):428-32. doi: 10.1111/hpb.12002. Epub 2012 Nov 22.
October 2012
Karagianni VT, Papalois AE, Triantafillidis JK.
Indian J Surg Oncol. 2012 Dec;3(4):348-59. doi: 10.1007/s13193-012-0189-4. Epub 2012 Oct 30. Review.
Wentz SC, Zhao ZG, Shyr Y, Shi CJ, Merchant NB, Washington K, Xia F, Chakravarthy AB.
World J Gastrointest Oncol. 2012 Oct 15;4(10):207-15. doi: 10.4251/wjgo.v4.i10.207.
September 2012
Duan L, Hu XQ, Feng DY, Lei SY, Hu GH.
Asian J Surg. 2013 Jan;36(1):7-12. doi: 10.1016/j.asjsur.2012.08.001. Epub 2012 Sep 16.
Role of PET/CT in the clinical management of locally advanced pancreatic cancer.
Picchio M, Giovannini E, Passoni P, Busnardo E, Landoni C, Giovacchini G, Bettinardi V, Crivellaro C, Gianolli L, Di Muzio N, Messa C.
Tumori. 2012 Sep-Oct;98(5):643-51. doi: 10.1700/1190.13207.
August 2012
Endoscopic ultrasound in the diagnosis of pancreatic cancer.
Munroe CA, Fehmi SM, Savides TJ.
Expert Opin Med Diagn. 2013 Jan;7(1):25-35. doi: 10.1517/17530059.2012.711313. Epub 2012 Aug 6. Review.
Arcaroli J, Quackenbush K, Dasari A, Powell R, McManus M, Tan AC, Foster NR, Picus J, Wright J, Nallapareddy S, Erlichman C, Hidalgo M, Messersmith WA.
Cancer Med. 2012 Oct;1(2):207-17. doi: 10.1002/cam4.27. Epub 2012 Aug 16.
July 2012
Leon-Takahashi AM, Gomez-Pedraza A, Cruz-Rodriguez A, Ruiz-Molina JM, Padilla-Rosciano A, Herrera-Gomez A.
Indian J Surg. 2013 Jun;75(Suppl 1):247-9. doi: 10.1007/s12262-012-0655-9. Epub 2012 Jul 5.
Skeletal Muscle Metastases from Pancreatic Carcinoma-A Case Report and Review of Literature.
Chisthi MM, Manju PA.
Indian J Surg. 2013 Jun;75(3):181-184. Epub 2012 Jul 4. Review.
June 2012
Eum YO, Kim YT, Lee SH, Park SW, Hwang JH, Yoon WJ, Ryu JK, Yoon YB, Han JK, Yoon CJ, Cho JH, Choi Y.
Dig Endosc. 2013 Jan;25(1):67-75. doi: 10.1111/j.1443-1661.2012.01335.x. Epub 2012 Jun 11.
Hagio M, Matsuda Y, Suzuki T, Ishiwata T.
Mol Clin Oncol. 2013 Jan;1(1):83-87. Epub 2012 Jun 8.
May 2012
Schuller HM, Al-Wadei HA.
Curr Cancer Ther Rev. 2012 May 1;8(2):116-127.
microRNA signature for human pancreatic cancer invasion and metastasis.
Cheng H, Shi S, Cai X, Long J, Xu J, Liu C, Yu X.
Exp Ther Med. 2012 Aug;4(2):181-187. Epub 2012 May 21.
April 2012
Suzuki R, Irisawa A, Bhutani MS, Hikichi T, Takagi T, Sato A, Sato M, Ikeda T, Watanabe K, Nakamura J, Tasaki K, Obara K, Ohira H.
Dig Endosc. 2012 Nov;24(6):452-6. doi: 10.1111/j.1443-1661.2012.01311.x. Epub 2012 Apr 10.
Kaffes AJ, Chen RY, Tam W, Norton I, Cho S, Devereaux B, Vaughan R.
Dig Endosc. 2012 Nov;24(6):448-51. doi: 10.1111/j.1443-1661.2012.01302.x. Epub 2012 Apr 8.
Vizio B, Novarino A, Giacobino A, Cristiano C, Prati A, Ciuffreda L, Montrucchio G, Bellone G.
Exp Ther Med. 2012 Jul;4(1):70-78. Epub 2012 Apr 18.
March 2012
Pancreaticoduodenectomy in a tertiary referral center in Saudi Arabia: a retrospective case series.
Aziz AM, Abbas A, Gad H, Al-Saif OH, Leung K, Meshikhes AW.
J Egypt Natl Canc Inst. 2012 Mar;24(1):47-54. doi: 10.1016/j.jnci.2011.12.007. Epub 2012 Feb 24.
Einama T, Ueda S, Tsuda H, Ogasawara K, Hatsuse K, Matsubara O, Todo S, Yamamoto J.
Exp Ther Med. 2012 Jun;3(6):931-936. Epub 2012 Mar 15.
Rong L, Kida M, Yamauchi H, Okuwaki K, Miyazawa S, Iwai T, Kikuchi H, Watanabe M, Imaizumi H, Koizumi W.
Dig Endosc. 2012 Sep;24(5):358-63. doi: 10.1111/j.1443-1661.2012.01243.x. Epub 2012 Mar 13.
February 2012
Surgery for pancreatic carcinoma: state of the art.
Shrikhande SV, Barreto SG.
Indian J Surg. 2012 Feb;74(1):79-86. doi: 10.1007/s12262-011-0373-8. Epub 2011 Nov 24.
Yamamoto T, Matsuda Y, Kawahara K, Naito Z, Ishiwata T.
Oncol Lett. 2012 Feb;3(2):307-310. Epub 2011 Oct 31.
Nakata B, Amano R, Matsuoka J, Sugimori S, Ohsawa M, Wakasa K, Egashira Y, Kimura K, Yamada N, Hirakawa K.
Pancreatology. 2012 May-Jun;12(3):215-8. doi: 10.1016/j.pan.2012.02.011. Epub 2012 Feb 24.
JANUARY 2012
Adjuvant PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) or Gemcitabine Followed by Chemoradiation in Pancreatic Cancer: A Randomized Phase II Trial.
Reni M, Balzano G, Aprile G, Cereda S, Passoni P, Zerbi A, Tronconi MC, Milandri C, Saletti P, Rognone A, Fugazza C, Magli A, Muzio ND, Carlo VD, Villa E.
Ann Surg Oncol. 2012 Jan 12 [Epub]. S. Raffaele Scientific Institute, Milan, Italy.
[Link to Abstract]
Effect of Neoadjuvant Chemoradiation and Surgical Technique on Recurrence of Localized Pancreatic Cancer.
Katz MH, Wang H, Balachandran A, Bhosale P, Crane CH, Wang X, Pisters PW, Lee JE, Vauthey JN, Abdalla EK, Wolff R, Abbruzzese J, Varadhachary G, Chopin-Laly X, Charnsangavej C, Fleming JB.
J Gastrointest Surg. 2012 Jan;16(1):68-78. The University of Texas MD Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
The GOFURTGO Study: AGITG Phase II Study of Fixed Dose Rate Gemcitabine-oxaliplatin Integrated with Concomitant 5FU and 3-D Conformal Radiotherapy for the Treatment of Localised Pancreatic Cancer.
Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro
J, Porter IW, Hruby G, Horvath L, Bydder S, Underhill C, Harvey J, Gebski VJ; Australasian Gastro-Intestinal Trials Group.
Br J Cancer. 2012 Jan 3;106(1):61-9. Prince of Wales Hospital, Randwick, New South Wales, Australia.
[Link to Abstract]
The Potential for Induction Peptide Receptor Chemoradionuclide Therapy to Render Inoperable Pancreatic and Duodenal Neuroendocrine Tumours Resectable.
Barber TW, Hofman MS, Thomson BN, Hicks RJ.
Eur J Surg Oncol. 2012 Jan;38(1):64-71. Peter MacCallum Cancer Centre, Melbourne, Australia.
[Link to Abstract]
DECEMBER 2011
Downstaging in Pancreatic Cancer: A Matched Analysis of Patients Resected Following Systemic Treatment of Initially Locally Unresectable Disease.
Bickenbach KA, Gonen M, Tang LH, O’Reilly E, Goodman K, Brennan MF, D’Angelica MI, Dematteo RP, Fong Y, Jarnagin WR, Allen PJ.
Ann Surg Oncol. 2011 Dec 1 [Epub]. Memorial Sloan-Kettering Cancer Center, New York.
[Link to Abstract]
Everolimus Plus Octreotide Long-acting Repeatable for the Treatment of Advanced Neuroendocrine Tumours Associated with Carcinoid Syndrome (RADIANT-2): A Randomised, Placebo-controlled, Phase 3 Study.
Pavel ME, Hainsworth JD, Baudin E, Peeters M, Hörsch D, Winkler RE, Klimovsky J, Lebwohl D, Jehl V, Wolin EM, Oberg K, Van Cutsem E, Yao JC; RADIANT-2 Study Group.
Lancet. 2011 Dec 10;378(9808):2005-12. Charité-Universitätsmedizin Berlin/Campus Virchow Klinikum, Berlin, Germany..
[Link to Abstract]
Phase II Study of Gemcitabine in Combination with Regional Arterial Infusion of Nafamostat Mesilate for Advanced Pancreatic Cancer.
Uwagawa T, Misawa T, Tsutsui N, Ito R, Gocho T, Hirohara S, Sadaoka S, Yanaga K.
Am J Clin Oncol. 2011 Dec 12 [Epub]. The Jikei University School of Medicine, Tokyo, Japan.
[Link to Abstract]
Radiation Therapy with Full-Dose Gemcitabine and Oxaliplatin for Unresectable Pancreatic Cancer.
Hunter KU, Feng FY, Griffith KA, Francis IR, Lawrence TS, Desai S, Murphy JD, Zalupski MM, Ben-Josef E.
Int J Radiat Oncol Biol Phys. 2011 Dec 28 [Epub]. Department of Radiation Oncology, University of Michigan.
[Link to Abstract]
NOVEMBER 2011
Gemcitabine Alone Versus Gemcitabine Plus Radiotherapy in Patients With Locally Advanced Pancreatic Cancer: An Eastern Cooperative Oncology Group Trial.
Loehrer PJ Sr, Feng Y, Cardenes H, Wagner L, Brell JM, Cella D, Flynn P,
Ramanathan RK, Crane CH, Alberts SR, Benson AB 3rd.
J Clin Oncol. 2011 Nov 1;29(31):4105-12. Indiana University Melvin and Bren Simon Cancer Center, Indianapolis, Indiana.
[Link to Abstract]
Intra-arterial Chemoinfusion Prior to Chemoradiotherapy With Full-dose Systemic Gemcitabine for Management of Locally Advanced Pancreatic Cancer.
Tanaka T, Nishiofuku H, Tamamoto T, Sho M, Anai H, Sueyoshi S, Sakaguchi
H, Hasegawa M, Nakajima Y, Kichikawa K.
Anticancer Res. 2011 Nov;31(11):3909-12. Nara Medical University, Kashihara, Japan.
[Link to Abstract]
Phase I/II Study of Gemcitabine as a Fixed Dose Rate Infusion and S-1 Combination Therapy (FGS) in Gemcitabine-refractory Pancreatic Cancer Patients.
Morizane C, Okusaka T, Ueno H, Kondo S, Ikeda M, Furuse J, Shinichi O, Nakachi K, Mitsunaga S, Kojima Y, Suzuki E, Ueno M, Yamaguchi T.
Cancer Chemother Pharmacol. 2011 Nov 26 [Epub]. National Cancer Center Hospital, Tokyo, Japan.
[Link to Abstract]
Phase II Study of First-line FOLFIRI for Progressive Metastatic Well-differentiated Pancreatic Endocrine Carcinoma.
Brixi-Benmansour H, Jouve JL, Mitry E, Bonnetain F, Landi B, Hentic O, Bedenne L, Cadiot G.
Dig Liver Dis. 2011 Nov;43(11):912-6. CHU de Reims, Hôpital Robert-Debré, Reims, France.
[Link to Abstract]
OCTOBER 2011
Adjuvant Radiotherapy in the Treatment of Invasive Intraductal Papillary Mucinous Neoplasm of the Pancreas: An Analysis of the Surveillance, Epidemiology, and End Results Registry.
Worni M, Akushevich I, Gloor B, Scarborough J, Chino JP, Jacobs DO, Hahn SM, Clary BM, Pietrobon R, Shah A.
Ann Surg Oncol. 2011 Oct 15 [Epub]. Duke University Medical Center, Durham, North Carolina.
[Link to Abstract]
Gemcitabine Plus Nab-Paclitaxel is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial.
Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL, Zhang H, Soon-Shiong P, Shi T, Rajeshkumar NV, Maitra A, Hidalgo M.
J Clin Oncol. 2011 Dec 1;29(34):4548-54. Epub 2011 Oct 3. TGen/Virginia G. Piper Cancer Center, Phoenix, Arizona.
[Link to Abstract]
Long-Term Outcome of High-Intensity Focused Ultrasound in Advanced Pancreatic Cancer.
Sung HY, Jung SE, Cho SH, Zhou K, Han JY, Han ST, Kim JI, Kim JK, Choi JY, Yoon SK, Yang JM, Han CW, Lee YS.
Pancreas. 2011 Oct;40(7):1080-6. The Catholic University of Korea; St Mary’s Hospital, Seoul, Korea.
[Link to Abstract]
Long-Term Outcomes of Neoadjuvant Chemotherapy Before Chemoradiation for Locally Advanced Pancreatic Cancer.
Arvold ND, Ryan DP, Niemierko A, Blaszkowsky LS, Kwak EL, Wo JY, Allen JN, Clark JW, Wadlow RC, Zhu AX, Fernandez-Del Castillo C, Hong TS.
Cancer. 2011 Oct 21 [Epub]. Harvard Radiation Oncology Program, Boston, Massachusetts.
[Link to Abstract]
SEPTEMBER 2011
A 67-Year-Old Woman With BRCA 1 Mutation Associated With Pancreatic Adenocarcinoma.
Lowery M, Shah MA, Smyth E, Epstein A, Segal A, Rosengarten O, Isacson R, Drukker L, Keinan A, Rachkiman M, Reissman P, Gabizon A, Kelsen D, O’Reilly EM.
J Gastrointest Cancer. 2011 Sep;42(3):160-4. Memorial Sloan-Kettering Cancer Center, New York City.
[Link to Abstract]
Cationic Liposomal Paclitaxel Plus Gemcitabine or Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Randomized Controlled Phase II Trial.
Löhr JM, Haas SL, Bechstein WO, Bodoky G, Cwiertka K, Fischbach W, Fölsch UR, Jäger D, Osinsky D, Prausova J, Schmidt WE, Lutz MP; CT4001 Study Group.
Ann Oncol. 2011 Sep 6 [Epub]. University Hospital Mannheim, Germany.
[Link to Abstract]
Neoadjuvant Therapy in Pancreatic Adenocarcinoma: A Meta-Analysis of Phase II Trials.
Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ.
Surgery. 2011 Sep;150(3):466-73. UCLA School of Public Health, Los Angeles, California.
[Link to Abstract]
Stereotactic Body Radiation Therapy for Nonresectable Tumors of The Pancreas.
Goyal K, Einstein D, Ibarra RA, Yao M, Kunos C, Ellis R, Brindle J, Singh D, Hardacre J, Zhang Y, Fabians J, Funkhouser G, Machtay M, Sanabria JR.
J Surg Res. 2011 Sep 5 [Epub]. Case Western Reserve University, Cleveland, Ohio.
[Link to Abstract]
AUGUST 2011
Complete Remission in BRCA2 Mutation Carrier With Metastatic Pancreatic Adenocarcinoma Treated With Cisplatin Based Therapy.
Sonnenblick A, Kadouri L, Appelbaum L, Peretz T, Sagi M, Goldberg Y, Hubert A.
Cancer Biol Ther. 2011 Aug 1;12(3):165-8. Sharett Institute of Oncology, Hadassah – Hebrew University Medical Center, Jerusalem, Israel.
[Link to Abstract]
Neoadjuvant GTX Chemotherapy and IMRT-Based Chemoradiation for Borderline Resectable Pancreatic Cancer.
Patel M, Hoffe S, Malafa M, Hodul P, Klapman J, Centeno B, Kim J, Helm J, Valone T, Springett G.
J Surg Oncol. 2011 Aug 1;104(2):155-61. H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
[Link to Abstract]
Phase II Trial of Cetuximab, Gemcitabine, and Oxaliplatin Followed by Chemoradiation With Cetuximab for Locally Advanced (T4) Pancreatic Adenocarcinoma: Correlation of Smad4(Dpc4) Immunostaining With Pattern of Disease Progression.
Crane CH, Varadhachary GR, Yordy JS, Staerkel GA, Javle MM, Safran H, Haque W, Hobbs BD, Krishnan S, Fleming JB, Das P, Lee JE, Abbruzzese JL, Wolff RA.
J Clin Oncol. 2011 Aug 1;29(22):3037-43. The University of Texas MD Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis.
Dakik HK, Moskovic DJ, Carlson PJ, Tamm EP, Qiao W, Wolff RA, Abbruzzese JL, Fogelman DR.
Cancer Chemother Pharmacol. 2011 Aug 18 [Epub]. Duke University Medical Center, Durham, North Carolina.
[Link to Abstract]
JULY 2011
Clinical and Immunologic Evaluation of Dendritic Cell-Based Immunotherapy in Combination With Gemcitabine and/or S-1 in Patients With Advanced Pancreatic Carcinoma.
Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S, Koido S, Homma S, Okamoto M.
Pancreas. 2011 Jul 22 [Epub]. Tella Inc.; Musashino University; Seren Clinic; Tohoku University school of medicine; Kyushu University; Shinshu University Hospital; and Jikei University School of Medicine, Japan.
[Link to Abstract]
Gemcitabine/Cisplatin Versus 5-Fluorouracil/Mitomycin C Chemoradiotherapy in Locally Advanced Pancreatic Cancer: A Retrospective Analysis of 93 Patients.
Brunner TB, Sauer R, Fietkau R.
Radiat Oncol. 2011 Jul 27;6:88. Friedrich-Alexander University of Erlangen-Nuremberg, Germany.
[Link to Abstract]
A Multicenter Analysis of GTX Chemotherapy in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma.
De Jesus-Acosta A, Oliver GR, Blackford A, Kinsman K, Flores EI, Wilfong LS, Zheng L, Donehower RC, Cosgrove D, Laheru D, Le DT, Chung K, Diaz LA Jr.
Cancer Chemother Pharmacol. 2011 Jul 29 [Epub]. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
[Link to Abstract]
Survival Benefit With the Combination of Docetaxel, Gemcitabine and Erlotinib in Advanced and/or Metastatic Pancreatic Cancer Patients.
Samelis GF, Ekmektzoglou K, Tsiakou A, Giannakaki S, Konstadoulakis M.
Hepatogastroenterology. 2011 Jul 15;58(110-111). Athens, Greece.
[Link to Abstract]
JUNE 2011
hTERT mRNA Dendritic Cell Vaccination: Complete Response in a Pancreatic Cancer Patient Associated With Response Against Several hTERT Epitopes.
Suso EM, Dueland S, Rasmussen AM, Vetrhus T, Aamdal S, Kvalheim G, Gaudernack G.
Cancer Immunol Immunother. 2011 Jun;60(6):809-18. Oslo University Hospital and University of Oslo, Norway.
[Link to Abstract]
Induction Gemcitabine and Stereotactic Body Radiotherapy for Locally Advanced Nonmetastatic Pancreas Cancer.
Mahadevan A, Miksad R, Goldstein M, Sullivan R, Bullock A, Buchbinder E, Pleskow D, Sawhney M, Kent T, Vollmer C, Callery M.
Int J Radiat Oncol Biol Phys. 2011 Jun 8 [Epub]. Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
[Link to Abstract]
Phase II Trial of Full-Dose Gemcitabine and Bevacizumab in Combination With Attenuated Three-Dimensional Conformal Radiotherapy in Patients With Localized Pancreatic Cancer.
Small W Jr, Mulcahy MF, Rademaker A, Bentrem DJ, Benson AB, Weitner BB, Talamonti MS.
Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):476-82. Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.
[Link to Abstract]
Survival and Quality of Life of Patients With Resected Pancreatic Adenocarcinoma Treated With Adjuvant Interferon-Based Chemoradiation: A Phase II Trial.
Katz MH, Wolff R, Crane CH, Varadhachary G, Javle M, Lin E, Evans DB, Lee JE, Fleming JB, Pisters PW.
Ann Surg Oncol. 2011 Jun 24 [Epub]. The University of Texas / M. D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
MAY 2011
FOLFIRINOX Versus Gemcitabine for Metastatic Pancreatic Cancer.
Conroy T, Groupe Tumeurs Digestives of Unicancer; PRODIGE Intergroup, Collaborators (34).
N Engl J Med. 2011 May 12;364(19):1817-25. Nancy University and Department of Medical Oncology, Centre Alexis Vautrin, Nancy, France.
[Link to Abstract]
Long-Term Results of Full-Dose Gemcitabine With Radiation Therapy Compared to 5-Fluorouracil With Radiation Therapy for Locally Advanced Pancreas Cancer.
Huang J, Robertson JM, Margolis J, Balaraman S, Gustafson G, Khilanani P, Nadeau L, Jury R, McIntosh B.
Radiother Oncol. 2011 May;99(2):114-9. Department of Radiation Oncology, William Beaumont Hospital, Royal Oak, Michigan.
[Link to Abstract]
Neoadjuvant Therapy is Associated With Improved Survival in Resectable Pancreatic Adenocarcinoma.
Artinyan A, Anaya DA, McKenzie S, Ellenhorn JD, Kim J.
Cancer. 2011 May 15;117(10):2044-9. Michael E. DeBakey Department of Surgery and Houston Health Services & Research Center of Excellence, Michael E. DeBakey Veterans Affairs Medical Center, Baylor College of Medicine, Houston, Texas.
[Link to Abstract]
A Randomized Phase II Trial of Two Different 4-Drug Combinations in Advanced Pancreatic Adenocarcinoma: Cisplatin, Capecitabine, Gemcitabine Plus Either Epirubicin or Docetaxel (PEXG or PDXG Regimen).
Reni M, Cereda S, Rognone A, Belli C, Ghidini M, Longoni S, Fugazza C, Rezzonico S, Passoni P, Slim N, Balzano G, Nicoletti R, Cappio S, Doglioni C, Villa E.
Cancer Chemother Pharmacol. 2011 May 28 [Epub]. Department of Oncology, San Raffaele Scientific Institute, Milan, Italy.
[Link to Abstract]
APRIL 2011
Evidence for the Efficacy of Iniparib, a PARP-1 Inhibitor, in BRCA2-associated Pancreatic Cancer.
Fogelman DR, Wolff RA, Kopetz S, Javle M, Bradley C, Mok I, Cabanillas F, Abbruzzese JL.
Anticancer Res. 2011 Apr;31(4):1417-20. M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Feasibility and Yield of Screening in Relatives from Familial Pancreatic Cancer Families.
Ludwig E, Olson SH, Bayuga S, Simon J, Schattner MA, Gerdes H, Allen PJ, Jarnagin WR, Kurtz RC.
Am J Gastroenterol. 2011 May;106(5):946-54. [Epub 2011 Apr 5]. Memorial Sloan-Kettering Cancer Center, New York City.
[Link to Abstract]
Neogemtax: Gemcitabine and Docetaxel as Neoadjuvant Treatment for Locally Advanced Nonmetastasized Pancreatic Cancer.
Sahora K, Kuehrer I, Schindl M, Koelblinger C, Goetzinger P, Gnant M.
World J Surg. 2011 Apr 27[Epub]. Medical University of Vienna, Austria.
[Link to Abstract]
Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer.
Bao PQ, Ramanathan RK, Krasinkas A, Bahary N, Lembersky BC, Bartlett DL, Hughes SJ, Lee KK, Moser AJ, Zeh HJ 3rd.
Ann Surg Oncol. 2011 Apr;18(4):1122-9. Stony Brook University Hospital, Stony Brook, New York.
[Link to Abstract]
MARCH 2011
First-Line Treatment of Pancreatic Cancer Patients with the Combination of 5-Fluorouracil/Folinic Acid Plus Gemcitabine: A Multicenter Phase II Trial by the CONKO-Study Group.
Pelzer U, Arnold D, Reitzig P, Herrenberger J, Korsten FW, Kindler M, Stieler J, Dörken B, Riess H, Oettle H.
Cancer Chemother Pharmacol. 2011 Mar 15 [Epub]. Charité Centrum für Tumormedizin, Universitätsmedizin Berlin, Germany.
[Link to Abstract]
Hepatic Arterial Chemoembolization Using Drug-Eluting Beads in Gastrointestinal Neuroendocrine Tumor Metastatic to the Liver.
Gaur SK, Friese JL, Sadow CA, Ayyagari R, Binkert CA, Schenker MP, Kulke M, Baum R.
Cardiovasc Intervent Radiol. 34(3):566-72; 2011 Mar 24 [Epub]. Brigham & Women’s Hospital, Boston, Massachusetts.
[Link to Abstract]
Induction Chemotherapy with Gemcitabine, Oxaliplatin, and 5-Fluorouracil/Leucovorin Followed by Concomitant Chemoradiotherapy in Patients with Locally Advanced Pancreatic Cancer: A Taiwan Cooperative Oncology Group Phase II Study.
Ch’ang HJ, Lin YL, Wang HP, Chiu YF, Chang MC, Hsu CH, Tien YW, Chen JS, Hsieh RK, Lin PW, Shan YS, Cheng AL, Chang JY, Whang-Peng J, Hwang TL, Chen LT.
Int J Radiat Oncol Biol Phys. 2011 Mar 21 [Epub]. National Institute of Cancer Research, National Health Research Institutes, National Cheng Kung University Hospital, Taiwan.
[Link to Abstract]
Phase II Study of Single Agent Capecitabine in the Treatment of Metastatic Non-Pancreatic Neuroendocrine Tumours.
Medley L, Morel AN, Farrugia D, Reed N, Hayward N, Davies JM, Kirichek O, Thakker RV, Talbot DC.
Br J Cancer. 2011 Mar 29;104(7):1067-70. Churchill Hospital, Headington, UK.
[Link to Abstract]
FEBRUARY 2011
Efficacy of Infusional 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Ifam) in the Treatment of Patients With Gemcitabine-Pretreated Pancreatic Cancer and Analysis of Prognostic Factors in a Salvage Setting.
Lim KH, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ.
Cancer Chemother Pharmacol. 2011 Feb 17 [Epub]. Seoul National University Hospital, Seoul National University College of Medicine, Korea.
[Link to Abstract]
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D, Öberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group.
N Engl J Med. 2011 Feb 10;364(6):514-23. University of Texas / M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Second-Line Chemotherapy With Capecitabine (Xeloda) and Docetaxel (Taxotere) in Previously Treated, Unresectable Adenocarcinoma of Pancreas: The Final Results of a Phase II Trial.
Katopodis O, Polyzos A, Kentepozidis N, Giassas S, Rovithi M, Bozionelou V, Kalbakis K, Vamvakas L, Mavroudis D, Georgoulias V.
[Link to Abstract]
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, Valle J, Metrakos P, Smith D, Vinik A, Chen JS, Hörsch D, Hammel P, Wiedenmann B, Van Cutsem E, Patyna S, Lu DR, Blanckmeister C, Chao R, Ruszniewski P.
N Engl J Med. 2011 Feb 10;364(6):501-13. Service Inter-Hospitalier de Cancérologie et Service de Gastroenteropancréatologie, Hôpital Beaujon, Clichy, France.
[Link to Abstract]
JANUARY 2011
First-Line Chemotherapy with Capecitabine and Temozolomide in Patients with Metastatic Pancreatic Endocrine Carcinomas.
Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L.
Cancer. 2011 Jan 15;117(2):268-75. H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
[Link to Abstract]
Is the Need for an Arterial Resection a Contraindication to Pancreatic Resection for Locally Advanced Pancreatic Adenocarcinoma? A Case-Matched Controlled Study.
Bachellier P, Rosso E, Lucescu I, Oussoultzoglou E, Tracey J, Pessaux P, Ferreira N, Jaeck D.
J Surg Oncol. 2011 Jan 1;103(1):75-84. Hôpitaux Universitaires de Strasbourg, CHU Hautepierre, Strasbourg Cedex, France.
[Link to Abstract]
Phase 1 Clinical Trials in 83 Patients with Pancreatic Cancer: The M. D. Anderson Cancer Center Experience.Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R.
Cancer. 2011 Jan 1;117(1):77-85. The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Prospective Phase I Study of Capecitabine and Oxaliplatin Concurrent with Radiation Therapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma, and Retrospective Comparison to Concurrent 5-Fluorouracil/Radiation and Gemcitabine/Radiation.
Hazard L, Jones K, Shaban A, Anker C, Scaife C, Weis J, Mulvihill S.
J Gastrointest Cancer. 2011 Jan 18 [Epub]. University of Arizona, Tucson, Arizona.
[Link to Abstract]
DECEMBER 2010
ABO Blood Group and Cancer.
Iodice S, Maisonneuve P, Botteri E, Sandri MT, Lowenfels AB.
Eur J Cancer. 2010 Dec;46(18):3345-50. European Institute of Oncology, Milan, Italy.
[Link to Abstract]
Phase II Study of Nimotuzumab, A Humanized Monoclonal Anti-Epidermal Growth Factor Receptor (EGFR) Antibody, in Patients with Locally Advanced or Metastatic Pancreatic Cancer.
Strumberg D, Schultheis B, Scheulen ME, Hilger RA, Krauss J, Marschner N, Lordick F, Bach F, Reuter D, Edler L, Mross K.
Invest New Drugs. 2010 Dec 21. [Epub]. University of Bochum, Marienhospital Herne, Germany.
[Link to Abstract]
A Phase 2 Trial of Gemcitabine, 5-Florouracil, and Radiation Therapy in Locally Advanced Nonmetastatic Pancreatic Adenocarcinoma : Cancer and Leukemia Group B (CALGB) 80003.
Mamon HJ, Niedzwiecki D, Hollis D, Tan BR, Mayer RJ, Tepper JE, Goldberg RM, Blackstock AW, Fuchs CS; for the Cancer and Leukemia Group B.
Cancer. 2010 Dec 23. [Epub]. Dana Farber Cancer Institute, Boston, Massachusetts.
[Link to Abstract]
A Tolerability and Pharmacokinetic Study of Adjuvant Erlotinib and Capecitabine with Concurrent Radiation in Resected Pancreatic Cancer.
Ma WW, Herman JM, Jimeno A, Laheru D, Messersmith WA, Wolfgang CL, Cameron JL, Pawlik TM, Donehower RC, Rudek MA, Hidalgo M.
Transl Oncol. 2010 Dec 1;3(6):373-9. Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, Maryland.
[Link to Abstract]
NOVEMBER 2010
Curcumin and Gemcitabine in Patients with Advanced Pancreatic Cancer.
Epelbaum R, Schaffer M, Vizel B, Badmaev V, Bar-Sela G.
Nutr Cancer. 2010 Nov;62(8):1137-41. Rambam Health Care Campus, Haifa, Israel.
[Link to Abstract]
Hepatic Artery Chemoembolization for the Treatment of Liver Metastases from Neuroendocrine Tumors: A Long-Term Follow-Up in 123 Patients.
Dong XD, Carr BI.
Med Oncol. 2010 Nov 24 [Epub]. UPMC Liver Cancer Center, University of Pittsburgh, Starzl Transplant Institute, Pittsburgh, Pennsylvania.
[Link to Abstract]
Inhibition of Renin-Angiotensin System Affects Prognosis of Advanced Pancreatic Cancer Receiving Gemcitabine.
Nakai Y, Isayama H, Ijichi H, Sasaki T, Sasahira N, Hirano K, Kogure H, Kawakubo K, Yagioka H, Yashima Y, Mizuno S, Yamamoto K, Arizumi T, Togawa O, Matsubara S, Tsujino T, Tateishi K, Tada M, Omata M, Koike K.
Br J Cancer. 2010 Nov 23;103(11):1644-8. Graduate School of Medicine, The University of Tokyo.
[Link to Abstract]
Phase II Study of Gemcitabine and Erlotinib as Adjuvant Therapy for Patients with Resected Pancreatic Cancer.
Bao PQ, Ramanathan RK, Krasinkas A, Bahary N, Lembersky BC, Bartlett DL, Hughes SJ, Lee KK, Moser AJ, Zeh HJ 3rd.
Ann Surg Oncol. 2010 Nov 23 [Epub]. Stony Brook University Hospital, New York.
[Link to Abstract]
OCTOBER 2010
Evaluation of the Combination 5-Fluorouracil, Dacarbazine, and Epirubicin in Patients With Advanced Well-Differentiated Neuroendocrine Tumors.
Walter T, Bruneton D, Cassier PA, Hervieu V, Pilleul F, Scoazec JY, Chayvialle JA, Lombard-Bohas C.
Clin Colorectal Cancer. 2010 Oct;9(4):248-54. Hospices Civils de Lyon, Hôpital Edouard Herriot, Fédération des Spécialités Digestives, Lyon, France.
[Link to Abstract]
Image-Guided Stereotactic Radiosurgery for Locally Advanced Pancreatic Adenocarcinoma Results of First 85 Patients.
Didolkar MS, Coleman CW, Brenner MJ, Chu KU, Olexa N, Stanwyck E, Yu A, Neerchal N, Rabinowitz S.
J Gastrointest Surg. 2010 Oct;14(10):1547-59. Sinai Hospital of Baltimore, Maryland.
[Link to Abstract]
Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients With Pretreated Advanced Pancreatic Carcinoma: A Multicenter Experience of the Gruppo Oncologico Italia Meridionale.
Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G.
Am J Clin Oncol. 2010 Oct;33(5):461-4. University of Palermo, Italy.
[Link to Abstract]
Neoadjuvant Docetaxel-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreas: New Neoadjuvant Regimen Was Safe and Provided an Interesting Pathologic Response.
Turrini O, Ychou M, Moureau-Zabotto L, Rouanet P, Giovannini M, Moutardier V, Azria D, Delpero JR, Viret F.
Eur J Surg Oncol. 2010 Oct;36(10):987-92. Department of Surgical Oncology, Institut Paoli-Calmettes and Université de la Méditerranée, Marseille, France.
[Link to Abstract]
SEPTEMBER 2010
Adjuvant Chemotherapy With Fluorouracil Plus Folinic Acid Vs Gemcitabine Following Pancreatic Cancer Resection: A Randomized Controlled Trial.
Neoptolemos JP et al.
JAMA. 2010 Sep 8;304(10):1073-81. Liverpool Cancer Research UK Cancer Trials Unit, Cancer Research UK Centre, University of Liverpool, United Kingdom.
[Link to Abstract]
Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas.
Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, Helm J, Kvols L.
Cancer. [Epub] 2010 Sep 7. H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
[Link to Abstract]
NeoGemOx: Gemcitabine and Oxaliplatin as Neoadjuvant Treatment for Locally Advanced, Nonmetastasized Pancreatic Cancer.
Sahora K, Kuehrer I, Eisenhut A, Akan B, Koellblinger C, Goetzinger P, Teleky B, Jakesz R, Peck-Radosavljevic M, Ba’ssalamah A, Zielinski C, Gnant M.
Surgery. [Epub] 2010 Sep 2. Medical University of Vienna, Austria.
[Link to Abstract]
A Phase I/II Study of Gemcitabine-Based Chemotherapy Plus Curcumin for Patients With Gemcitabine-Resistant Pancreatic Cancer.
Kanai M, Yoshimura K, Asada M, Imaizumi A, Suzuki C, Matsumoto S, Nishimura T, Mori Y, Masui T, Kawaguchi Y, Yanagihara K, Yazumi S, Chiba T, Guha S, Aggarwal BB.
Cancer Chemother Pharmacol. [Epub] 2010 Sep 22. Kyoto University Hospital, Japan.
[Link to Abstract]
AUGUST 2010
Adjuvant Chemoradiation Therapy for Adenocarcinoma of the Distal Pancreas.
Redmond KJ, Wolfgang CL, Sugar EA, Ahn J, Nathan H, Laheru D, Edil BH, Choti MA, Pawlik TM, Hruban RH, Cameron JL, Herman JM.
Ann Surg Oncol. 2010 Aug 3 [Epub]. Johns Hopkins University School of Medicine, Baltimore, Maryland.
[Link to Abstract]
Estimating Optimal Dose of Twice-Weekly Gemcitabine for Concurrent Chemoradiotherapy in Unresectable Pancreatic Carcinoma: Mature Results of GEMRT-01 Phase I Trial.
Girard N, Mornex F, Bossard N, Ychou M, Chauffert B, Wautot V.
Int J Radiat Oncol Biol Phys. 2010 Aug 1;77(5):1426-32. Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, France.
[Link to Abstract]
Unresectable Locally Advanced Pancreatic Cancer: A Multimodal Treatment Using Neoadjuvant Chemoradiotherapy (Gemcitabine Plus Stereotactic Radiosurgery) and Subsequent Surgical Exploration.
Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G.
Ann Surg Oncol. 2010 Aug;17(8):2092-101. San Bortolo Hospital, Vicenza, Italy.
[Link to Abstract]
JULY 2010
Adjuvant Chemoradiation Therapy After Pancreaticoduodenectomy in Elderly Patients with Pancreatic Adenocarcinoma.
Horowitz DP, Hsu CC, Wang J, Makary MA, Winter JM, Robinson R, Schulick RD, Cameron JL, Pawlik TM, Herman JM.
Int J Radiat Oncol Biol Phys. 2010 Jul 17. [Epub]. Johns Hopkins University School of Medicine, Baltimore, Maryland.
[Link to Abstract]
Docetaxel Second-Line Therapy in Patients with Advanced Pancreatic Cancer: A Retrospective Study.
Saif MW, Syrigos K, Penney R, Kaley K.
Anticancer Res. 2010 Jul;30(7):2905-9. Yale University School of Medicine, New Haven, Connecticut.
[Link to Abstract]
Postoperative External Beam Radiotherapy for Resected Pancreatic Adenocarcinoma: Impact of Chemotherapy on Local Control and Survival.
Ogawa K, Shibuya H, Uchida N, Onishi H, Okuno Y, Myojin M, Kobayashi M, Ogawa Y, Kanesaka N, Shibuya K, Tokumaru S, Sasamoto R, Karasawa K, Nemoto K, Nishimura Y; JROSG WORKING SUBGROUP of GASTROINTESTINAL CANCER.
Anticancer Res. 2010 Jul;30(7):2959-67. University of the Ryukyus, Okinawa, Japan.
[Link to Abstract]
Weekly Paclitaxel After Failure of Gemcitabine in Pancreatic Cancer Patients with Malignant Ascites: A Retrospective Study.
Shukuya T, Yasui H, Boku N, Onozawa Y, Fukutomi A, Yamazaki K, Taku K, Kojima T, Machida N.
Jpn J Clin Oncol. 2010 Jul 22. [Epub]. Shizuoka Cancer Center, Nagaizumi, Shizuoka, Japan.
[Link to Abstract]
JUNE 2010
A Case of Complete Response to Combination Therapy of S-1 and Gemcitabine for Unresectable Pancreatic Cancer.
Miyagawa K, Yata Y, Yamaoka N, Sagara Y
Gan To Kagaku Ryoho. 2010 Jun;37(6):1145-7. Horikawa Hospital, Kyoto, Japan
[Link to Abstract]
Gemcitabine and Lenalidomide Combination in a Patient With Metastatic Pancreatic Cancer: A Case Study.
Liu WM, Nizar S, Dalgleish AG.
Med Oncol. 2010 Jun;27(2):430-3. St George’s University of London, UK.
[Link to Abstract]
Randomized Phase II Study of Gemcitabine Plus Radiotherapy Versus Gemcitabine, 5-Fluorouracil, and Cisplatin Followed by Radiotherapy and 5-Fluorouracil for Patients with Locally Advanced, Potentially Resectable Pancreatic Adenocarcinoma.
Landry J, Catalano PJ, Staley C, Harris W, Hoffman J, Talamonti M, Xu N, Cooper H, Benson AB 3rd.
J Surg Oncol. 2010 Jun 1;101(7):587-92. Emory University School of Medicine, Atlanta, Georgia.
[Link to Abstract]
Safety and Activity of Masitinib in Combination With Gemcitabine in Patients With Advanced Pancreatic Cancer.
Mitry E, Hammel P, Deplanque G, Mornex F, Levy P, Seitz JF, Moussy A, Kinet JP, Hermine O, Rougier P, Raymond E.
Cancer Chemother Pharmacol. 2010 Jul;66(2):395-403. Assistance Publique des Hôpitaux de Paris, Hôpital Ambroise Paré, Boulogne Billancourt, France.
[Link to Abstract]
MAY 2010
Beneficial Effects of 5-Fluorouracil and Heparin-Based Portal Infusion Chemotherapy
Combined with Mitomycin C and Cisplatin After Curative Resection of Pancreatic Cancer.
Aiura K, Takahashi S, Matsui J, Ueda M, Kitagawa Y.
Pancreatology. 2010;10(2-3):250-8. [Epub 2010 May 13]. Keio University School of Medicine, Tokyo, Japan.
[Link to Abstract]
Combining Gemcitabine, Oxaliplatin and Capecitabine (GEMOXEL) for Patients with Advanced Pancreatic Carcinoma (APC): A Phase I/II Trial.
Hess V, Pratsch S, Potthast S, Lee L, Winterhalder R, Widmer L, Cescato C, Lohri A, Jost L,
Stillhart P, Pestalozzi B, Herrmann R.
Ann Oncol. [Epub 2010 May 5]. University Hospital Basel, Basel, Switzerland.
[Link to Abstract]
Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients with Pretreated
Advanced Pancreatic Carcinoma: A Multicenter Experience of the Gruppo Oncologico
Italia Meridionale.
Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G.
Am J Clin Oncol. [Epub 2010 May 3]. University of Palermo, Sollievo della Sofferenza, double
daggerIstituto Oncologico, AND section signOspedale Buccheri La Ferla, Italy.
[Link to Abstract]
A Phase I Study of The Biomodulation of Capecitabine by Docetaxel and Gemcitabine
(Mgtx) in Previously Untreated Patients with Metastatic Adenocarcinoma of The Pancreas.
Hill ME, Li X, Kim S, Campbell A, Culler K, Bloomston M, Zalupski M, Hejna G, Bekaii-Saab T.
Cancer Center, Arthur James Cancer Hospital, Columbus, Ohio.
[Link to Abstract]
APRIL 2010
Beneficial Effects of 5-Fluorouracil and Heparin-Based Portal Infusion Chemotherapy Combined with Mitomycin C and Displatin After Curative Resection of Pancreatic Cancer.
IAiura K, Takahashi S, Matsui J, Ueda M, Kitagawa Y.
Pancreatology. 2010;10(2-3):250-8. [Epub 2010 May 13]. Keio University School of Medicine, Tokyo, Japan.
[Link to Abstract]
Combining Gemcitabine, Oxaliplatin andCapecitabine (GEMOXEL) for Paitents with Advanced Pancreatic Carcinoma (APC): A Phase I/II Trial.
Hess V, Pratsch S, Potthast S, Lee L, Winterhalder R, Widmer L, Cescato C, Lohri A, Jost L, Stillhart P, Pestalozzi B, Herrmann R.
Ann Oncol. [Epub 2010 May 5]. University Hospital Basel, Basel, Switzerland.
[Link to Abstract]
Irinotecan Plus Bolus/Infusional 5-Fluorouracil and Leucovorin in Patients with Pretreated Advanced Pancreatic Carcinoma: A Multicenter Experience of the Gruppo Oncologico Italia Meridionale.
Gebbia V, Maiello E, Giuliani F, Borsellino N, Arcara C, Colucci G.
Am J Clin Oncol. [Epub 2010 May 3]. University of Palermo, Sollievo della Sofferenza, double daggerIstituto Oncologico, AND section signOspedale Buccheri La Ferla, Italy.
[Link to Abstract]
A Phase I Study of The Biomodulation of Capecitabine by Docetaxel and Gemcitabine (Mgtx) in Previously Untreated Patients with Metastatic Adenocarcinoma of The Pancreas
Hill ME, Li X, Kim S, Campbell A, Culler K, Bloomston M, Zalupski M, Hejna G, Bekaii-Saab T.
Cancer Chemother Pharmacol. [Epub 2010 May 12]. Ohio State University Comprehensive Cancer Center, Arthur James Cancer Hospital, Columbus, Ohio.
[Link to Abstract]
MARCH 2010
A Case of Metastatic Pancreatic Cancer with a Remarkable Response to Combination Therapy of Gemcitabine and Adoptive Immune Cell Therapy.
Imai N, Takeda K, Utsunomiya S, Taga M, Kawata N, Ikeda T, Mizutani Y, Hirose K, Ishikawa T, Yoshida S.
Gan To Kagaku Ryoho. 2010 Mar;37(3):527-9. Nagoya Kyoritsu Hospital, Japan.
[Link to Abstract]
Chemotherapy with 5-Fluorouracil, Cisplatin and Streptozocin for Neuroendocrine Tumours.
Turner NC, Strauss SJ, Sarker D, Gillmore R, Kirkwood A, Hackshaw A, Papadopoulou A, Bell J, Kayani I, Toumpanakis C, Grillo F, Mayer A, Hochhauser D, Begent RH, Caplin ME, Meyer T.
Br J Cancer. 2010 Mar 30;102(7):1106-12. UCL Medical School, Royal Free Campus, London, UK.
[Link to Abstract]
Unresectable Locally Advanced Pancreatic Cancer: A Multimodal Treatment Using Neoadjuvant Chemoradiotherapy (Gemcitabine Plus Stereotactic Radiosurgery) and Subsequent Surgical Exploration.
Polistina F, Costantin G, Casamassima F, Francescon P, Guglielmi R, Panizzoni G, Febbraro A, Ambrosino G.
Ann Surg Oncol. 2010 Mar 12 [Epub]. San Bortolo Hospital, Vicenza, Italy.
[Link to Abstract]
Safety and Efficacy of Single-Day Gemox Regimen in Patients with Pancreatobiliary Cancer: A Single Institution Experience.
Li J, Merl M, Lee MX, Kaley K, Saif MW.
Expert Opin Drug Saf. 2010 Mar;9(2):207-13. Yale School of Medicine, New Haven, Connecticut.
[Link to Abstract]
FEBRUARY 2010
Feasibility and Safety of Radiofrequency Ablation for Locally Advanced Pancreatic Cancer.
Girelli R, Frigerio I, Salvia R, Barbi E, Tinazzi Martini P, Bassi C.
Br J Surg. 2010 Feb;97(2):220-5. University of Verona, Italy.
[Link to Abstract]
Phase II Clinical Trial of Paclitaxel Loaded Polymeric Micelle in Patients with Advanced Pancreatic Cancer.
Saif MW, Podoltsev NA, Rubin MS, Figueroa JA, Lee MY, Kwon J, Rowen E, Yu J, Kerr RO.
Cancer Invest. 2010 Feb;28(2):186-94. Yale University School of Medicine, New Haven, Connecticut.
[Link to Abstract]
Prognosis and Feasibility of En-Bloc Vascular Resection in Stage II Pancreatic Adenocarcinoma.
Chakravarty KD, Hsu JT, Liu KH, Yeh CN, Yeh TS, Hwang TL, Jan YY, Chen MF.
World J Gastroenterol. 2010 Feb 28;16(8):997-1002. Chang Gung Memorial Hospital, Taiwan, China.
[Link to Abstract]
Stereotactic Body Radiotherapy and Gemcitabine for Locally Advanced Pancreatic Cancer.
Mahadevan A, Jain S, Goldstein M, Miksad R, Pleskow D, Sawhney M, Brennan D, Callery M, Vollmer C.
Int J Radiat Oncol Biol Phys. [Epub] 2010 Feb 18. Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts.
[Link to Abstract]
JANUARY 2010
Daily Oral Everolimus Activity in Patients with Metastatic Pancreatic Neuroendocrine Tumors after Failure of Cytotoxic Chemotherapy: A Phase II Trial.
Yao JC, Lombard-Bohas C, Baudin E, Kvols LK, Rougier P, Ruszniewski P, Hoosen S, St Peter J, Haas T, Lebwohl D, Van Cutsem E, Kulke MH, Hobday TJ, O’Dorisio TM, Shah MH, Cadiot G, Luppi G, Posey JA, Wiedenmann B.
J Clin Oncol. 2010 Jan 1;28(1):69-76. The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
Ardavanis A, Kountourakis P, Karagiannis A, Doufexis D, Tzovaras AA, Rigatos G.
Anticancer Res. 2009 Dec;29(12):5211-7. St. Savvas Anticancer Hospital, Athens, Greece.
[Link to Abstract]
Estimating Optimal Dose of Twice-Weekly Gemcitabine for Concurrent Chemoradiotherapy in Unresectable Pancreatic Carcinoma: Mature Results of GEMRT-01 Phase I Trial.
Girard N, Mornex F, Bossard N, Ychou M, Chauffert B, Wautot V.
Int J Radiat Oncol Biol Phys. 2010 Jan 5 [Epub]. Centre Hospitalier Lyon-Sud, Hospices Civils de Lyon, France.
[Link to Abstract]
Outcomes of Adjuvant Chemoradiation After Pancreaticoduodenectomy with Mesenterico-Portal Vein Resection for Adenocarcinoma of The Pancreas.
Hristov B, Reddy S, Lin SH, Cameron JL, Pawlik TM, Hruban RH, Swartz MJ, Edil BH, Kemp C, Wolfgang CL, Herman JM.
Int J Radiat Oncol Biol Phys. 2010 Jan 1;76(1):176-80. Johns Hopkins University, Baltimore, Maryland.
[Link to Abstract]
Phase II Study of Radiation Therapy Combined with Weekly Low-Dose Gemcitabine for Locally Advanced, Unresectable Pancreatic Cancer.
Shibuya K, Oya N, Fujii T, Doi R, Nakamura A, Matsuo Y, Mitsumori M, Hiraoka M.
Am J Clin Oncol. 2010 Jan 8 [Epub]. Kyoto University Graduate School of Medicine; Kumamoto University Graduate School of Medical Sciences; Ehime University Graduate School of Medicine, Japan.
[Link to Abstract]
2009
DECEMBER
Biweekly Gemcitabine (GEM) in Combination with Erlotinib (ERL): An Active and Convenient Regimen for Advanced Pancreatic Cancer.
Ardavanis A, Kountourakis P, Karagiannis A, Doufexis D, Tzovaras AA, Rigatos G.
Anticancer Res. 2009 Dec;29(12):5211-7. St. Savvas Anticancer Hospital, Athens, Greece.
[Link to Abstract]
Neoadjuvant Peptide Receptor Radionuclide Therapy for an Inoperable Neuroendocrine Pancreatic Tumor.
Kaemmerer D, Prasad V, Daffner W, Hörsch D, Klöppel G, Hommann M, Baum RP.
World J Gastroenterol. 2009 Dec 14;15(46):5867-70. Zentralklinik Bad Berka, Germany.
[Link to Abstract]
Phase I Study of Fixed Dose Gemcitabine Plus Epirubicin in Patients with Advanced Solid Malignancies.
Mahadevan D, Dreisbach L, Kristedja T, Williams D, Obregon Y, Kurtin S, Von Hoff DD.
Am J Clin Oncol. 2009 Dec;32(6):607-11. University of Arizona Health Sciences Center, Tucson, Arizona, USA.
[Link to Abstract]
Survival Data Justifies Resection for Pancreatic Metastases.
Strobel O, Hackert T, Hartwig W, Bergmann F, Hinz U, Wente MN, Fritz S, Schneider L, Büchler MW, Werner J.
Ann Surg Oncol. 2009 Dec;16(12):3340-9. University of Heidelberg, Germany.
[Link to Abstract]
NOVEMBER
Elevated Cancer Mortality in the Relatives of Patients with Pancreatic Cancer.
Wang L, Brune KA, Visvanathan K, Laheru D, Herman J, Wolfgang C, Schulick R, Cameron JL, Goggins M, Hruban RH, Klein AP.
Cancer Epidemiol Biomarkers Prev. 2009 Nov;18(11):2829-34. Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
[Link to Abstract]
Induction Chemotherapy Followed by Chemoradiation in Locally Advanced Pancreatic Cancer: An Effective and Well-Tolerated Treatment.
Hudson E, Hurt C, Mort D, Brewster AE, Iqbal N, Joseph G, Crosby TD, Mukherjee S.
Clin Oncol (R Coll Radiol). 2009 Nov 4. [Epub]. Clinical Oncology, Velindre Hospital, Cardiff, UK.
[Link to Abstract]
Phase III Randomized Comparison of Gemcitabine Versus Gemcitabine plus Capecitabine in Patients with Advanced Pancreatic Cancer.
Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, Harper PG, Dunn J, Tudur-Smith C, West J, Falk S, Crellin A, Adab F, Thompson J, Leonard P, Ostrowski J, Eatock M, Scheithauer W, Herrmann R, Neoptolemos JP.
J Clin Oncol. 2009 Nov 20;27(33):5513-8. Royal Marsden National Health Service (NHS) Foundation Trust, London and Surrey, UK.
[Link to Abstract]
A Randomised Phase II Study of Modified FOLFIRI.3 Vs Modified FOLFOX as Second-Line Therapy in Patients with Gemcitabine-Refractory Advanced Pancreatic Cancer.
Yoo C, Hwang JY, Kim JE, Kim TW, Lee JS, Park DH, Lee SS, Seo DW, Lee SK, Kim MH, Han DJ, Kim SC, Lee JL.
Br J Cancer. 2009 Nov 17;101(10):1658-63. Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
[Link to Abstract]
OCTOBER
Advanced Phase I/II Studies of Targeted Gene Delivery in Vivo: Intravenous Rexin-G for Gemcitabine-Resistant Metastatic Pancreatic Cancer.
Chawla SP, Chua VS, Fernandez L, Quon D, Blackwelder WC, Gordon EM, Hall FL.
Mol Ther. 2009 Oct 13.[Epub]. Sarcoma Oncology Center, Santa Monica, California.
[Link to Abstract]
Seamguard – No Increased Incidence of Pancreatic Fistulas After the Introduction of a Bioabsorbable Staple Line Reinforcement in Distal Pancreatic Resections.
Guzman EA, Nelson RA, Kim J, Pigazzi A, Trisal V, Paz B, Di Ellenhorn J.
Am Surg. 2009 Oct;75(10):954-7. City of Hope National Medical Center, Duarte, California.
[Link to Abstract]
A Systematic Review of Resectability and Survival after Concurrent Chemoradiation in Primarily Unresectable Pancreatic Cancer.
Morganti AG, Massaccesi M, La Torre G, Caravatta L, Piscopo A, Tambaro R, Sofo L, Sallustio G, Ingrosso M, Macchia G, Deodato F, Picardi V, Ippolito E, Cellini N, Valentini V.
Ann Surg Oncol. 2009 Oct 24.[Epub]. Catholic University, Campobasso, Italy.
[Link to Abstract]
Use of Seamguard to Prevent Pancreatic Leak Following Distal Pancreatectomy.
Yamamoto M, Hayashi MS, Nguyen NT, Nguyen TD, McCloud S, Imagawa DK.
Arch Surg. 2009 Oct;144(10):894-9. University of California-Irvine Medical Center, Orange, California.
[Link to Abstract]
SEPTEMBER
Downstaging of Pancreatic Carcinoma after Neoadjuvant Chemoradiation.
Tinkl D, Grabenbauer GG, Golcher H, Meyer T, Papadopoulos T, Hohenberger W, Sauer R, Brunner TB.
Strahlenther Onkol. 2009 Sep;185(9):557-66. Friedrich Alexander University of Erlangen-Nuremberg, Germany.
[Link to Abstract]
Pancreatic Incidentalomas: High Rate of Potentially Malignant Tumors.
Lahat G, Ben Haim M, Nachmany I, Sever R, Blachar A, Nakache R, Klausner JM.
J Am Coll Surg. 2009 Sep;209(3):313-9. Tel Aviv Sourasky Medical Center, Israel.
[Link to Abstract]
Phase II Study of Bevacizumab with Concurrent Capecitabine and Radiation Followed by Maintenance Gemcitabine and Bevacizumab for Locally Advanced Pancreatic Cancer: Radiation Therapy Oncology Group RTOG 0411.
Crane CH, Winter K, Regine WF, Safran H, Rich TA, Curran W, Wolff RA, Willett CG.
J Clin Oncol. 2009 Sep 1;27(25):4096-102. University of Texas / M. D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Radiofrequency Ablation of Solitary Pancreatic Insulinoma in a Patient with Episodes of Severe Hypoglycemia.
Limmer S, Huppert PE, Juette V, Lenhart A, Welte M, Wietholtz H.
Eur J Gastroenterol Hepatol. 2009 Sep;21(9):1097-101. Klinikum Darmstadt, Academic Teaching Hospital of University Frankfurt and Heidelberg, Germany.
[Link to Abstract]
AUGUST
Clinical Overview on Lipoplatin: A Successful Liposomal Formulation of Cisplatin.
Boulikas T.
Expert Opin Investig Drugs. 2009 Aug;18(8):1197-218. Regulon Inc., Mountain View, California.
[Link to Abstract]
Gemcitabine Combined with Uracil-Tegafur in Patients with Advanced Pancreatic Cancer.
Coskun U, Alkis N, Celenkoglu G, Buyukberber S, Ozkan M, Camci C, Uner A, Er O, Aslan UY, Sevinc A, Tokluoglu S, Ozturk B, Yildiz R, Benekli M; Anatolian Society of Medical Oncology.
J Natl Med Assoc. 2009 Aug;101(8):761-4. Gazi University Medical School, Ankara, Turkey.
[Link to Abstract]
Management of Advanced Neuroendocrine Tumors with Hepatic Metastasis.
Khasraw M, Gill A, Harrington T, Pavlakis N, Modlin I.
J Clin Gastroenterol. [2009 Aug 3 Epub]. Royal North Shore Hospital, Sydney, Australia; and Yale University School of Medicine, New Haven, Connecticut.
[Link to Abstract]
Multidetector CT Evaluation of the Course of Nonresectable Pancreatic Carcinomas with Neoadjuvant Therapy.
Klauss M, Alt CD, Welzel T, Werner J, Büchler MW, Richter GM, Kauffmann GW, Kauczor HU, Grenacher L.
Pancreatology. 2009 Aug 4;9(5):621-630[Epub]. University of Heidelberg, Germany.
[Link to Abstract]
JULY
Adjuvant Chemoradiotherapy After Pancreatic Resection for Invasive Carcinoma Associated with Intraductal Papillary Mucinous Neoplasm of the Pancreas.
Swartz MJ, Hsu CC, Pawlik TM, Winter J, Hruban RH, Guler M, Schulick RD, Cameron JL, Laheru DA, Wolfgang CL, Herman JM.
Int J Radiat Oncol Biol Phys.[Epub 2009 Jul 31]. Johns Hopkins Hospital, Baltimore, Maryland.
[Link to Abstract]
Feasibility and Efficacy of Combination Therapy with Preoperative Full-Dose Gemcitabine, Concurrent Three-Dimensional Conformal Radiation, Surgery, and Postoperative Liver Perfusion Chemotherapy for T3-Pancreatic Cancer.
Ohigashi H, Ishikawa O, Eguchi H, Takahashi H, Gotoh K, Yamada T, Yano M, Nakaizumi A, Uehara H, Tomita Y, Nishiyama K.
Ann Surg. 2009 Jul;250(1):88-95. Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan.
[Link to Abstract]
A Multicenter Phase II Study of Gemcitabine and S-1 Combination Chemotherapy in Patients with Unresectable Pancreatic Cancer.
Oh DY, Cha Y, Choi IS, Yoon SY, Choi IK, Kim JH, Oh SC, Kim CD, Kim JS, Bang YJ, Kim YH.Cancer Chemother Pharmacol.[Epub 2009 Jul 4]. Seoul National University College of Medicine, Korea.
[Link to Abstract]
Sirolimus Can Reverse Resistance to Gemcitabine, Capecitabine and Docetaxel Combination Therapy in Pancreatic Cancer.
Sherman WH.
JOP.2009 Jul 6;10(4):393-5. Columbia University, College Physicians and Surgeons, New York.
[Link to Abstract]
JUNE
Chemoradioimmunotherapy in Locally Advanced Pancreatic and Biliary Tree Adenocarcinoma: A Multicenter Phase II Study.
Recchia F, Sica G, Candeloro G, Bisegna R, Bratta M, Bonfili P, Necozione S, Tombolini V, Rea S.
Pancreas. 2009 Aug;38(6):e163-8. [Epub June 12]. Unità Operativa di Oncologia, Ospedale Civile di Avezzano, Italy.
[Link to Abstract]
Rationale for an Intraperitoneal Gemcitabine Chemotherapy Treatment for Patients with Resected Pancreatic Cancer.
Kamath A, Yoo D, Stuart OA, Bijelic L, Sugarbaker PH.
Recent Pat Anticancer Drug Discov. 2009 Jun;4 (2):174-9. Washington Cancer Institute, Washington, DC.
[Link to Abstract]
Staged Surgery with Neoadjuvant (90)Y-DOTATOC Therapy for Down-sizing Synchronous Bilobular Hepatic Metastases from a Neuroendocrine Pancreatic Tumor.
Stoeltzing O, Loss M, Huber E, Gross V, Eilles C, Mueller-Brand J, Schlitt HJ.Langenbecks Arch Surg.2009. [Epub Jun 9]. University of Regensburg Medical Center, Germany.
[Link to Abstract]
Successful Control of Intractable Hypoglycemia Using Rapamycin in an 86-Year Old Man with A Pancreatic Insulin-Secreting Islet Cell Tumor and Metastases.
Bourcier ME, Sherrod A, Diguardo M, Vinik AI.
J Clin Endocrinol Metab. 2009. [Epub Jun 30]. Eastern Virginia Medical School, Norfolk, Virginia.
[Link to Abstract]
MAY
Gemcitabine and Lenalidomide Combination in a Patient with Metastatic Pancreatic Cancer: A Case Study.
Liu WM, Nizar S, Dalgleish AG.
Med Oncol. 2009 [Epub May 12]. St. George’s University of London.
[Link to Abstract]
Gemcitabine and Oxaliplatin Combination Chemotherapy for Metastatic Well-Differentiated Neuroendocrine Carcinomas: A Single-Center Experience.
Cassier PA, Walter T, Eymard B, Ardisson P, Perol M, Paillet C, Chayvialle JA, Scoazec JY, Hervieu V, Bohas CL.
Cancer. 2009 [Epub May 26]. Edouard Herriot Hospital, Lyon, France.
[Link to Abstract]
Pilot Study of Irinotecan/Oxalipltin (IROX) Combination Chemotherapy for Patients with Gemcitabine- and 5-Fluorouracil- Refractory Pancreatic Cancer.
Oh SY, Kim HJ, Kim TH, Lee GW, Kim HG, Jeong CY, Kwon HC, Kang JH.
Invest New Drugs. 2009 [Epub May 15]. Dong-A University College of Medicine, Busan, Korea.
[Link to Abstract]
Long-Term Results of Concurrent Radiotherapy and UFT in Patients with Locally Advanced Pancreatic Cancer.
Bjerregaard JK, Mortensen MB, Jensen HA, Fristrup C, Svolgaard B, Schønnemann KR, Hansen TP, Nielsen M, Johansen J, Pfeiffer P.
Radiother Oncol. 2009 [Epub May 10]. Odense University Hospital, Denmark.
[Link to Abstract]
APRIL
A Combination Therapy of Gemcitabine with Immunotherapy for Patients with Inoperable Locally Advanced Pancreatic Cancer.
Hirooka Y, Itoh A, Kawashima H, Hara K, Nonogaki K, Kasugai T, Ohno E, Ishikawa T, Matsubara H, Ishigami M, Katano Y, Ohmiya N, Niwa Y, Yamamoto K, Kaneko T, Nieda M, Yokokawa K, Goto H.
Pancreas. 2009 Apr;38(3):e69-74. Nagoya University, Nagoya City, Japan.
[Link to Abstract]
Liver Resection Versus Other Treatments for Neuroendocrine Tumours in Patients with Resectable Liver Metastases.
Gurusamy KS, Ramamoorthy R, Sharma D, Davidson BR.
Mol Pharmacol. 2006 Mar;69(3):718-26. 2009 Apr 15;(2):CD007060. Royal Free Hospital and University College School of Medicine, London.
[Link to Abstract]
Outcome of Upfront Combination Chemotherapy Followed by Chemoradiation for Locally Advanced Pancreatic Adenocarcinoma.
Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Zerbi A, Nicoletti R, Mazza E, Arcidiacono PG, Di Carlo V, Villa E.
Cancer Chemother Pharmacol. 2009 Apr 21 [Epub]. S. Raffaele Scientific Institute, Milan, Italy.
[Link to Abstract]
Second-Line Treatment with a Combination of Continuous 5-Fluorouracil, Doxorubicin, and Mitomycin-C (Conti-Fam) in Gemcitabine-Pretreated Pancreatic and Biliary Tract Cancer.
Lee S, Oh SY, Kim BG, Kwon HC, Kim SH, Rho MH, Kim YH, Rho MS, Jeong JS, Kim HJ.
Am J Clin Oncol. 2009 Apr 10 [Epub]. Dong-A University College of Medicine, Busan, Korea.
[Link to Abstract]
MARCH
Management of the Primary Tumor in Patients with Metastatic Pancreatic Neuroendocrine Tumor: A Contemporary Single-Institution Review.
Bruzoni M, Parikh P, Celis R, Are C, Ly QP, Meza JL, Sasson AR.
Am J Surg. 2009 Mar;197(3):376-81. Eppley Cancer Center, University of Nebraska Medical Center, Omaha, Nebraska.
[Link to Abstract]
Radiotherapy for Pancreatic Neuroendocrine Tumors.
Contessa JN, Griffith KA, Wolff E, Ensminger W, Zalupski M, Lawrence TS, Ben-Josef E.
Int J Radiat Oncol Biol Phys. 2009 Mar 25 [Epub]. Department of Radiation Oncology, University of Michigan, Ann Arbor, Michigan.
[Link to Abstract]
Results of a Phase I Trial of 12 Patients with Locally Advanced Pancreatic Carcinoma Combining Gefitinib, Paclitaxel, and 3-Dimensional Conformal Radiation: Report of Toxicity and Evaluation of Circulating K-Ras as a Potential Biomarker of Response to Therapy.
Olsen CC, Schefter TE, Chen H, Kane M, Leong S, McCarter MD, Chen Y, Mack P, Eckhardt SG, Stiegmann G, Raben D.
Am J Clin Oncol. 2009 Mar 20 [Epub]. University of Colorado Denver Health Sciences Center, and University of California Davis Cancer Center.
[Link to Abstract]
Selective Internal Radiotherapy with Yttrium-90 Microspheres for Hepatic Metastatic Neuroendocrine Tumors: A Prospective Single Center Study.
Kalinowski M, Dressler M, König A, El-Sheik M, Rinke A, Höffken H, Gress TM, Arnold R, Klose KJ, Wagner HJ.
Digestion. 2009;79(3):137-42. 2009 Mar 23 [Epub]. Philipps University Hospital, Marburg, Germany.
[Link to Abstract]
FEBRUARY
An Explorative Randomised Phase II Study of Sequential Chemotherapy in Advanced Upper Gastrointestinal Cancer.
Berglund A, Byström P, Johansson B, Nygren P, Frödin JE, Pedersen D, Letocha H, Glimelius B.
Med Oncol. Epub 2009 Feb 11. Akademiska sjukhuset, University of Uppsala, Sweden.
[Link to Abstract]
Arterial and Venous Resection for Pancreatic Adenocarcinoma: Operative and Long-Term Outcomes.
Martin RC 2nd, Scoggins CR, Egnatashvili V, Staley CA, McMasters KM, Kooby DA.
Arch Surg. 2009 Feb;144(2):154-9. James Graham Brown Cancer Center, University of Louisville School of Medicine, Kentucky.
[Link to Abstract]
Capecitabine and Celecoxib as Second-Line Treatment of Advanced Pancreatic and Biliary Tract Cancers.
Pino MS, Milella M, Gelibter A, Sperduti I, De Marco S, Nuzzo C, Bria E, Carpanese L, Ruggeri EM, Carlini P, Cognetti F.
Oncology. 2009;76(4):254-61. Epub 2009 Feb 26. Regina Elena National Cancer Institute, Rome, Italy.
[Link to Abstract]
Surgical Palliation of Unresectable Pancreatic Head Cancer in Elderly Patients.
Hwang SI, Kim HO, Son BH, Yoo CH, Kim H, Shin JH.
World J Gastroenterol. 2009 Feb 28;15(8):978-82. Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Jongno-Ku, Seoul, South Korea.
[Link to Abstract]
JANUARY
Adjuvant Radiotherapy for Pancreatic Cancer is Associated with a Survival Benefit Primarily in Stage IIB Patients.
Moody JS, Sawrie SM, Kozak KR, Plastaras JP, Howard G, Bonner JA. J Gastroenterol. 2009;44(1):84-91.[Epub 2009 Jan 22]. University of Alabama at Birmingham School of Medicine.
[Link to Abstract]
Does Portal-Superior Mesenteric Vein Invasion Still Indicate Irresectability for Pancreatic Carcinoma?
Ramacciato G, Mercantini P, Petrucciani N, Giaccaglia V, Nigri G, Ravaioli M, Cescon M, Cucchetti A, Del Gaudio M.
Ann Surg Oncol. 2009 Apr;16(4):817-25.[Epub 2009 Jan 21]. Faculty of Medicine, University of Rome La Sapienza, Italy.
[Link to Abstract]
Surgical Resection Versus Palliative Chemoradiotherapy for the Management of Pancreatic Cancer with Local Venous Invasion: A Decision Analysis.
Abramson MA, Swanson EW, Whang EE.
J Gastrointest Surg. 2009 Jan;13(1):26-34. Brigham and Women’s Hospital, Harvard Medical School, Boston.
[Link to Abstract]
Surgical Results After Preoperative Chemoradiation Therapy for Patients with Pancreatic Cancer.
Satoi S, Yanagimoto H, Toyokawa H, Takahashi K, Matsui Y, Kitade H, Mergental H, Tanigawa N, Takai S, Kwon AH.
Pancreas. 2009 Apr;38(3):282-8. Kansai Medical University, Hirakata City, Osaka, Japan.
[Link to Abstract]
2008
DECEMBER
Chemoradioimmunotherapy with 5-Fluorouracil, Cisplatin and Interferon-Alpha in Pancreatic and Periampullary Cancer: Results of a Feasibility Study.
Nitsche M, Horstmann O, Christiansen H, Hermann RM, Hess CF, Becker H, Pradier O, Schmidberger H.
Cancer Radiother. 2008 Dec;12(8):817-21. University of Goettingen, Germany.
[Link to Abstract]
Concurrent Chemoradiotherapy with Gemcitabine Plus Regional Hyperthermia for Locally Advanced Pancreatic Carcinoma: Initial Experience.
Ohguri T, Imada H, Yahara K, Narisada H, Morioka T, Nakano K, Korogi Y.
Radiat Med. 2008 Dec;26(10):587-96. University of Occupational and
Environmental Health, Kitakyushu, Japan.
[Link to Abstract]
Histopathological Response to Preoperative Chemoradiation for Resectable Pancreatic Adenocarcinoma: The French Phase II FFCD 9704-SFRO Trial.
Le Scodan R, Mornex F, Partensky C, Mercier C, Valette PJ, Ychou M, Roy P, Scoazec JY.
Am J Clin Oncol. 2008 Dec;31(6):545-52. Centre Hospitalier Lyon-Sud, Pierre-Bénite, France.
[Link to Abstract]
Neoadjuvant Chemotherapy Generates a Significant Tumor Response in Resectable Pancreatic Cancer Without Increasing Morbidity: Results of a Prospective Phase II Trial.
Heinrich S, Schäfer M, Weber A, Hany TF, Bhure U, Pestalozzi BC, Clavien PA.
Ann Surg. 2008 Dec;248(6):1014-22. Swiss HPB-Center, Department of Surgery and Institute of Surgical Pathology, Zurich, Switzerland.
[Link to Abstract]
NOVEMBER
A Case of Successful Management of Liver Metastases of Pancreatic Carcinoma by Hepatectomy and Adjuvant Chemotherapy.
Fujisaki S, Takashina M, Sakurai K, Tomita R, Takayama T.
Gan To Kagaku Ryoho. 2008 Nov;35(12):2109-11. Fujisaki Hospital. Japan.
[Link to Abstract]
Intraoperative Hand Held Gamma Probe Detection of a Recurrent Nonfunctional Neuroendocrine Tumor.
Van Haren RM, Fitzgerald TL.
JOP. 2008 Nov 3;9(6):704-7. College of Human Medicine, Michigan State University, Lansing, Michigan.
[Link to Abstract]
Results of a Retrospective Analysis of Gemcitabine as a Second-Line Treatment After Chemoradiotherapy and Maintenance Chemotherapy Using 5-Fluorouracil in Patients with Locally Advanced Pancreatic Cancer.
Taira K, Boku N, Fukutomi A, Onozawa Y, Hironaka S, Yoshino T, Yasui H, Yamazaki K, Taku K, Hashimoto T, Nishimura T.
J Gastroenterol. 2008;43(11):875-80, Epub 2008 Nov 18. Shizuoka Cancer Center, Shizuoka, Japan.
[Link to Abstract]
Surgery Versus Radiochemotherapy for Resectable Locally Invasive Pancreatic Cancer: Final Results of a Randomized Multi-Institutional Trial.
Doi R, Imamura M, Hosotani R, Imaizumi T, Hatori T, Takasaki K, Funakoshi A, Wakasugi H, Asano T, Hishinuma S, Ogata Y, Sunamura M, Yamaguchi K, Tanaka M, Takao S, Aikou T, Hirata K, Maguchi H, Aiura K, Aoki T, Kakita A, Sasaki M, Ozaki M, Matsusue S, Higashide S, Noda H, Ikeda S, Maetani S, Yoshida S; The Japan Pancreatic Cancer Study Group.
Surg Today. 2008 Nov;38(11):1021-1028. Department of Surgery, Kyoto University, Japan.
[Link to Abstract]
OCTOBER
Association Between Hepatitis B Virus and Pancreatic Cancer.
Hassan MM, Li D, El-Deeb AS, Wolff RA, Bondy ML, Davila M, Abbruzzese JL.
J Clin Oncol. 2008 Oct 1;26(28):4557-62. The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Gemcitabine Combined with Gefitinib in Patients with Inoperable or Metastatic Pancreatic Cancer: A Phase II Study of The Hellenic Cooperative Oncology Group with Biomarker Evaluation.
Fountzilas G, Bobos M, Kalogera-Fountzila A, Xiros N, Murray S, Linardou H, Karayannopoulou G, Koutras AK, Bafaloukos D, Samantas E, Christodoulou C, Economopoulos T, Kalogeras KT, Kosmidis P.
Cancer Invest. 2008 Oct;26(8):784-93. Papageorgiou Hospital, Aristotle University of Thessaloniki School of Medicine, Greece.
[Link to Abstract]
Phase I/II Trial of Induction Chemotherapy Followed by Concurrent Chemoradiotherapy and Surgery for Locoregionally Advanced Pancreatic Cancer.
Marti JL, Hochster HS, Hiotis SP, Donahue B, Ryan T, Newman E.
Ann Surg Oncol. 2008 Dec;15(12):3521-31 [Epub 2008 Oct 2]. NYU Cancer Institute, New York University School of Medicine.
[Link to Abstract]
Phase 2 Trial of Oxaliplatin Plus Capecitabine (XELOX) as Second-Line Therapy for Patients with Advanced Pancreatic Cancer.
Xiong HQ, Varadhachary GR, Blais JC, Hess KR, Abbruzzese JL, Wolff RA.
Cancer. 2008 Oct 15;113(8):2046-52. Center for Cancer and Blood Disorders, Fort Worth, Texas.
[Link to Abstract]
SEPTEMBER
Do Not Deny Pancreatic Resection to Elderly Patients.
Ballarin R, Spaggiari M, Di Benedetto F, Montalti R, Masetti M, De Ruvo N, Romano A, Guerrini GP, De Blasiis MG, Gerunda GE.
J Gastrointest Surg. [Epub] 2008 Sep 11. University of Modena and Reggio Emilia, Italy.
[Link to Abstract]
Efficacy of RAD001 (Everolimus) and Octreotide LAR in Advanced Low-To Intermediate- Grade Neuroendocrine Tumors: Results of a Phase II Study.
Yao JC, Phan AT, Chang DZ, Wolff RA, Hess K, Gupta S, Jacobs C, Mares JE, Landgraf AN, Rashid A, Meric-Bernstam F.
J Clin Oncol. 2008 Sep 10;26(26):4311-8. University of Texas / MD Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Phase II Study of 5-Fluorouracil and Paclitaxel in Patients with Gemcitabine-Refractory Pancreatic Cancer.
Kim YJ, Bang S, Park JY, Park SW, Chung JB, Song SY.
Cancer Chemother Pharmacol. [Epub] 2008 Sep 3. Yonsei University College of Medicine, Seoul, South Korea.
[Link to Abstract]
Prospective Study on Warfarin and Regional Chemotherapy in Patients with Pancreatic Carcinoma.
Nakchbandi W, Müller H, Singer MV, Lohr JM, Nakchbandi IA.
J Gastrointestin Liver Dis. 2008 Sep;17(3):285-90. Carl von Hess Hospital, Hammelburg, Germany.
[Link to Abstract]
AUGUST
Adjuvant Interferon-Based Chemoradiation Followed by Gemcitabine for Resected Pancreatic Adenocarcinoma: A Single-Institution Phase II Study.
Linehan DC, Tan MC, Strasberg SM, Drebin JA, Hawkins WG, Picus J, Myerson RJ, Malyapa RS, Hull M, Trinkaus K, Tan BR Jr.
Ann Surg. 2008 Aug;248(2):145-51. Barnes-Jewish Hospital, Washington University Medical Center, Siteman Cancer Center, St. Louis, Missouri.
[Link to Abstract]
The Combination of Epidermal Growth Factor Receptor Inhibitors with Gemcitabine and Radiation in Pancreatic Cancer.
Morgan MA, Parsels LA, Kollar LE, Normolle DP, Maybaum J, Lawrence TS.
Clin Cancer Res. 2008 Aug 15;14(16):5142-9. University of Michigan, Ann Arbor, Michigan.
[Link to Abstract]
Outcomes Following Pancreatic Resection: Variability Among High-Volume Providers.
Riall TS, Nealon WH, Goodwin JS, Townsend CM Jr, Freeman JL.
Surgery. 2008 Aug;144(2):133-40. University of Texas Medical Branch, Galveston, Texas.
[Link to Abstract]
Synergistic Effects of Multiple Natural Products in Pancreatic Cancer Cells.
Wang Z, Desmoulin S, Banerjee S, Kong D, Li Y, Deraniyagala RL, Abbruzzese J, Sarkar FH.
Life Sci. 2008 Aug 15;83(7-8):293-300. Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
[Link to Abstract]
JULY
Adjuvant Radiotherapy and Chemotherapy for Pancreatic Carcinoma: The Mayo Clinic Experience (1975-2005).
Corsini MM, Miller RC, Haddock MG, Donohue JH, Farnell MB, Nagorney DM, Jatoi A, McWilliams RR, Kim GP, Bhatia S, Iott MJ, Gunderson LL.
J Clin Oncol. 2008 Jul 20;26(21):3511-6. Mayo Clinic, Rochester, Minnesota.
[Link to Abstract]
Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation After Pancreaticoduodenectomy for Ductal Adenocarcinoma of The Pancreas: Results of a Large, Prospectively Collected Database at the Johns Hopkins Hospital.
Herman JM, Swartz MJ, Hsu CC, Winter J, Pawlik TM, Sugar E, Robinson R, Laheru DA, Jaffee E, Hruban RH, Campbell KA, Wolfgang CL, Asrari F, Donehower R, Hidalgo M, Diaz LA Jr, Yeo C, Cameron JL, Schulick RD, Abrams R.
J Clin Oncol. 2008 Jul 20;26(21):3503-10. Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Hospital, Baltimore, Maryland.
[Link to Abstract]
Phase II Trial of Curcumin in Patients with Advanced Pancreatic Cancer.
Dhillon N, Aggarwal BB, Newman RA, Wolff RA, Kunnumakkara AB, Abbruzzese JL, Ng CS, Badmaev V, Kurzrock R.
Clin Cancer Res. 2008 Jul 15;14(14):4491-9. University of Texas / M. D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Preoperative Gemcitabine-Based Chemoradiation for Patients with Resectable Adenocarcinoma of the Pancreatic Head.
Evans DB, Varadhachary GR, Crane CH, Sun CC, Lee JE, Pisters PW, Vauthey JN, Wang H, Cleary KR, Staerkel GA, Charnsangavej C, Lano EA, Ho L, Lenzi R, Abbruzzese JL, Wolff RA.
J Clin Oncol. 2008 Jul 20;26(21):3496-502. University of Texas / M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
JUNE
Neoadjuvant Radiation Is Associated With Improved Survival in Patients With Resectable Pancreatic Cancer: An Analysis of Data From the Surveillance, Epidemiology, and End Results (SEER) Registry.
Stessin AM, Meyer JE, Sherr DL.
Int J Radiat Oncol Biol Phys. 2008 [Epub] Jun 4. Weill Medical College of Cornell University, New York.
[Link to Abstract]
PET/CT Fusion Scan Enhances CT Staging in Patients With Pancreatic Neoplasms.
Farma JM, Santillan AA, Melis M, Walters J, Belinc D, Chen DT, Eikman EA, Malafa M.
Ann Surg Oncol. 2008 Sep;15(9):2465-71. [Epub] 2008 Jun 13. H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
[Link to Abstract]
Phase I Trial of The Human Immunodeficiency Virus Protease Inhibitor Nelfinavir and Chemoradiation for Locally Advanced Pancreatic Cancer.
Brunner TB, Geiger M, Grabenbauer GG, Lang-Welzenbach M, Mantoni TS, Cavallaro A, Sauer R, Hohenberger W, McKenna WG.
J Clin Oncol. 2008 Jun 1;26(16):2699-706. Gray Institute of Radiation Oncology and Biology, University of Oxford, Churchill Hospital, Oxford, United Kingdom.
[Link to Abstract]
Radioembolization for Unresectable Neuroendocrine Hepatic Metastases Using Resin 90Y-Microspheres: Early Results in 148 Patients.
Kennedy AS, Dezarn WA, McNeillie P, Coldwell D, Nutting C, Carter D, Murthy R, Rose S, Warner RR, Liu D, Palmedo H, Overton C, Jones B, Salem R.
Am J Clin Oncol. 2008 Jun;31(3):271-9. Wake Radiology Oncology, Cary, North Carolina.
[Link to Abstract]
MAY
Borderline Resectable Pancreatic Cancer: The Importance of this Emerging Stage of Disease.
Katz MH, Pisters PW, Evans DB, Sun CC, Lee JE, Fleming JB, Vauthey JN, Abdalla EK, Crane CH, Wolff RA, Varadhachary GR, Hwang RF.
J Am Coll Surg. 2008 May;206(5):833-46; discussion 846-8. The University of Texas / MD Anderson Cancer Center, Houston.
[Link to Abstract]
Prospective Phase II Trial of Neoadjuvant Chemotherapy with Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head.
Heinrich S, Pestalozzi BC, Scha”fer M, Weber A, Bauerfeind P, Knuth A, Clavien PA.
J Clin Oncol. 2008 May 20;26(15):2526-31. Institute of Surgical Pathology, Swiss Hepato-Pancreato-Biliary Center, Zurich.
[Link to Abstract]
Response to a Third-Line Mitomycin C (MMC)-Based Chemotherapy in a Patient with Metastatic Pancreatic Adenocarcinoma Carrying Germline BRCA2 Mutation.
Chalasani P, Kurtin S, Dragovich T.
JOP. 2008 May 8;9(3):305-8. Arizona Cancer Center, University Medical Center, Tucson.
[Link to Abstract]
Surgery and Radiofrequency Ablation for Treatment of Liver Metastases from Midgut and Foregut Carcinoids and Endocrine Pancreatic Tumors.
Eriksson J, Sta*lberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, Granberg D, Eriksson B, Akerstro”m G, Hellman P.
World J Surg. 2008 May;32(5):930-8. University Hospital, Uppsala, Sweden.
[Link to Abstract]
APRIL
Lapatinib/Gemcitabine and Lapatinib/Gemcitabine/Oxaliplatin: A Phase I Study for Advanced Pancreaticobiliary Cancer.
Safran H, Miner T, Resnick M, Dipetrillo T, McNulty B, Evans D, Joseph P, Plette A, Millis R, Sears D, Gutman N, Kennedy T.
Am J Clin Oncol. 2008 Apr;31(2):140-4. The Miriam Hospital, Brown University Oncology Group, Providence, Rhode Island.
[Link to Abstract]
Oral Capecitabine in Gemcitabine-Pretreated Patients with Advanced Pancreatic Cancer.
Boeck S, Wilkowski R, Bruns CJ, Issels RD, Schulz C, Moosmann N, Laessig D, Haas M, Golf A, Heinemann V.
Oncology. 2007;73(3-4):221-7.[Epub 2008 Apr 17]. Klinikum Grosshadern, Ludwig Maximilians University of Munich, Germany.
[Link to Abstract]
PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) Regimen as Second-Line Therapy in Patients with Progressive or Recurrent Pancreatic Cancer after Gemcitabine-Containing Chemotherapy.
Reni M, Cereda S, Mazza E, Passoni P, Nicoletti R, Balzano G, Zerbi A, Arcidiacono PG, Staudacher C, Di Carlo V.
Am J Clin Oncol. 2008 Apr;31(2):145-50. S. Raffaele Scientific Institute, Milan, Italy.
[Link to Abstract]
A Phase II Study Evaluating Bevacizumab in Combination with Fixed-Dose Rate Gemcitabine and Low-Dose Cisplatin for Metastatic Pancreatic Cancer: Is an Anti-VEGF Strategy Still Applicable?
Ko AH, Dito E, Schillinger B, Venook AP, Xu Z, Bergsland EK, Wong D, Scott J, Hwang J, Tempero MA.
Invest New Drugs. 2008 Apr 1.[Epub]. University of California at San Francisco Comprehensive Cancer Center.
[Link to Abstract]
MARCH
Antitumor Activity of Rapamycin and Octreotide as Single Agents or in Combination in Neuroendocrine Tumors.
Moreno A, Akcakanat A, Munsell MF, Soni A, Yao JC, Meric-Bernstam F.
Endocr Relat Cancer. 2008 Mar;15(1):257-66. University of Texas / MD Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
A Pilot Study on Combination of Cryosurgery and (125)Iodine Seed Implantation for Treatment of Locally Advanced Pancreatic Cancer.
Xu KC, Niu LZ, Hu YZ, He WB, He YS, Li YF, Zuo JS.
World J Gastroenterol. 2008 Mar 14;14(10):1603-11. Fuda Cancer Hospital Guangzhou, Guangdong Province, China.
[Link to Abstract]
Targeted Delivery of Gemcitabine to Pancreatic Adenocarcinoma Using Cetuximab as a Targeting Agent.
Patra CR, Bhattacharya R, Wang E, Katarya A, Lau JS, Dutta S, Muders M, Wang S, Buhrow SA, Safgren SL, Yaszemski MJ, Reid JM, Ames MM, Mukherjee P, Mukhopadhyay D.
Cancer Res. 2008 Mar 15;68(6):1970-8. Mayo Clinic, Rochester, Minnesota.
[Link to Abstract]
Targeting Vascular Endothelial Growth Factor in Advanced Carcinoid Tumor: A Random Assignment Phase II Study of Depot Octreotide with Bevacizumab and Pegylated Interferon Alpha-2b.
Yao JC, Phan A, Hoff PM, Chen HX, Charnsangavej C, Yeung SC, Hess K, Ng C, Abbruzzese JL, Ajani JA.
J Clin Oncol. 2008 Mar 10;26(8):1316-23. University of Texas / M.D. Anderson Cancer, Houston, Texas.
[Link to Abstract]
FEBRUARY
Biweekly Triple Combination Chemotherapy with Gemcitabine, Oxaliplatin, Levofolinic Acid and 5-Fluorouracil (GOLF) is a Safe and Active Treatment.
Correale P, Montagnani F, Miano S, Sciandivasci A, Pascucci A, Petrioli R, Testi W, Tanzini G, Francini G.
J Chemother. 2008 Feb;20(1):119-25. Siena University School of Medicine, Italy.
[Link to Abstract]
Full-Dose Gemcitabine with Concurrent Radiation Therapy in Patients with Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial.
Small W Jr, Berlin J, Freedman GM, Lawrence T, Talamonti MS, Mulcahy MF, Chakravarthy AB, Konski AA, Zalupski MM, Philip PA, Kinsella TJ, Merchant NB, Hoffman JP, Benson AB, Nicol S, Xu RM, Gill JF, McGinn CJ.
J Clin Oncol. 2008 Feb 20;26(6):942-7. Northwestern University, Chicago, Illinois.
[Link to Abstract]
Pilot Study of Mutant Ras Peptide-Based Vaccine as an Adjuvant Treatment in Pancreatic and Colorectal Cancers.
Toubaji A, Achtar M, Provenzano M, Herrin VE, Behrens R, Hamilton M, Bernstein S, Venzon D, Gause B, Marincola F, Khleif SN.
Cancer Immunol Immunother. [Epub] 2008 Feb 23. Vaccine Branch, NCI, NIH, NNMC, Bethesda, Maryland.
[Link to Abstract]
Treatment with Combined Streptozotocin and Liposomal Doxorubicin in Metastatic Endocrine Pancreatic Tumors.
Fjällskog ML, Janson ET, Falkmer UG, Vatn MH, Oberg KE, Eriksson BK.
Neuroendocrinology. [Epub] 2008 Feb 18. Uppsala University, Sweden.
[Link to Abstract]
JANUARY
Irinotecan Plus Gemcitabine and 5-Fluorouracil in Advanced Pancreatic Cancer: A Phase II Study.
Endlicher E, Troppmann M, Kullmann A, Golder S, Herold T, Herfarth H, Grossmann J, Schlottmann K, Kullmann F.
Oncology. 2007;72(5-6):279-84. Epub 2008 Jan 11. University of Regensburg, Germany.
[Link to Abstract]
Neoadjuvant Chemoradiation in Patients with Potentially Resectable Pancreatic Cancer.
Takai S, Satoi S, Yanagimoto H, Toyokawa H, Takahashi K, Terakawa N, Araki H, Matsui Y, Sohgawa M, Kamiyama Y.
Pancreas. 2008 Jan;36(1):e26-32. Kansai Medical University, Hirakata-City, Osaka, Japan.
[Link to Abstract]
A Phase II Study of Capecitabine Plus Gemcitabine in Patients with Locally Advanced or Metastatic Pancreatic Cancer.
Song HS, Do YR, Chang HM, Ryu MH, Lee KH, Kim YH, Hong DS, Cho JY, Lee KE, Kim SY.
Cancer Chemother Pharmacol. Epub 2008 Jan 3. Dongsan Medical Center, Keimyung University School of Medicine, Dongsan-Dong, Chung-Gu, Daegu, South Korea.
[Link to Abstract]
Preoperative Chemoradiation in Adenocarcinoma of the Pancreas. A Single Centre Experience Advocating a New Treatment Strategy.
Golcher H, Brunner T, Grabenbauer G, Merkel S, Papadopoulos T, Hohenberger W, Meyer T.
Eur J Surg Oncol. Epub 2008 Jan 9. University of Erlangen, Germany.
[Link to Abstract]
2007
DECEMBER
3D Radiotherapy Can Be Safely Combined with Sandwich Systemic Gemcitabine Chemotherapy in the Management of Pancreatic Cancer: Factors Influencing Outcome.
Spry N, Harvey J, Macleod C, Borg M, Ngan SY, Millar JL, Graham P, Zissiadis Y, Kneebone A, Carroll S, Davies T, Reece WH, Iacopetta B, Goldstein D.
Int J Radiat Oncol Biol Phys., Epub: Dec 28, 2007. Sir Charles Gairdner Hospital, Nedlands, WA, Australia.
[Link to Abstract]
Clinical Efficacy of Intra-Arterial Pharmacokinetic Chemotherapy with 5-Fluorouracil, CDDP, Gemcitabine, and Angiotensin-II in Patients with Advanced Pancreatic Cancer.
Ishikawa T, Kamimura H, Tsuchiya A, Togashi T, Watanabe K, Seki K, Ohta H, Yoshida T, Takeda K, Kamimura T.
Hepatogastroenterology. 2007 Dec;54(80):2378-82. Saiseikai Niigata Second Hospital, Niigata, Japan.
[Link to Abstract]
Erlotinib/Gemcitabine for First-Line Treatment of Locally Advanced Or Metastatic Adenocarcinoma of the Pancreas.
Senderowicz AM, Johnson JR, Sridhara R, Zimmerman P, Justice R, Pazdur R.
Oncology (Williston Park). 2007 Dec;21(14):1696-706; discussion 1706-9, 1712, 1715. Office of Oncology Drug Products, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
[Link to Abstract]
Use of Octreotide for the Prevention of Pancreatic Fistula After Elective Pancreatic Surgery: A Systematic Review and Meta-Analysis.
Alghamdi AA, Jawas AM, Hart RS.
Can J Surg. 2007 Dec;50(6):459-66. University of Toronto, Ontario, Canada.
[Link to Abstract]
NOVEMBER
Capecitabine in Combination with Docetaxel and Mitomycin C in Patients with Pre-Treated Tumours: Results of an Extended Phase-I Trial.
Ernst T, Merx K, Gnad-Vogt U, Lukan N, Kripp M, Schultheis B, Hochhaus A, Hofheinz RD.
Br J Cancer. 2007 Dec 3;97(11):1475-9; Epub 2007 Nov 13. Medizinische Fakultät Mannheim der Universität Heidelberg, Germany.
[Link to Abstract]
Long-Term Survival on Capecitabine in Two Gemcitabine Refractory Pancreatic Cancer Patients. Is There a Pharmacogenetic Explanation?
Saif MW, Kang SP, Ledbetter L, Steg A, Diasio R, Johnson M.
JOP. 2007 Nov 9;8(6):799-805. Yale University School of Medicine. New Haven, Connecticut; University of Alabama at Birmingham, Alabama.
[Link to Abstract]
Poxvirus-Based Vaccine Therapy for Patients with Advanced Pancreatic Cancer.
Kaufman HL, Kim-Schulze S, Manson K, DeRaffele G, Mitcham J, Seo KS, Kim DW, Marshall J.
J Transl Med. 2007 Nov 26;5:60. Division of Surgical Oncology, Columbia University, New York.
[Link to Abstract]
Transarterial Chemoperfusion with Gemcitabine and Mitomycin C in Pancreatic Carcinoma: Results in Locally Recurrent Tumors and Advanced Tumor Stages.
Vogl TJ, Zangos S, Heller M, Hammerstingl RM, Böcher E, Jacob U, Bauer RW.
Rofo. 2007 Nov;179(11):1181-8. Institut für Diagnostische und Interventionelle Radiologie, J. W. Goethe-Universität Frankfurt, Germany.
[Link to Abstract]
OCTOBER
Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors.
Ali Y, Lin Y, Gharibo MM, Gounder MK, Stein MN, Lagattuta TF, Egorin MJ, Rubin EH, Poplin EA.
Clin Cancer Res. 2007 Oct 1;13(19):5876-82. The Cancer Institute of New Jersey, University of Medicine & Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick, New Jersey.
[Link to Abstract]
Phase I Dose-Finding Study of Weekly Docetaxel Followed by Flavopiridol for Patients with Advanced Solid Tumors.
Fornier MN, Rathkopf D, Shah M, Patil S, O’Reilly E, Tse AN, Hudis C, Lefkowitz R, Kelsen DP, Schwartz GK.
Clin Cancer Res. 2007 Oct 1;13(19):5841-6. Memorial Sloan-Kettering Cancer Center, New York.
[Link to Abstract]
Phase I Study of Oxaliplatin, Full-Dose Gemcitabine, and Concurrent Radiation Therapy in Pancreatic Cancer.
Desai SP, Ben-Josef E, Normolle DP, Francis IR, Greenson JK, Simeone DM, Chang AE, Colletti LM, Lawrence TS, Zalupski MM.
J Clin Oncol. 2007 Oct 10;25(29):4587-92. University of Michigan, Ann Arbor.
[Link to Abstract]
Capecitabine Plus Erlotinib in Gemcitabine-Refractory Advanced Pancreatic Cancer.
Kulke MH, Blaszkowsky LS, Ryan DP, Clark JW, Meyerhardt JA, Zhu AX, Enzinger PC, Kwak EL, Muzikansky A, Lawrence C, Fuchs CS.
J Clin Oncol. 2007 Oct 20;25(30):4787-92. Dana-Farber Cancer Institute, Boston, Massachusetts.
[Link to Abstract]
SEPTEMBER
Complete Remission of a Metastatic Pancreatic Carcinoma after Modified G-FLIP Therapy.
Alldinger I, Tsamaloukas AG, Germing U, Hosch SB, Knoefel WT.
Chemotherapy. 2007;53(5):356-9.Epub 2007 Sep 3. University Hospital Dusseldorf, Germany.
[Link to Abstract]
Curcumin Augments Gemcitabine Cytotoxic Effect on Pancreatic Adenocarcinoma Cell Lines.
Lev-Ari S, Vexler A, Starr A, Ashkenazy-Voghera M, Greif J, Aderka D, Ben-Yosef R.
Cancer Invest. 2007 Sep;25(6):411-8. Tel-Aviv University, Israel.
[Link to Abstract]
Efficacy of Preoperative Radiochemotherapy in Patients with Locally Advanced Pancreatic Carcinoma.
Lind PA, Isaksson B, Almström M, Johnsson A, Albiin N, Byström P, Permert J.
Acta Oncol. Epub 2007 Sep 20;:1-8. Karolinska-Stockholm Söder Hospital, Stockholm, Sweden.
[Link to Abstract]
Neoadjuvant Chemotherapy and Radiation for Patients with Locally Unresectable Pancreatic Adenocarcinoma: Feasibility, Efficacy, and Survival.
Allendorf JD, Lauerman M, Bill A, Digiorgi M, Goetz N, Vakiani E, Remotti H, Schrope B, Sherman W, Hall M, Fine RL, Chabot JA.
J Gastrointest Surg. Epub 2007 Sep 5. Columbia University College of Physicians and Surgeons, New York.
[Link to Abstract]
A Phase I Study of Erlotinib in Combination with Gemcitabine and Radiation in Locally Advanced, Non-Operable Pancreatic Adenocarcinoma.
Duffy A, Kortmansky J, Schwartz GK, Capanu M, Puleio S, Minsky B, Saltz L, Kelsen DP, O’reilly EM.
Ann Oncol. Epub 2007 Sep 17. Memorial Sloan-Kettering Cancer Center, New York.
[Link to Abstract]
AUGUST
Arterial Infusion of 5-Fluorouracil Combined with Concurrent Radiotherapy for Unresectable Pancreatic Cancer: Results From a Pilot Study.
Tanaka T, Sakaguchi H, Anai H, Yamamoto K, Morimoto K, Tamamoto T, Kichikawa K.
AJR Am J Roentgenol. 2007 Aug;189(2):421-8. Nara Medical University, Kashihara, Japan.
[Link to Abstract]
Effect of Low-Molecular-Weight Heparin on Survival in Patients with Advanced Pancreatic Adenocarcinoma.
von Delius S, Ayvaz M, Wagenpfeil S, Eckel F, Schmid RM, Lersch C.
Thromb Haemost. 2007 Aug;98(2):434-9. Technical University of Munich, Germany.
[Link to Abstract]
Meta-Analysis on Gemcitabine of Fixed-Dose Rate Infusion Plus Oxaliplatin as First-Line Therapy for Advanced Pancreatic Cancer.
Xie DR, Liang HL, Yang Q, Guo SS, Jiang ZM.
Ai Zheng. 2007 Aug;26(8):895-9. The Second Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
[Link to Abstract]
Phase I Trial of Fixed Dose Rate Infusion Gemcitabine with Gefitinib in Patients with Pancreatic Carcinoma.
Carneiro BA, Brand RE, Fine E, Knop RH, Khandekar JD, Uhlig W, Locker GY.
Cancer Invest. 2007 Aug;25(5):366-71. Kellogg Cancer Care Center, Evanston Northwestern Healthcare, Evanston, Illinois.
[Link to Abstract]
JULY
Correlation Between Development of Rash and Efficacy in Patients Treated with the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Erlotinib in Two Large Phase III Studies.
Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ.
Clin Cancer Res. 2007 Jul 1;13(13):3913-21. OSI Pharmaceuticals, Boulder, Colorado.
[Link to Abstract]
Laparoscopic Radiofrequency Ablation of Neuroendocrine Liver Metastases: A 10-Year Experience Evaluating Predictors of Survival.
Mazzaglia PJ, Berber E, Milas M, Siperstein AE.
Surgery. 2007 Jul;142(1):10-9. Rhode Island Hospital, Providence, Rhode Island.
[Link to Abstract]
Phase II Study of Capecitabine with Concomitant Radiotherapy for Patients with Locally Advanced Pancreatic Cancer: Up-Regulation of Thymidine Phosphorylase.
Saif MW, Black G, Roy S, Bell D, Russo S, Eloubeidi MA, Steg A, Johnson MR, Zelterman D, Diasio RB.
Cancer J. 2007 Jul-Aug;13(4):247-56. Yale University School of Medicine, New Haven, Connecticut.
[Link to Abstract]
Phase II Trial of Weekly Docetaxel/Irinotecan Combination in Advanced Pancreatic Cancer.
Burtness B, Thomas L, Sipples R, McGurk M, Salikooti S, Christoforou M, Mirto G, Salem R, Sosa J, Kloss R, Rahman Z, Chung G, Lacy J, Murren JR.
Cancer J. 2007 Jul-Aug;13(4):257-62. Fox Chase Cancer Center, Philadelphia, Pennsylvania.
[Link to Abstract]
JUNE
Concurrent Chemoradiotherapy for Advanced Pancreatic Cancer : 1,000 Mg/M(2) Gemcitabine Can Be Administered Using Limited-Field Radiotherapy.
Yamazaki H, Nishiyama K, Koizumi M, Tanaka E, Ioka T, Uehara H, Iishi H, Nakaizumi A, Ohigashi H, Ishikawa O.
Strahlenther Onkol. 2007 Jun;183(6):301-306. Medical Center for Cancer and Cardiovascular Disease, Japan.
[Link to Abstract]
Dosimetric Feasibility of Hypofractionated Proton Radiotherapy for Neoadjuvant Pancreatic Cancer Treatment.
Kozak KR, Kachnic LA, Adams J, Crowley EM, Alexander BM, Mamon HJ, Fernandez-Del Castillo C, Ryan DP, Delaney TF, Hong TS.
I Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1557-66. [Epub ahead of print June 4, 2007]. Massachusetts General Hospital, Boston.
[Link to Abstract]
A New Liposomal Formulation of Gemcitabine is Active in an Orthotopic Mouse Model of Pancreatic Cancer Accessible to Bioluminescence Imaging.
Bornmann C, Graeser R, Esser N, Ziroli V, Jantscheff P, Keck T, Unger C, Hopt UT, Adam U, Schaechtele C, Massing U, von Dobschuetz E.
Cancer Chemother Pharmacol. [Epub ahead of print June 7,2007]. Albert-Ludwigs-University Freiburg, Germany.
[Link to Abstract]
Successful Pancreatectomy with En-Bloc Resection of the Celiac Artery and Portal Vein for Pancreatic Endocrine Carcinoma.
Akatsu T, Aiura K, Shimazu M, Ueda M, Wakabayashi G, Tanabe M, Kawachi S, Shinoda M, Kameyama K, Kitajima M, Kitagawa Y.
IHepatogastroenterology. 2007 Jun;54(76):1269-71. Keio University School of Medicine, Tokyo, Japan.
[Link to Abstract]
MAY
3,3′,5-Triiodo-L-Thyronine Inhibits Ductal Pancreatic Adenocarcinoma Proliferation Improving the Cytotoxic Effect of Chemotherapy.
Michienzi S, Bucci B, Verga Falzacappa C, Patriarca V, Stigliano A, Panacchia L, Brunetti E, Toscano V, Misiti S.
J Endocrinol. 2007 May;193(2):209-23. University La Sapienza, Rome, Italy.
[Link to Abstract]
Erlotinib Plus Gemcitabine Compared with Gemcitabine Alone in Patients with Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group.
Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, Campos D, Lim R, Ding K, Clark G, Voskoglou-Nomikos T, Ptasynski M, Parulekar W.
IJ Clin Oncol. 2007 May 20;25(15):1960-6. Princess Margaret Hospital, Toronto, Canada.
[Link to Abstract]
Hp39p Use of the Superficial Femoral Vein as a Conduit for Portal Vein Reconstruction During Pancreaticoduodenectomy.
Gillespie C, Jauffret B.
ANZ J Surg. 2007 May;77 Suppl 1:A48-9. Gisborne Hospital, New Zealand.
[Link to Abstract]
Phase II Trial of Infusional Fluorouracil, Leucovorin, Mitomycin, and Dipyridamole in Locally Advanced Unresectable Pancreatic Adenocarcinoma: SWOG S9700.
Isacoff WH, Bendetti JK, Barstis JJ, Jazieh AR, Macdonald JS, Philip PA.
J Clin Oncol. 2007 May 1;25(13):1665-9. University of California, Los Angeles Medical Center.
[Link to Abstract]
APRIL
Erbb3 Expression and Dimerization with EGFR Influence Pancreatic Cancer Cell Sensitivity to Erlotinib.
Frolov A, Schuller K, Tzeng CW, Cannon EE, Ku BC, Howard JH, Vickers SM, Heslin MJ, Buchsbaum DJ, Arnoletti JP.
Cancer Biol Ther. 2007 Apr 13;6(4) [Epub]. University of Alabama at Birmingham, Alabama.
[Link to Abstract]
The Gemcitabine, Docetaxel, and Capecitabine (GTX) Regimen for Metastatic Pancreatic Cancer: A Retrospective Analysis.
Fine RL, Fogelman DR, Schreibman SM, Desai M, Sherman W, Strauss J, Guba S, Andrade R, Chabot J.
Cancer Chemother Pharmacol. 2007 Apr 18; [Epub]. New York Presbyterian Medical Center, Columbia University College of Physicians and Surgeons, New York.
[Link to Abstract]
A Phase I Pilot Study of Autologous Heat Shock Protein Vaccine HSPPC-96 in Patients with Resected Pancreatic Adenocarcinoma.
Maki RG, Livingston PO, Lewis JJ, Janetzki S, Klimstra D, Desantis D, Srivastava PK, Brennan MF.
Dig Dis Sci. 2007 Apr 10; [Epub]. Memorial Sloan- Kettering Cancer Center, New York.
[Link to Abstract]
A Randomized Phase 2 Trial of Neoadjuvant Chemotherapy in Resectable Pancreatic Cancer: Gemcitabine Alone Versus Gemcitabine Combined with Cisplatin.
Palmer DH, Stocken DD, Hewitt H, Markham CE, Hassan AB, Johnson PJ, Buckels JA, Bramhall SR.
Ann Surg Oncol. 2007 Jul;14(7):2088-96. 2007 Apr 24; [Epub]. Cancer Research UK Institute for Cancer Studies and Clinical Trials Unit, University of Birmingham, UK.
[Link to Abstract]
MARCH
Full-Dose Gemcitabine and Concurrent Radiotherapy for Unresectable Pancreatic Cancer.
Murphy JD, Adusumilli S, Griffith KA, Ray ME, Zalupski MM, Lawrence TS, Ben-Josef E.
Int J Radiat Oncol Biol Phys. 2007 Mar 20, Epub. University of Michigan, Ann Arbor, MI, USA.
[Link to Abstract]
A Phase II Study of Fixed-Dose Rate Gemcitabine Plus Low-Dose Cisplatin Followed by Consolidative Chemoradiation for Locally Advanced Pancreatic Cancer.
Ko AH, Quivey JM, Venook AP, Bergsland EK, Dito E, Schillinger B, Tempero MA.
Int J Radiat Oncol Biol Phys. 2007 Mar 13, Epub. University of California at San Francisco, CA, USA.
[Link to Abstract]
A Phase II Trial of Gemcitabine Plus Capecitabine for Patients with Advanced Pancreatic Adenocarcinoma.
Park BB, Park JO, Lee HR, Lee J, Choi DW, Choi SH, Heo JS, Lee JK, Lee KT, Lim DH, Park YS, Lim HY, Kang WK, Park K.
Cancer Chemother Pharmacol. 2007 Mar 30, Epub. Sungkyunkwan University School of Medicine, Seoul, South Korea.
[Link to Abstract]
Pooled Efficacy Analysis from a Phase I-II Study of Biweekly Irinotecan in Combination with Gemcitabine, 5-Fluorouracil, Leucovorin and Cisplatin in Patients with Metastatic Pancreatic Cancer.
Goel A, Grossbard ML, Malamud S, Homel P, Dietrich M, Rodriguez T, Mirzoyev T, Kozuch P.
Anticancer Drugs. 2007 Mar;18(3):263-71. St Luke’s-Roosevelt Hospital Center, New York, NY, USA.
[Link to Abstract]
FEBRUARY
Aggressive Surgery Improves Long-Term Survival in Neuroendocrine Pancreatic Tumors: An Institutional Experience.
Schurr PG, Strate T, Rese K, Kaifi JT, Reichelt U, Petri S, Kleinhans H, Yekebas EF, Izbicki JR.
Ann Surg. 2007 Feb;245(2):273-81. University Medical Center of Hamburg-Eppendorf, University of Hamburg, Germany.
[Link to Abstract]
FOLFOX-6 Combination as the First-Line Treatment of Locally Advanced and/or Metastatic Pancreatic Cancer.
Ghosn M, Farhat F, Kattan J, Younes F, Moukadem W, Nasr F, Chahine G.
Am J Clin Oncol. 2007 Feb;30(1):15-20. Hotel-Dieu de France University Hospital, Beirut, Lebanon.
[Link to Abstract]
In Vitro and In Vivo Molecular Evidence of Genistein Action in Augmenting the Efficacy of Cisplatin in Pancreatic Cancer.
Banerjee S, Zhang Y, Wang Z, Che M, Chiao PJ, Abbruzzese JL, Sarkar FH.
Int J Cancer. 2007 Feb 15;120(4):906-17. Barbara Ann Karmanos Cancer Institute, Wayne State University School of Medicine, Detroit, Michigan.
[Link to Abstract]
Low-Dose Radiotherapy as a Chemopotentiator of Gemcitabine in Tumors of the Pancreas or Small Bowel: A Phase I Study Exploring a New Treatment Paradigm.
Regine WF, Hanna N, Garofalo MC, Doyle A, Arnold S, Kataria R, Sims J, Tan M, Mohiuddin M.
Int J Radiat Oncol Biol Phys. 2007 May 1;68(1):172-7. [Epub 2007 Feb 2]. University of Maryland, Baltimore, Maryland.
[Link to Abstract]
JANUARY
Clinical and In Vitro Studies of Imatinib in Advanced Carcinoid Tumors.
Yao JC, Zhang JX, Rashid A, Yeung SC, Szklaruk J, Hess K, Xie K, Ellis L, Abbruzzese JL, Ajani JA.
Clin Cancer Res. 2007 Jan 1;13(1):234-40. The University of Texas / M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Impact of Interferon-Alpha in Combined Chemoradioimmunotherapy for Pancreatic Adenocarcinoma (Capri): First Data from the Immunomonitoring.
Schmidt J, Jager D, Hoffmann K, Buchler MW, Marten A.
J Immunother. 2007 Jan;30(1):108-15. University of Heidelberg, Germany.
[Link to Abstract]
Phase I Study of Oral S-1 and Concurrent Radiotherapy in Patients with Unresectable Locally Advanced Pancreatic Cancer.
Sudo K, Yamaguchi T, Ishihara T, Nakamura K, Shirai Y, Nakagawa A, Kawakami H, Uno T, Ito H, Saisho H.
Int J Radiat Oncol Biol Phys. 2007 Jan 1;67(1):219-24. Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan.
[Link to Abstract]
Second-Line Chemotherapy with Pemetrexed After Gemcitabine Failure in Patients with Advanced Pancreatic Cancer: A Multicenter Phase II Trial.
Boeck S, Weigang-Kohler K, Fuchs M, Kettner E, Quietzsch D, Trojan J, Stotzer O, Zeuzem S, Lordick F, Kohne CH, Kroning H, Steinmetz T, Depenbrock H, Heinemann V.
Ann Oncol. 2007 Apr;18(4):745-51. Epub 2007 Jan 17. University Hospital Grosshadern, Ludwigs-Maximilians University, Munich, Germany.
[Link to Abstract]
2006
DECEMBER
An Aggressive Surgical Approach Leads to Long-Term Survival in Patients with Pancreatic Endocrine Tumors.
Fendrich V, Langer P, Celik I, Bartsch DK, Zielke A, Ramaswamy A, Rothmund M.
Ann Surg. 2006 Dec;244(6):845-51; discussion 852-3. Philipps-University Marburg, Germany.
[Link to Abstract]
Erlotinib Plus Gemcitabine in Patients with Unresectable Pancreatic Cancer and Other Solid Tumors: Phase IB Trial.
Dragovich T, Huberman M, Von Hoff DD, Rowinsky EK, Nadler P, Wood D, Hamilton M, Hage G, Wolf J, Patnaik A.
Cancer Chemother Pharmacol. 2006 Dec 6, Epub. University of Arizona, Tucson, Arizona.
[Link to Abstract]
Low Molecular Weight Heparin (LMWH) Increases the Efficacy of Cisplatinum Plus Gemcitabine Combination in Advanced Pancreatic Cancer.
Icli F, Akbulut H, Utkan G, Yalcin B, Dincol D, Isikdogan A, Demirkazik A, Onur H, Cay F, Buyukcelik A.
J Surg Oncol. 2006 Dec 27, Epub. Ankara University School of Medicine, Turkey.
[Link to Abstract]
Phase II Study of Cisplatin Combined With Weekly Gemcitabine in the Treatment of Patients with Metastatic Pancreatic Carcinoma.
Bang S, Jeon TJ, Kim MH, Park JY, Park SW, Chung JB, Song SY.
Pancreatology. 2006 Dec 6;6(6):635-641, Epub. Yonsei University College of Medicine, Seoul, Korea.
[Link to Abstract]
FOLFIRI.3, A New Regimen Combining 5-Fluorouracil, Folinic Acid and Irinotecan, for Advanced Pancreatic Cancer: Results of an Association Des Gastro-Enterologues Oncologues (Gastroenterologist Oncologist Association) Multicenter Phase II Study.
Taieb J, Lecomte T, Aparicio T, Asnacios A, Mansourbakht T, Artru P, Fallik D, Spano J, Landi B, Lledo G, Desrame J.
Ann Oncol. 2006 Dec 8, Epub. Groupe Hospitalier Pitie Salpetriere, Paris, France.
[Link to Abstract]
NOVEMBER
Intra-Arterial Infusion of 5-Fluorouracil, Leucovorin, Epirubicin and Carboplatin (FLEC Regimen) in Unresectable Pancreatic Cancer: Results of a Ten-Year Experience.
Mambrini A, Sanguinetti F, Pacetti P, Caudana R, Iacono C, Guglielmi A, Guadagni S, Del Freo A, Fiorentini G, Cantore M.
In Vivo. 2006 Nov-Dec;20(6A):751-5. Massa-Carrara City Hospital, Italy.
[Link to Abstract]
Potentiation of the Effect of Erlotinib by Genistein in Pancreatic Cancer: The Role of Akt and Nuclear Factor-Kappab.
El-Rayes BF, Ali S, Ali IF, Philip PA, Abbruzzese J, Sarkar FH.
Cancer Res. 2006 Nov 1;66(21):10553-9. Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
[Link to Abstract]
Radiofrequency Ablation Combined with Palliative Surgery May Prolong Survival of Patients with Advanced Cancer of The Pancreas.
Spiliotis JD, Datsis AC, Michalopoulos NV, Kekelos SP, Vaxevanidou A, Rogdakis AG, Christopoulou AN.
Langenbecks Arch Surg. 2007 Jan;392(1):55-60. Epub 2006 Nov 7. Hatzikostas General Hospital, Messologi, Greece.
[Link to Abstract]
Rapamycin Synergizes with the Epidermal Growth Factor Receptor Inhibitor Erlotinib in Non-Small-Cell Lung, Pancreatic, Colon, and Breast Tumors.
Buck E, Eyzaguirre A, Brown E, Petti F, McCormack S, Haley JD, Iwata KK, Gibson NW, Griffin G.
Mol Cancer Ther. 2006 Nov;5(11):2676-84. OSI Pharmaceuticals, Farmingdale, New York.
[Link to Abstract]
OCTOBER
Clinical Results on Intra-Arterial Adjuvant Chemotherapy for Prevention of Liver Metastasis Following Curative Resection of Pancreatic Cancer.
Hayashibe A, Kameyama M, Shinbo M, Makimoto S.
Ann Surg Oncol. 2007 Jan;14(1):190-4. Epub 2006 Oct 26. Bell Land General Hospital, Sakai City, Osaka, Japan.
[Link to Abstract]
Pancreatic Resection for M1 Pancreatic Ductal Adenocarcinoma.
Shrikhande SV, Kleeff J, Reiser C, Weitz J, Hinz U, Esposito I, Schmidt J, Friess H, Buchler MW.
Ann Surg Oncol. 2007 Jan;14(1):118-27.Epub 2006 Oct 25. Tata Memorial Hospital, Mumbai, India.
[Link to Abstract]
RP101 Improves the Efficacy of Chemotherapy in Pancreas Carcinoma Cell Lines and Pancreatic Cancer Patients.
Fahrig R, Quietzsch D, Heinrich JC, Heinemann V, Boeck S, Schmid RM, Praha C, Liebert A, Sonntag D, Krupitza G, Hanel M.
Anticancer Drugs. 2006 Oct;17(9):1045-56. RESprotect, Dresden Germany.
[Link to Abstract]
Telomerase Peptide Vaccination of Patients with Non-Resectable Pancreatic Cancer: A Dose Escalating Phase I/II Study.
Bernhardt SL, Gjertsen MK, Trachsel S, Moller M, Eriksen JA, Meo M, Buanes T, Gaudernack G.
Br J Cancer. 2006 Dec 4;95(11):1474-82. Epub 2006 Oct 24. Ulleval University Hospital, Oslo, Norway.
[Link to Abstract]
SEPTEMBER
Effects of Low-Dose Warfarin and Regional Chemotherapy on Survival in Patients with Pancreatic Carcinoma.
Nakchbandi W, Muller H, Singer MV, Lohr M, Nakchbandi IA.
Scand J Gastroenterol. 2006 Sep;41(9):1095-104. Carl von Hess Hospital, Hammelburg, Germany.
[Link to Abstract]
Pancreatic Resections after Chemoradiotherapy for Locally Advanced Ductal Adenocarcinoma: Analysis of Perioperative Outcome and Survival.
Massucco P, Capussotti L, Magnino A, Sperti E, Gatti M, Muratore A, Sgotto E, Gabriele P, Aglietta M.
Ann Surg Oncol. 2006 Sep;13(9):1201-8. Institute for Research and Cure of Cancer, Candiolo, Italy.
[Link to Abstract]
Postoperative Morbidity and Long-Term Survival after Pancreaticoduodenectomy with Superior Mesenterico-Portal Vein Resection.
Riediger H, Makowiec F, Fischer E, Adam U, Hopt UT.
J Gastrointest Surg. 2006 Sep-Oct;10(8):1106-15. University of Freiburg, Germany.
[Link to Abstract]
Staging of Pancreatic Cancer with Multidetector CT in the Setting of Preoperative Chemoradiation Therapy.
Tamm EP, Loyer EM, Faria S, Raut CP, Evans DB, Wolff RA, Crane CH, Dubrow RA, Charnsangavej C.
Abdom Imaging. 2006 Sep 12; [Epub]. University of Texas / M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
AUGUST
Antitumor Effect of Trastuzumab for Pancreatic Cancer with High HER-2 Expression and Enhancement of Effect by Combined Therapy with Gemcitabine.
Kimura K, Sawada T, Komatsu M, Inoue M, Muguruma K, Nishihara T, Yamashita Y, Yamada N, Ohira M, Hirakawa K.
Clin Cancer Res. 2006 Aug 15;12(16):4925-32. Osaka City University Graduate School of Medicine, Japan.
[Link to Abstract]
Are Capecitabine and Oxaliplatin (XELOX) Suitable Treatments for Progressing Low-Grade and High-Grade Neuroendocrine Tumours?
Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, Martinetti A, Platania M, Verzoni E, Formisano B, Bajetta R.
Cancer Chemother Pharmacol. 2006 Aug 26; [Epub]. Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
[Link to Abstract]
Randomized Phase III Trial of Gemcitabine Plus Cisplatin Compared with Gemcitabine Alone in Advanced Pancreatic Cancer.
Heinemann V, Quietzsch D, Gieseler F, Gonnermann M, Schonekas H, Rost A, Neuhaus H, Haag C, Clemens M, Heinrich B, Vehling-Kaiser U, Fuchs M, Fleckenstein D, Gesierich W, Uthgenannt D, Einsele H, Holstege A, Hinke A, Schalhorn A, Wilkowski R.
J Clin Oncol. 2006 Aug 20;24(24):3946-52. Klinikum Grosshadern, Munich, Germany.
[Link to Abstract]
Resection of Pancreatic Neuroendocrine Tumors: Results of 70 Cases.
Kazanjian KK, Reber HA, Hines OJ.
Arch Surg. 2006 Aug;141(8):765-9; discussion 769-70. University of California, Los Angeles.
[Link to Abstract]
JULY
Chemoradiotherapy with Gemcitabine and Continuous 5-FU in Patients with Primary Inoperable Pancreatic Cancer.
Wilkowski R, Thoma M, Bruns C, Wagner A, Heinemann V.
JOP. 2006 Jul 10;7(4):349-60. LMU University Hospital Grosshadern, Munich, Germany.
[Link to Abstract]
Interferon-Alpha + Cisplatin + 5-FU Therapy for Gemcitabine-Refractory Unresectable and Recurrent Pancreatic Cancer.
Ueda M, Endo I, Fujii Y, Miura Y, Kubota T, Tanaka K, Ichikawa Y, Togo S, Shimada H.
Gan To Kagaku Ryoho. 2006 Jul;33(7):937-40. Yokohama City University Graduate School of Medicine, Japan.
[Link to Abstract]
Phase I/II Trial of Hyperfractionated Accelerated Chemoradiotherapy for Unresectable Advanced Pancreatic Cancer.
Tsujie M, Nakamori S, Tanaka E, Nagano H, Umeshita K, Dono K, Sakon M, Inoue T, Inoue T, Monden M.
Jpn J Clin Oncol. 2006 Aug;36(8):504-10. Epub 2006 Jul 19. Osaka National Hospital, Japan.
[Link to Abstract]
A Phase II Study of Weekly Irinotecan as First-Line Therapy for Patients with Metastatic Pancreatic Cancer.
Ueno H, Okusaka T, Funakoshi A, Ishii H, Yamao K, Ishikawa O, Ohkawa S, Saitoh S.
Cancer Chemother Pharmacol. 2006 Jul 20;[Epub]. National Cancer Center Hospital, Tokyo, Japan.
[Link to Abstract]
JUNE
Combination Chemotherapy with Gemcitabine and S-1 for Advanced Pancreatic Cancer.
Nakamura K, Yamaguchi T, Sudo K, Ishihara T, Saisho H.
Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:219-23. Shimizu Kousei Hospital, Shizuoka, Japan.
[Link to Abstract]
Dose-Intense PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) in Advanced Pancreatic Adenocarcinoma.
Reni M, Cereda S, Bonetto E, Vigano MG, Passoni P, Zerbi A, Balzano G, Nicoletti R, Staudacher C, Di Carlo V.
Cancer Chemother Pharmacol. 2006 Jun 29; [Epub]. San Raffaele Scientific Institute, Milan, Italy.
[Link to Abstract]
Phase I and Pharmacokinetic Study of S-1 Administered for 14 Days in a 21-Day Cycle in Patients with Advanced Upper Gastrointestinal Cancer.
Zhu AX, Clark JW, Ryan DP, Meyerhardt JA, Enzinger PC, Earle CC, Fuchs CS, Regan E, Anbe H, Houghton M, Zhang J, Urrea P, Kulke MH.
Cancer Chemother Pharmacol. 2006 Jun 20; [Epub]. Massachusetts General Hospital, Boston.
[Link to Abstract]
S-1 Monotherapy for Pancreatic Cancer.
Okusaka T, Ueno H, Ikeda M, Morizane C.
Gan To Kagaku Ryoho. 2006 Jun;33 Suppl 1:207-12. National Cancer Center Hospital, Tokyo, Japan.
[Link to Abstract]
MAY
Liposomal Cisplatin Combined with Gemcitabine in Pretreated Advanced Pancreatic Cancer Patients: A Phase I-II Study.
Stathopoulos GP, Boulikas T, Vougiouka M, Rigatos SK, Stathopoulos JG.
Oncol Rep. 2006 May;15(5):1201-4. Errikos Dunant Hospital and Medical School of Athens, Greece.
[Link to Abstract]
Phase I Study of The Humanised Anti-EGFR Monoclonal Antibody Matuzumab (EMD 72000) Combined with Gemcitabine in Advanced Pancreatic Cancer.
Graeven U, Kremer B, Sudhoff T, Killing B, Rojo F, Weber D, Tillner J, Unal C, Schmiegel W. Br J Cancer. 2006 May 8;94(9):1293-9. Ruhr University Bochum, and University Hospital of Schleswig-Holstein, Kiel, Germany.
[Link to Abstract]
A Phase II Trial of Epothilone B Analogue BMS-247550 (NSC #710428) Ixabepilone, in Patients with Advanced Pancreas Cancer: A Southwest Oncology Group Study.
Whitehead RP, McCoy S, Rivkin SE, Gross HM, Conrad ME, Doolittle GC, Wolff RA, Goodwin JW, Dakhil SR, Abbruzzese JL.
Invest New Drugs. 2006 May 11;[Epub]. University of Texas Medical Branch, Galveston, Texas.
[Link to Abstract]
Unfavourable Prognosis Associated with K-Ras Gene Mutation in Pancreatic Cancer Surgical Margins
Kim J, Reber HA, Dry SM, Elashoff D, Chen SL, Umetani N, Kitago M, Hines OJ, Kazanjian KK, Hiramatsu SH, Bilchik AJ, Yong S, Shoup M, Hoon DS.
Gut. 2006 May 8;[Epub]. John Wayne Cancer Institute, Santa Monica, California.
[Link to Abstract]
APRIL
Adjuvant Intra-Arterial 5-Fluoruracil, Leucovorin, Epirubicin and Carboplatin With or Without Systemic Gemcitabine After Curative Resection for Pancreatic Adenocarcinoma.
Cantore M, Serio G, Pederzoli P, Mambrini A, Iacono C, Pulica C, Capelli P, Lombardi M, Torri T, Pacetti P, Pagani M, Fiorentini G.
Cancer Chemother Pharmacol. 2006 Apr 22; Epub. General City Hospital, Massa Carrara, Italy.
[Link to Abstract]
The Argument for Pre-operative Chemoradiation for Localized, Radiographically Resectable Pancreatic Cancer.
Crane CH, Varadhachary G, Wolff RA, Pisters PW, Evans DB.
Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):365-82. University of Texas / M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Maintenance Chemotherapy After Chemoradiation Improves Survival of Patients with Locally Advanced Pancreatic Carcinoma: A Retrospective Analysis of Prospectively Recruited Patients.
Brunner TB, Tinkl D, Grabenbauer GG, Meyer T, Brueckl WM, Sauer R.
Strahlenther Onkol. 2006 Apr;182(4):210-5. Friedrich Alexander University of Erlangen-Nuremberg, Germany.
[Link to Abstract]
Venous Resection in Pancreatic Cancer Surgery.
Tseng JF, Tamm EP, Lee JE, Pisters PW, Evans DB.
Best Pract Res Clin Gastroenterol. 2006 Apr;20(2):349-64. University of Massachusetts Medical School, Worcester, Massachusetts.
[Link to Abstract]
MARCH
The Long-Term Survival of a Patient with Pancreatic Cancer with Metastases to the Liver after Treatment with the Intravenous alpha-lipoic acid/low-dose naltrexone Protocol.
Berkson BM, Rubin DM, Berkson AJ.
Integr Cancer Ther. 2006 Mar;5(1):83-9. Integrative Medical Center of New Mexico and New Mexico State University, Las Cruces, New Mexico.
[Link to Abstract]
A Phase I Study of Oral Uracil-Tegafur Prior to Weekly Intravenous Gemcitabine in Patients with Advanced Pancreatic Cancer.
Tanno S, Nakano Y, Osanai M, Koizumi K, Izawa T, Habiro A, Mizukami Y, Yanagawa N, Fujii T, Okumura T, Kohgo Y.
Chemotherapy. 2006;52(2):98-102. Epub 2006 Mar 27. Asahikawa Medical College, Asahikawa, Japan.
[Link to Abstract]
Phase I Trial Evaluating the Safety of Bevacizumab with Concurrent Radiotherapy and Capecitabine in Locally Advanced Pancreatic Cancer.
Crane CH, Ellis LM, Abbruzzese JL, Amos C, Xiong HQ, Ho L, Evans DB, Tamm EP, Ng C, Pisters PW, Charnsangavej C, Delclos ME, O’Reilly M, Lee JE, Wolff RA.
J Clin Oncol. 2006 Mar 1;24(7):1145-51. University of Texas / M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Raltitrexed-Eloxatin Salvage Chemotherapy in Gemcitabine-Resistant Metastatic Pancreatic Cancer.
Reni M, Pasetto L, Aprile G, Cordio S, Bonetto E, Dell’Oro S, Passoni P, Piemonti L, Fugazza C, Luppi G, Milandri C, Nicoletti R, Zerbi A, Balzano G, Di Carlo V, Brandes AA.
Br J Cancer. 2006 Mar 27;94(6):785-91. San Raffaele Scientific Institute., Milan, Italy.
[Link to Abstract]
FEBRUARY
Evaluation of the Efficacy of Combined Continuous Arterial Infusion and Systemic Chemotherapy for the Treatment of Advanced Pancreatic Carcinoma.
Ikeda O, Kusunoki S, Kudoh K, Takamori H, Tsuji T, Kanemitsu K, Yamashita Y.
Cardiovasc Intervent Radiol. 2006 May-Jun;29(3):362-70. Kumamoto University Graduate School of Medical and Pharmaceutical Sciences, Japan.
[Link to Abstract]
Immunomodulatory Impact of Interferon-Alpha in Combination with Chemoradiation of Pancreatic Adenocarcinoma (Capri).
Schmidt J, Patrut EM, Ma J, Jager D, Knaebel HP, Buchler MW, Marten A.
Cancer Immunol Immunother. 2006 Epub Feb 17, 2006. University of Heidelberg, Germany.
[Link to Abstract]
Multicenter Phase-I/II Study Using a Combination of Gemcitabine and Docetaxel in Metastasized and Unresectable, Locally Advanced Pancreatic Carcinoma.
Ridwelski K, Fahlke J, Kuhn R, Hribaschek A, Kettner E, Greiner C, Florschuetz A, Manger T, Wilhelm G, Klein H, Hahnfeld S, Lippert H, Meyer F.
Eur J Surg Oncol. 2006 Apr;32(3):297-302. Epub 2006 Jan 18. Otto von Guericke University, Magdeburg, Germany.
[Link to Abstract]
Phase II Study 0f Temozolomide and Thalidomide in Patients with Metastatic Neuroendocrine Tumors.
Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS.
J Clin Oncol. 2006 Jan 20;24(3):401-6. Dana-Farber Cancer Institute, Boston, Massachusetts.
[Link to Abstract]
JANUARY
Comparison of Standard-Dose and Low-Dose Gemcitabine Regimens in Pancreatic Adenocarcinoma Patients: A Prospective Randomized Trial.
Sakamoto H, Kitano M, Suetomi Y, Takeyama Y, Ohyanagi H, Nakai T, Yasuda C, Kudo M.
J Gastroenterol. 2006 Jan;41(1):70-6. Kinki University School of Medicine, Osaka-Sayama, Japan.
[Link to Abstract]
Gemcitabine and Oxaliplatin (GEMOX) in Gemcitabine Refractory Advanced Pancreatic Adenocarcinoma: A Phase II Study.
Demols A, Peeters M, Polus M, Marechal R, Gay F, Monsaert E, Hendlisz A, Van Laethem JL.
Br J Cancer. 2006 Feb 27;94(4):481-5 (Epub 2006 Jan24). Erasme University Hospital, Brussels, Belgium.
[Link to Abstract]
A Multi-Institutional Phase II Trial of Preoperative Full-Dose Gemcitabine and Concurrent Radiation for Patients with Potentially Resectable Pancreatic Carcinoma.
Talamonti MS, Small W Jr, Mulcahy MF, Wayne JD, Attaluri V, Colletti LM, Zalupski MM, Hoffman JP, Freedman GM, Kinsella TJ, Philip PA, McGinn CJ.
Ann Surg Oncol. 2006 Feb;13(2):150-8 (Epub 2006 Jan 19). Feinberg School of Medicine, Northwestern University, Chicago.
[Link to Abstract]
Phase II Study of Fixed Dose Rate Gemcitabine with Cisplatin for Metastatic Adenocarcinoma of The Pancreas.
Ko AH, Dito E, Schillinger B, Venook AP, Bergsland EK, Tempero MA.
J Clin Oncol. 2006 Jan 20;24(3):379-85. University of California at San Francisco Comprehensive Cancer Center, San Francisco.
[Link to Abstract]
2005
DECEMBER
Brief Communication: A New Combination in the Treatment of Advanced Pancreatic Cancer.
Moore MJ.
Semin Oncol. 2005 Dec;32(6 Suppl 8):5-6. Princess Margaret Hospital, Toronto, Canada.
[Link to Abstract]
Chemoradiotherapy in Patients with Pancreatic Carcinoma: Phase-I Study with a Fixed Radiation Dose and Escalating Doses of Weekly Gemcitabine.
Oya N, Shibuya K, Sakamoto T, Mizowaki T, Doi R, Fujimoto K, Imamura M, Nagata Y, Hiraoka M.
Pancreatology. 2005 Dec 1;6(1-2):109-116. Graduate School of Medicine, Kyoto University, Japan.
[Link to Abstract]
Docetaxel Plus Gemcitabine or Docetaxel Plus Cisplatin in Advanced Pancreatic Carcinoma: Randomized Phase II Study 40984 of The European Organisation for Research and Treatment of Cancer Gastrointestinal Group.
Lutz MP, Cutsem EV, Wagener T, Van Laethem JL, Vanhoefer U, Wils JA, Gamelin E, Koehne CH, Arnaud JP, Mitry E, Husseini F, Reichardt P, El-Serafi M, Etienne PL, Lingenfelser T, Praet M, Genicot B, Debois M, Nordlinger B, Ducreux MP.
J Clin Oncol. 2005 Dec 20;23(36):9250-6. University of Ulm, Germany
[Link to Abstract]
Erlotinib and Chemoradiation Followed by Maintenance Erlotinib for Locally Advanced Pancreatic Cancer: A Phase I Study.
Iannitti D, Dipetrillo T, Akerman P, Barnett JM, Maia-Acuna C, Cruff D, Miner T, Martel D, Cioffi W, Remis M, Kennedy T, Safran H.
Am J Clin Oncol. 2005 Dec;28(6):570-5. Brown University Oncology Group, Providence, Rhode Island.
[Link to Abstract]
NOVEMBER
Complete Remission of Liver Metastasis of Pancreatic Cancer Under Vaccination with a HLA-A2 Restricted Peptide Derived from the Universal Tumor Antigen Survivin.
Wobser M, Keikavoussi P, Kunzmann V, Weininger M, Andersen MH, Becker JC.
Cancer Immunol Immunother. 2005 Nov 29;1-5. University of Wuerzburg, Germany.
[Link to Abstract]
Docetaxel/Gemcitabine Followed by Gemcitabine and External Beam Radiotherapy in Patients with Pancreatic Adenocarcinoma.
Pipas JM, Barth RJ Jr, Zaki B, Tsapakos MJ, Suriawinata AA, Bettmann MA, Cates JM, Ripple GH, Sutton JE, Gordon SR, McDonnell CE, Perez RP, Redfield N, Meyer LP, Marshall JF, Cole BF, Colacchio TA.
Ann Surg Oncol. 2005 Dec;12(12):995-1004. Epub 2005 Nov 1. Dartmouth-Hitchcock Medical Center/Norris Cotton Cancer Center, Lebanon, New Hampshire.
[Link to Abstract]
Phase II Trial of Bevacizumab Plus Gemcitabine in Patients with Advanced Pancreatic Cancer.
Kindler HL, Friberg G, Singh DA, Locker G, Nattam S, Kozloff M, Taber DA, Karrison T, Dachman A, Stadler WM, Vokes EE.
J Clin Oncol. 2005 Nov 1;23(31):8033-40. University of Chicago Medical Center, Illinois.
[Link to Abstract]
Phase III Randomised Comparison of Gemcitabine (GEM) Versus Gemcitabine Plus Capecitabine (GEM-CAP) in Patients with Advanced Pancreatic Cancer.
Chua YJ, Cunningham D, et al.
European Cancer Conference (ECCO 13), presentation/abstract PS11, Paris, France, 2005 November 2. Royal Marsden Hospital, London, England.
[Link to Abstract]
OCTOBER
Borderline Resectable Pancreatic Cancer.
Varadhachary GR, Tamm EP, Crane C, Evans DB, Wolff RA
Curr Treat Options Gastroenterol. 2005 Oct;8(5):377-84. M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Combination Therapy for Advanced Pancreatic Cancer Using Herceptin Plus Chemotherapy.
Buchler P, Reber HA, Eibl G, Roth MA, Buchler MW, Friess H, Isacoff WH, Hines OJ.
Int J Oncol. 2005 Oct;27(4):1125-30. University of Heidelberg, Germany.
[Link to Abstract]
Combined Systemic and Intraarterial Chemotherapy with Gemcitabine and Concomitant External-Beam Radiotherapy in Patients with Liver Metastasis from Pancreatic Cancer – A Report of Two Cases.
Matsugu Y, Tanaka T, Kagawa N, Nakahara H, Ishimoto T, Fukuda Y.
Gan To Kagaku Ryoho. 2005 Oct;32(10):1489-92. Hiroshima Prefectural Hospital, Japan.
[Link to Abstract]
Phase II Study to Assess the Efficacy of Conventionally Fractionated Radiotherapy Followed By a Stereotactic Radiosurgery Boost in Patients with Locally Advanced Pancreatic Cancer.
Koong AC, Christofferson E, Le QT, Goodman KA, Ho A, Kuo T, Ford JM, Fisher GA, Greco R, Norton J, Yang GP.
Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):320-3. Stanford University School of Medicine, Stanford, California.
[Link to Abstract]
SEPTEMBER
Bevacizumab as Treatment for Chemotherapy-Resistant Pancreatic Cancer.
Bruckner HW, Hrehorovich VR, Sawhney HS.
Anticancer Res. 2005 Sep-Oct;25(5):3637-9. Lutheran Medical Center, Brooklyn, New York.
[Link to Abstract]
Fixed Dose-Rate Gemcitabine Infusion as First-Line Treatment for Advanced-Stage Carcinoma of The Pancreas and Biliary Tree.
Gelibter A, Malaguti P, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Carboni F, Ettorre GM, Pellicciotta M, Giannarelli D, Terzoli E, Cognetti F, Milella M.
Cancer. 2005 Sep 15;104(6):1237-45. Regina Elena National Cancer Institute, Rome, Italy.
[Link to Abstract]
Gemcitabine Plus Celecoxib (GECO) in Advanced Pancreatic Cancer: A Phase II Trial.
Ferrari V, Valcamonico F, Amoroso V, Simoncini E, Vassalli L, Marpicati P, Rangoni G, Grisanti S, Tiberio GA, Nodari F, Strina C, Marini G.
Cancer Chemother Pharmacol. 2005 Sep 3;:1-6. U.O. Oncologia Medica, Beretta Foundation, Brescia, Italy.
[Link to Abstract]
Surgical Resection After Radiochemotherapy in Patients with Unresectable Adenocarcinoma of the Pancreas.
Sa Cunha A, Rault A, Laurent C, Adhoute X, Vendrely V, Bellannee G, Brunet R, Collet D, Masson B.
J Am Coll Surg. 2005 Sep;201(3):359-65. Groupe Hospitalier Sud, CHU Bordeaux, Pessac, France.
[Link to Abstract]
AUGUST
Adjuvant Gemcitabine and Concurrent Continuous Radiation (45 Gy) for Resected Pancreatic Head Carcinoma: A Multicenter Belgian Phase II Study.
Demols A, Peeters M, Polus M, Honore P, Boterberg T, Gay F, Closon MT, Van Houtte P, Closset J, Van Laethem JL.
Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1351-6. Erasme University Hospital, Brussels, Belgium.
[Link to Abstract]
Phase II Study on Low Dose Gemcitabine Plus Oral Chemotherapy with Uracil-Tegafur and Cyclophosphamide in Combination with Radiotherapy Against Recurrent and Advanced Pancreatic Cancer.
Nio Y, Hashimoto K, Yano S, Itakura M, Koike M, Yamaguchi K, Endo S, Tsuji M, Higami T, Maruyama R.
Oncol Rep. 2005 Aug;14(2):401-8. Shimane University School of Medicine, Japan.
[Link to Abstract]
Second-Line Treatment with Oxaliplatin, Leucovorin and 5-Fluorouracil in Gemcitabine-Pretreated Advanced Pancreatic Cancer: A Phase II Study.
Tsavaris N, Kosmas C, Skopelitis H, Gouveris P, Kopteridis P, Loukeris D, Sigala F, Zorbala-Sypsa A, Felekouras E, Papalambros E.
Invest New Drugs. 2005 Aug;23(4):369-75. Metaxa Memorial Cancer Hospital, Piraeus, Greece.
[Link to Abstract]
Toxicities and Effects of Involved-Field Irradiation with Concurrent Cisplatin for Unresectable Carcinoma of The Pancreas.
Kawakami H, Uno T, Isobe K, Ueno N, Aruga T, Sudo K, Yamaguchi T, Saisho H, Kawata T, Ito H.
Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1357-62. Chiba University Graduate School of Medicine, Japan.
[Link to Abstract]
JULY
An Early Phase II Study of S-1 in Patients with Metastatic Pancreatic Cancer.
Ueno H, Okusaka T, Ikeda M, Takezako Y, Morizane C.
Oncology. 2005;68(2-3):171-8. 2005 Jul 4. National Cancer Center Hospital, Tokyo, Japan.
[Link to Abstract]
Feasibility of US-Guided High-Intensity Focused Ultrasound Treatment in Patients with Advanced Pancreatic Cancer: Initial Experience.
Wu F, Wang ZB, Zhu H, Chen WZ, Zou JZ, Bai J, Li KQ, Jin CB, Xie FL, Su HB.
Radiology. 2005 Sep;236(3):1034-40. 2005 Jul 29. Chongqing University of Medical Sciences, Chongqing, China
[Link to Abstract]
Phase II Trial of Primary Radiation Therapy and Concurrent Chemotherapy for Patients with Locally Advanced Pancreatic Cancer.
Magnino A, Gatti M, Massucco P, Sperti E, Faggiuolo R, Regge D, Capussotti L, Gabriele P, Aglietta M.
Oncology. 2005;68(4-6):493-9. 2005 Jul 13. Institute for Research and Cure of Cancer, Candiolo, Italy.
[Link to Abstract]
Serum CA19-9 Response as a Surrogate for Clinical Outcome in Patients Receiving Fixed-Dose Rate Gemcitabine for Advanced Pancreatic Cancer.
Ko AH, Hwang J, Venook AP, Abbruzzese JL, Bergsland EK, Tempero MA.
Br J Cancer. 2005 Jul 25;93(2):195-9. University of California at San Francisco Comprehensive Cancer Center.
[Link to Abstract]
JUNE
Gemcitabine Versus Cisplatin, Epirubicin, Fluorouracil, and Gemcitabine in Advanced Pancreatic Cancer: A Randomised Controlled Multicentre Phase III Trial.
Reni M, Cordio S, Milandri C, Passoni P, Bonetto E, Oliani C, Luppi G, Nicoletti R, Galli L, Bordonaro R, Passardi A, Zerbi A, Balzano G, Aldrighetti L, Staudacher C, Villa E, Di Carlo V.
Lancet Oncol. 2005 Jun;6(6):369-76. S Raffaele H Scientific Institute, Milan, Italy.
[Link to Abstract]
A Novel Anti-Pancreatic Cancer Agent, LY293111.
Ding XZ, Talamonti MS, Bell RH Jr, Adrian TE.
Anticancer Drugs. 2005 Jun;16(5):467-73. Feinberg School of Medicine, Northwestern University, Chicago, Illinois.
[Link to Abstract]
Phase I Trial of Oral S-1 Combined with Gemcitabine in Metastatic Pancreatic Cancer.
Nakamura K, Yamaguchi T, Ishihara T, Kobayashi A, Tadenuma H, Sudo K, Kato H, Saisho H.
Br J Cancer. 2005 Jun 20;92(12):2134-9. Graduate School of Medicine, Chiba University, Inohana, Chiba, Japan.
[Link to Abstract]
A Phase II Study of Alternating Cycles of Split Course Radiation Therapy and Gemcitabine Chemotherapy for Inoperable Pancreatic or Biliary Tract Carcinoma.
Lin LL, Picus J, Drebin JA, Linehan DC, Solis J, Strasberg SM, Tan B, Thorstad WL, Myerson R.
Am J Clin Oncol. 2005 Jun;28(3):234-41. Washington University School of Medicine, St. Louis, Missouri.
[Link to Abstract]
MAY
Clinical Experience with Chronomodulated Infusional 5-Fluorouracil Chemoradiotherapy for Pancreatic Adenocarcinoma.
Keene KS, Rich TA, Penberthy DR, Shepard RC, Adams R, Jones RS.
Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):97-103. University of Virginia Health Science Center, Charlottesville, Virginia.
[Link to Abstract]
Epidermal Growth Factor Receptor and Activated Epidermal Growth Factor Receptor Expression in Gastrointestinal Carcinoids and Pancreatic Endocrine Carcinomas.
Papouchado B, Erickson LA, Rohlinger AL, Hobday TJ, Erlichman C, Ames MM, Lloyd RV.
Mod Pathol. 2005 May 6 [Epub]. Mayo Clinic College of Medicine, Rochester, Minnesota.
[Link to Abstract]
Neuroendocrine Hepatic Metastases: Does Aggressive Management Improve Survival?
Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, Pitt HA.
Ann Surg. 2005 May;241(5):776-83; discussion 783-5. Medical College of Wisconsin, Milwaukee, Wisconsin.
[Link to Abstract]
A Phase II Study of Combination Chemotherapy with Gemcitabine, 5-Fluorouracil, and Cisplatin for Advanced Pancreatic Cancer.
Choi SB, Lee HY, Yuh YJ, Kim SR.
Korean J Gastroenterol. 2005 May;45(5):348-53. Inje University Collage of Medicine, Sanggye Paik Hospital, Seoul, Korea.
[Link to Abstract]
APRIL
5-Fluorouracil Intra-Arterial Infusion Combined with Systemic Gemcitabine for Unresectable Pancreatic Cancer.
Takamori H, Kanemitsu K, Tsuji T, Tanaka H, Chikamoto A, Nakahara O, Hiraoka T, Ikeda O, Kudo K, Imuta M, Yamashita Y.
Pancreas. 2005 Apr;30(3):223-6. Graduate School of Medical Sciences, Kumamoto University, Japan.
[Link to Abstract]
Meta-Analysis of Randomised Adjuvant Therapy Trials for Pancreatic Cancer.
Stocken DD, Buchler MW, Dervenis C, Bassi C, Jeekel H, Klinkenbijl JH, Bakkevold KE, Takada T, Amano H, Neoptolemos JP; Pancreatic Cancer Meta-analysis Group.
Br J Cancer. 2005 Apr 25;92(8):1372-81. University of Birmingham, UK.
[Link to Abstract]
Parthenolide and Sulindac Cooperate to Mediate Growth Suppression and Inhibit the Nuclear Factor-Kappa B Pathway in Pancreatic Carcinoma Cells.
Yip-Schneider MT, Nakshatri H, Sweeney CJ, Marshall MS, Wiebke EA, Schmidt CM.
Mol Cancer Ther. 2005 Apr;4(4):587-94. Indiana University School of Medicine, Indianapolis, Indiana.
[Link to Abstract]
Thalidomide in the Treatment of Cancer Cachexia: A Randomised Placebo Controlled Trial.
Gordon JN, Trebble TM, Ellis RD, Duncan HD, Johns T, Goggin PM.
Gut. 2005 Apr;54(4):540-5. Southampton General Hospital, England.
[Link to Abstract]
MARCH
Increased Preoperative Platelet Count is Associated with Decreased Survival After Resection for Adenocarcinoma of The Pancreas.
Brown KM, Domin C, Aranha GV, Yong S, Shoup M.
Am J Surg. 2005 Mar;189(3):278-82. Loyola University Medical Center, Maywood, Illinois
[Link to Abstract]
Intra-Arterial Bolus Octreotide Administration During Whipple Procedure in Patients with Fragile Pancreas: A Novel Technique for Safer Pancreaticojejunostomy.
Konstadoulakis MM, Filippakis GM, Lagoudianakis E, Antonakis PT, Dervenis C, Bramis J.
J Surg Oncol. 2005 Mar 15;89(4):268-72. Hippocration Hospital, Athens Medical School, Greece.
[Link to Abstract]
Randomized Clinical Trial of Pylorus-Preserving Duodenopancreatectomy Versus Classical Whipple Resection -Long Term Results.
Seiler CA, Wagner M, Bachmann T, Redaelli CA, Schmied B, Uhl W, Friess H, Buchler MW.
Br J Surg. 2005 May;92(5):547-56. University of Berne, Inselspital, Switzerland.
[Link to Abstract]
Synergistic Effects of Interferon-Alpha in Combination with Chemoradiation on Human Pancreatic Adenocarcinoma.
Ma JH, Patrut E, Schmidt J, Knaebel HP, Buchler MW, Marten A.
World J Gastroenterol. 2005 Mar 14;11(10):1521-8. University of Heidelberg, Germany.
[Link to Abstract]
FEBRUARY
Growth Inhibition of Human Pancreatic Cancer Cells by Human Interferon-Beta Gene Combined with Gemcitabine.
Endou M, Mizuno M, Nagata T, Tsukada K, Nakahara N, Tsuno T, Osawa H, Kuno T, Fujita M, Hatano M, Yoshida J.
Int J Mol Med. 2005 Feb;15(2):277-83. Toyama Medical and Pharmaceutical University, Nagoya, Japan.
[Link to Abstract]
Growth Stimulation of COX-2-Negative Pancreatic Cancer by a Selective COX-2 Inhibitor.
Eibl G, Takata Y, Boros LG, Liu J, Okada Y, Reber HA, Hines OJ.
Cancer Res. 2005 Feb 1;65(3):982-90. David Geffen School of Medicine at University of California-Los Angeles.
[Link to Abstract]
A Pharmacological Study of Celecoxib and Gemcitabine in Patients with Advanced Pancreatic Cancer.
Xiong HQ, Plunkett W, Wolff R, Du M, Lenzi R, Abbruzzese JL.
Cancer Chemother Pharmacol. 2005 Feb 22. University of Texas / MD Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Photodynamic Therapy for Pancreatic and Biliary Tract Carcinoma.
Ayaru L, Bown SG, Pereira SP.
Int J Gastrointest Cancer. 2005;35(1):1-14. Royal Free & University College London Medical School, England.
[Link to Abstract]
JANUARY
Homozygous Deletion of the MTAP Gene in Invasive Adenocarcinoma of the Pancreas and in Periampullary Cancer: A Potential New Target for Therapy.
Hustinx SR, Hruban RH, Leoni LM, Iacobuzio-Donahue C, Cameron JL, Yeo CJ, Brown PN, Argani P, Asfaq R, Fukushima N, Goggins M, Kern SE, Maitra A.
Cancer Biol Ther. 2005 Jan 15;4(1). Johns Hopkins Medical Institutions, Baltimore, Maryland; Academic Medical Center, Amsterdam, Netherlands.
[Link to Abstract]
Phase I and Pharmacokinetic Study of DE-310 in Patients with Advanced Solid Tumors.
Soepenberg O, de Jonge MJ, Sparreboom A, de Bruin P, Eskens FA, de Heus G, Wanders J, Cheverton P, Ducharme MP, Verweij J.
Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):703-11. Erasmus University Medical Center, Rotterdam, Netherlands.
[Link to Abstract]
Quality of Life After Curative or Palliative Surgical Treatment of Pancreatic and Periampullary Carcinoma.
Nieveen van Dijkum EJ, Kuhlmann KF, Terwee CB, Obertop H, de Haes JC, Gouma DJ.
Br J Surg. 2005 Jan 25. Academic Medical Centre, University of Amsterdam, Netherlands.
[Link to Abstract]
Raltitrexed Plus Gemcitabine (TOMGEM) in Advanced Pancreatic Cancer. Results of a Belgian Multicentre Phase II Study.
Van Laethem JL, Van Maele P, Verslype C, Polus M, Demols A, Houbiers G, Caenepeel P, Leleux A, Vermaut RR, Van Cutsem E, Peeters M.
Oncology. 2004;67(5-6):338-43. Erasme University Hospital, Brussels, Belgium.
[Link to Abstract]
2004
DECEMBER
Efficacy of Selective Continuous Transarterial Infusion Chemotherapy on Advanced Pancreatic Cancer.
Zhou JX, Hong GB, Xu LY, Xu LF, Chen YT, Jiang RJ, Luo JH.
Ai Zheng. 2004 Dec;23(12):1677-80. Second Affiliated Hospital, Sun Yat-sen University, Guangzhou, Guangdong, China.
[Link to Abstract]
Fluorouracil, Doxorubicin, and Streptozocin in the Treatment of Patients with Locally Advanced and Metastatic Pancreatic Endocrine Carcinomas.
Kouvaraki MA, Ajani JA, Hoff P, Wolff R, Evans DB, Lozano R, Yao JC.
J Clin Oncol. 2004 Dec 1;22(23):4762-71. University of Texas / M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Gemcitabine Versus FLEC Regimen Given Intra-Arterially to Patients with Unresectable Pancreatic Cancer: A Prospective, Randomized Phase III Trial of the Italian Society for Integrated Locoregional Therapy in Oncology.
Cantore M, Fiorentini G, Luppi G, Rosati G, Caudana R, Piazza E, Comella G, Ceravolo C, Miserocchi L, Mambrini A, Del Freo A, Zamagni D, Rabbi C, Marangolo M.
J Chemother. 2004 Dec;16(6):589-94. Oncological Department, USL 1, Massa and Carrara, Italy.
[Link to Abstract]
Isolated Hepatic Perfusion for the Treatment of Patients with Advanced Liver Metastases from Pancreatic and Gastrointestinal Neuroendocrine Neoplasms.
Grover AC, Libutti SK, Pingpank JF, Helsabeck C, Beresnev T, Alexander HR Jr.
Surgery. 2004 Dec;136(6):1176-82. National Cancer Institute, Bethesda, Maryland.
[Link to Abstract]
NOVEMBER
Curative Resection for a Pancreatic Endocrine Carcinoma Involving the Portal Vein.
Sakamoto E, Hasegawa H, Ogiso S, Igami T, Mori T, Mizuno T, Hattori K, Sugimoto M, Fukami Y.
Hepatogastroenterology. 2004 Nov-Dec;51(60):1849-51. Nagoya Daini Red Cross Hospital, Nagoya, Japan.
[Link to Abstract]
Laparoscopic Pancreatic Surgery for Islet Cell Tumors of the Pancreas.
Assalia A, Gagner M.
World J Surg. 2004 Dec;28(12):1239-47. 2004 Nov 04. Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York City.
[Link to Abstract]
A Randomized Multicenter Trial Comparing Resection and Radiochemotherapy for Resectable Locally Invasive Pancreatic Cancer.
Imamura M, Doi R, Imaizumi T, Funakoshi A, Wakasugi H, Sunamura M, Ogata Y, Hishinuma S, Asano T, Aikou T, Hosotani R, Maetani S.
Surgery. 2004 Nov;136(5):1003-11. Kyoto University, Japan.
[Link to Abstract]
Sequential and/or Concurrent Hypofractionated Radiotherapy and Concurrent Chemotherapy in Neoadjuvant Treatment of Advanced Adenocarcinoma of The Pancreas. Outcome and Patterns of Failure.
Zimmermann FB, Schuhmacher C, Lersch C, Bernhardt B, Pickel P, Siewert JR, Molls M, Jeremic B.
Hepatogastroenterology. 2004 Nov-Dec;51(60):1842-6. Technische Universitaet Muenchen, Germany.
[Link to Abstract]
OCTOBER
Advances in the Genetic Screening, Work-Up, and Treatment of Pancreatic Cancer.
Frucht H, Stevens PD, Fogelman DR, Verna EC, Chen J, Chabot JA, Fine RL.
Curr Treat Options Gastroenterol. 2004 Oct;7(5):343-354. Columbia University, New York City.
[Link to Abstract]
A Case of Successful Management of Nonresectable Pancreas Cancer with Liver Metastasis by Intra-Arterial Infusion Chemotherapy with Gemcitabine Hydrochloride, 5-FU, CDDP and Administration of Tegafur/Uracil.
Ishikawa T, Mizuno K, Watanabe K, Baba Y, Oota H, Yoshida T, Kamimura T.
Gan To Kagaku Ryoho. 2004 Oct;31(10):1555-8. Saiseikai Niigata Second Hospital, Japan.
[Link to Abstract]
Phase I-II Trial of Twice-Weekly Gemcitabine and Concomitant Irradiation in Patients Undergoing Pancreaticoduodenectomy with Extended Lymphadenectomy for Locally Advanced Pancreatic Cancer.
Joensuu TK, Kiviluoto T, Karkkainen P, Vento P, Kivisaari L, Tenhunen M, Westberg R, Elomaa I.
Int J Radiat Oncol Biol Phys. 2004 Oct 1;60(2):444-52. Helsinki University Central Hospital, Finland.
[Link to Abstract]
A Phase II Trial of FUdR in Patients with Advanced Pancreatic Cancer.
Ardalan B, Lima M.
J Cancer Res Clin Oncol. 2004 Oct;130(10):561-6. University of Miami/Sylvester Comprehensive Cancer Center, Florida.
[Link to Abstract]
SEPTEMBER
Adjuvant Chemotherapy for Unresectable Locally Advanced Pancreatic Cancer in Light of Its Characteristics.
Taoka H, Hirano H, Mitsui Y, Umino W, Nobuoka Y, Yamashita M, Tanigawa K, Yoshimine S, Imai T, Kadowaki S, Miyashita K, Ikuma H, Nakamura T, Murata T.
Gan To Kagaku Ryoho. 2004 Sep;31(9):1365-70. HPB Interesting Group, Suzuka General Hospital, Japan.
[Link to Abstract]
Antiangiogenic Versus Cytotoxic Therapeutic Approaches to Human Pancreas Cancer: An Experimental Study with a Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor and Gemcitabine.
Bocci G, Danesi R, Marangoni G, Fioravanti A, Boggi U, Esposito I, Fasciani A, Boschi E, Campani D, Bevilacqua G, Mosca F, Del Tacca M.
Eur J Pharmacol. 2004 Sep 13;498(1-3):9-18. University of Pisa, Pisa, Italy.
[Link to Abstract]
Isolated Roux-Loop Pancreaticojejunostomy: A Series of 61 Patients with Zero Postoperative Pancreaticoenteric Leaks.
Sutton CD, Garcea G, White SA, O’Leary E, Marshall LJ, Berry DP, Dennison AR.
J Gastrointest Surg. 2004 Sep-Oct;8(6):701-5. Leicester General Hospital, Leicester, England.
[Link to Abstract]
Phase I Study of a MUC1 Vaccine Composed of Different Doses of MUC1 Peptide with SB-AS2 Adjuvant in Resected and Locally Advanced Pancreatic Cancer.
Ramanathan RK, Lee KM, McKolanis J, Hitbold E, Schraut W, Moser AJ, Warnick E, Whiteside T, Osborne J, Kim H, Day R, Troetschel M, Finn OJ.
Cancer Immunol Immunother. 2004 Sep 14. University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania.
[Link to Abstract]
AUGUST
5-Fluorouracil-Based Chemoradiation in Unresectable Pancreatic Carcinoma: Phase I-II Dose-Escalation Study.
Morganti AG, Valentini V, Macchia G, Mattiucci GC, Costamagna G, Deodato F, Smaniotto D, Luzi S, Balducci M, Barbi S, Perri V, Trodella L, Cellini N.
Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1454-60. Universita Cattolica del S. Cuore, Campobasso, Italy.
[Link to Abstract]
Adjuvant Therapy in Pancreatic Cancer: Phase I Trial of Radiation Dose Escalation with Concurrent Full-Dose Gemcitabine.
Allen AM, Zalupski MM, Robertson JM, Eckhauser FE, Simone D, Brown D, Hejna G, Normolle D, Lawrence TS, McGinn CJ.
Int J Radiat Oncol Biol Phys. 2004 Aug 1;59(5):1461-7. University of Michigan School of Medicine, Ann Arbor, Michigan.
[Link to Abstract]
Neoadjuvant Chemoradiation with Tegafur in Cancer of The Pancreas: Initial Analysis of Clinical Tolerance and Outcome.
Calvo FA, Matute R, Garcia-Sabrido JL, Gomez-Espi M, Martinez NE, Lozano MA, Herranz R.
Am J Clin Oncol. 2004 Aug;27(4):343-9. Hospital General Universitario Gregorio Maranon, Madrid, Spain.
[Link to Abstract]
A Phase I Trial of The Dual Farnesyltransferase and Geranylgeranyltransferase Inhibitor L-778,123 and Radiotherapy for Locally Advanced Pancreatic Cancer.
Martin NE, Brunner TB, Kiel KD, DeLaney TF, Regine WF, Mohiuddin M, Rosato EF, Haller DG, Stevenson JP, Smith D, Pramanik B, Tepper J, Tanaka WK, Morrison B, Deutsch P, Gupta AK, Muschel RJ, McKenna WG, Bernhard EJ, Hahn SM.
Clin Cancer Res. 2004 Aug 15;10(16):5447-54. University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania.
[Link to Abstract]
JULY
Cetuximab, a Monoclonal Antibody Targeting the Epidermal Growth Factor Receptor, in Combination with Gemcitabine for Advanced Pancreatic Cancer: A Multicenter Phase II Trial.
Xiong HQ, Rosenberg A, LoBuglio A, Schmidt W, Wolff RA, Deutsch J, Needle M, Abbruzzese JL.
J Clin Oncol. 2004 Jul 1;22(13):2610-6. University of Texas / M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Gefitinib (‘Iressa’, ZD1839), A Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, Inhibits Pancreatic Cancer Cell Growth, Invasion, and Colony Formation.
Li J, Kleeff J, Giese N, Buchler MW, Korc M, Friess H.
Int J Oncol. 2004 Jul;25(1):203-10. University of Heidelberg, Heidelberg, Germany.
[Link to Abstract]
A Phase II Trial of FudR in Patients with Advanced Pancreatic Cancer.
Ardalan B, Lima M.
J Cancer Res Clin Oncol. 2004 Jul 29. University of Miami / Sylvester Comprehensive Cancer Center, Miami, Florida.
[Link to Abstract]
Pilot Study of Celecoxib and Infusional 5-Fluorouracil as Second-Line Treatment for Advanced Pancreatic Carcinoma.
Milella M, Gelibter A, Di Cosimo S, Bria E, Ruggeri EM, Carlini P, Malaguti P, Pellicciotta M, Terzoli E, Cognetti F.
Cancer. 2004 Jul 1;101(1):133-8. Regina Elena National Cancer Institute, Rome, Italy.
[Link to Abstract]
JUNE
A Case of Advanced Pancreatic Cancer with Remarkable Response to Thalidomide, Celecoxib and Gemcitabine.
Hada M, Mizutari K.
Gan To Kagaku Ryoho. 2004 Jun;31(6):959-61. Ashitaka Hospital, Japan.
[Link to Abstract]
Gemcitabine Combined with Infusional 5-Fluorouracil and High-Dose Leucovorin for The Treatment of Advanced Carcinoma of The Pancreas.
Oztop I, Yilmaz U, Yavuzsen T, Yaren A, Tarhan O, Sagol O, Coker A, Alakavuklar M.
Chemotherapy. 2004 Jun;50(3):127-32. University of Dokuz Eylul, Izmir, Turkey.
[Link to Abstract]
Intensity-Modulated Radiotherapy (IMRT) and Concurrent Capecitabine for Pancreatic Cancer.
Ben-Josef E, Shields AF, Vaishampayan U, Vaitkevicius V, El-Rayes BF, McDermott P, Burmeister J, Bossenberger T, Philip PA.
Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):454-9. Wayne State University and the Karmanos Cancer Institute, Detroit, Michigan.
[Link to Abstract]
Intraductal Papillary Mucinous Neoplasms of the Pancreas: An Updated Experience.
Sohn TA, Yeo CJ, Cameron JL, Hruban RH, Fukushima N, Campbell KA, Lillemoe KD.
Ann Surg. 2004 Jun;239(6):788-97; discussion 797-9. Johns Hopkins Medical Institutions, Baltimore, Maryland.
[Link to Abstract]
MAY
5-Fluorouracil or Gemcitabine Combined with Adenoviral-Mediated Reintroduction of P16ink4a Greatly Enhanced Cytotoxicity in Panc-1 Pancreatic Adenocarcinoma Cells.
Halloran CM, Ghaneh P, Shore S, Greenhalf W, Zumstein L, Wilson D, Neoptolemos JP, Costello E.
J Gene Med. 2004 May;6(5):514-25. Royal Liverpool University Hospital, Liverpool, UK.
[Link to Abstract]
Fine Needle Aspiration Cytology of Endocrine Neoplasms of The Pancreas. Morphologic and Immunocytochemical Findings in 20 Cases.
Jimenez-Heffernan JA, Vicandi B, Lopez-Ferrer P, Gonzalez-Peramato P, Perez-Campos A, Viguer JM.
Acta Cytol. 2004 May-Jun;48(3):295-301. Department of Pathology, University Hospital, Guadalajara, Spain.
[Link to Abstract]
Islet Autotransplantation Combined with Pancreatectomy for Treatment of Pancreatic Adenocarcinoma: A Case Report.
Forster S, Liu X, Adam U, Schareck WD, Hopt UT.
Transplant Proc. 2004 May;36(4):1125-6. University of Rostock, Germany; University of Freiburg, Germany.
[Link to Abstract]
Pancreaticoduodenectomy with En Bloc Portal Vein Resection for Pancreatic Carcinoma with Suspected Portal Vein Involvement.
Poon RT, Fan ST, Lo CM, Liu CL, Lam CM, Yuen WK, Yeung C, Wong J.
World J Surg. 2004, May 6. Queen Mary Hospital, University of Hong Kong Medical Centre, China.
[Link to Abstract]
APRIL
Pancreatic Cancer Registry in Japan: 20 Years of Experience.
Matsuno S, Egawa S, Fukuyama S, Motoi F, Sunamura M, Isaji S, Imaizumi T, Okada S, Kato H, Suda K, Nakao A, Hiraoka T, Hosotani R, Takeda K.
Pancreas. 2004 Apr;28(3):219-30. Tohoku University Graduate School of Medicine, Sendai, Japan.
[Link to Abstract]
Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds.
Klein AP, Brune KA, Petersen GM, Goggins M, Tersmette AC, Offerhaus GJ, Griffin C, Cameron JL, Yeo CJ, Kern S, Hruban RH.
Cancer Res. 2004 Apr 1;64(7):2634-8. National Human Genome Research Institute, NIH, Baltimore, Maryland.
[Link to Abstract]
Time Interval Between Abnormalities Seen on CT and the Clinical Diagnosis of Pancreatic Cancer: Retrospective Review of CT Scans Obtained Before Diagnosis.
Gangi S, Fletcher JG, Nathan MA, Christensen JA, Harmsen WS, Crownhart BS, Chari ST.
AJR Am J Roentgenol. 2004 Apr;182(4):897-903. University of Medicine and Dentistry of New Jersey, Newark, New Jersey.
[Link to Abstract]
Weight Stabilisation is Associated with Improved Survival Duration and Quality Of Life in Unresectable Pancreatic Cancer.
Davidson W, Ash S, Capra S, Bauer J; Cancer Cachexia Study Group.
Clin Nutr. 2004 Apr;23(2):239-47. Princess Alexandra Hospital, Woolloongabba, Brisbane, Australia.
[Link to Abstract]
MARCH
Phase I Dose-Finding Study of Biweekly Irinotecan in Combination with Fixed Doses Of 5-Fluorouracil/Leucovorin, Gemcitabine and Cisplatin (G-FLIP) in Patients with Advanced Pancreatic Cancer or Other Solid Tumors.
Rachamalla R, Malamud S, Grossbard ML, Mathew S, Dietrich M, Kozuch P.
Anticancer Drugs. 2004 Mar;15(3):211-7. St Luke’s-Roosevelt Hospital Center, New York City.
[Link to Abstract]
Phase II Study of Cisplatin, Gemcitabine and 5-Fluorouracil in Advanced Pancreatic Cancer.
Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouche O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P.
Ann Oncol. 2004 Mar;15(3):467-73. Institut Gustave Roussy, Villejuif, France.
[Link to Abstract]
Randomized Phase II Study Evaluating Oxaliplatin Alone, Oxaliplatin Combined with Infusional 5-FU, and Infusional 5-FU Alone in Advanced Pancreatic Carcinoma Patients.
Ducreux M, Mitry E, Ould-Kaci M, Boige V, Seitz JF, Bugat R, Breau JL, Bouche O, Etienne PL, Tigaud JM, Morvan F, Cvitkovic E, Rougier P.
Ann Oncol. 2004 Mar;15(3):467-73. Institut Gustave Roussy, Villejuif, France.
[Link to Abstract]
A Randomized Trial of Chemoradiotherapy and Chemotherapy after Resection of Pancreatic Cancer.
Neoptolemos JP, Stocken DD, Friess H, Bassi C, Dunn JA, Hickey H, Beger H, Fernandez-Cruz L, Dervenis C, Lacaine F, Falconi M, Pederzoli P, Pap A, Spooner D, Kerr DJ, Buchler MW; European Study Group for Pancreatic Cancer.
N Engl J Med. 2004 Mar 18;350(12):1200-10. Liverpool University, Liverpool, United Kingdom.
[Link to Abstract]
FEBRUARY
Extracorporeal Focused Ultrasound Surgery For Treatment of Human Solid Carcinomas: Early Chinese Clinical Experience.
Wu F, Wang ZB, Chen WZ, Zou JZ, Bai J, Zhu H, Li KQ, Xie FL, Jin CB, Su HB, Gao GW.
Ultrasound Med Biol. 2004 Feb;30(2):245-60. Chongqing University of Medical Sciences, Chongqing, China.
[Link to Abstract]
Phase II Study of External Irradiation and Weekly Paclitaxel For Nonmetastatic, Unresectable Pancreatic Cancer: RTOG-98-12.
Rich T, Harris J, Abrams R, Erickson B, Doherty M, Paradelo J, Small W Jr, Safran H, Wanebo HJ.
Am J Clin Oncol. 2004 Feb;27(1):51-6. University of Virginia Health Science Center, Charlottesville, Virginia.
[Link to Abstract]
Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry.
Koopmann J, Zhang Z, White N, Rosenzweig J, Fedarko N, Jagannath S, Canto MI, Yeo CJ, Chan DW, Goggins M.
Clin Cancer Res. 2004 Feb 1;10(3):860-8. Johns Hopkins Medical Institutions, Baltimore, Maryland.
[Link to Abstract]
Therapeutic Effect of Three-Dimensional Conformal Radiotherapy on Locally Advanced Pancreatic Carcinoma.
Shi YS, Xu SJ, Zheng XK, Yan WP, Chen LH.
Di Yi Jun Yi Da Xue Xue Bao. 2004 Feb;24(2):213-5, 219. Nanfang Hospital, First Military Medical University, Guangzhou, China.
[Link to Abstract]
JANUARY
Antiangiogenic Activity of Genistein in Pancreatic Carcinoma Cells is Mediated by the Inhibition of Hypoxia-Inducible Factor-1 and the Down-Regulation of VEGF Gene Expression.
Buchler P, Reber HA, Buchler MW, Friess H, Lavey RS, Hines OJ.
Cancer. 2004 Jan 1;100(1):201-10. University of California at Los Angeles, School of Medicine, Los Angeles, California.
[Link to Abstract]
First Clinical Experience Using a ‘Pathotropic’ Injectable Retroviral Vector (Rexin-G) as Intervention for Stage IV Pancreatic Cancer.
Gordon EM, Cornelio GH, Lorenzo CC 3rd, Levy JP, Reed RA, Liu L, Hall FL.
Int J Oncol. 2004 Jan;24(1):177-85. Epeius Biotechnologies Corporation, Glendale, California.
[Link to Abstract]
The Proteasome Inhibitor Bortezomib Enhances the Activity of Docetaxel in Orthotopic Human Pancreatic Tumor Xenografts.
Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ.
Mol Cancer Ther. 2004 Jan;3(1):59-70. University of Texas / MD Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Red Oil A5 Inhibits Proliferation and Induces Apoptosis in Pancreatic Cancer Cells.
Dong ML, Ding XZ, Adrian TE.
World J Gastroenterol. 2004 Jan; 10(1): 105-11. Taizhou Hospital, Wenzhou Medical College, Zhejiang Province, China.
[Link to Abstract]
2003
DECEMBER
The Efficacy of Tyrosine Kinase Inhibitors on Human Pancreatic Cancer Cell Lines.
Farivar RS, Gardner-Thorpe J, Ito H, Arshad H, Zinner MJ, Ashley SW, Whang EE.
J Surg Res. 2003 Dec; 115(2): 219-25. Brigham and Women’s Hospital, Boston, Massachusetts.
[Link to Abstract]
Extended Lymphadenectomy and Vein Resection for Pancreatic
Head Cancer: Outcomes and Implications for Therapy.
Capussotti L, Massucco P, Ribero D, Vigano L, Muratore A, Calgaro M.
Arch Surg. 2003 Dec;138(12):1316-22. Institute for Research and Cure of Cancer, Candiolo, Italy.
[Link to Abstract]
Inhibition of Platelet-Derived Growth Factor Receptor Phosphorylation by STI571 (Gleevec) Reduces Growth and Metastasis of Human Pancreatic Carcinoma in an Orthotopic Nude Mouse Model
Hwang RF, Yokoi K, Bucana CD, Tsan R, Killion JJ, Evans DB, Fidler IJ.
Clin Cancer Res. 2003 Dec 15;9(17):6534-6544. University of Texas / M. D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Is Extended Resection for Adenocarcinoma of the Body or Tail of the Pancreas Justified?
Duffy JP, Hines OJ, Shinchi H, Isacoff WH, Reber HA.
J Gastrointest Surg. 2003 Dec;7(8):946-52. Memorial Sloan-Kettering Cancer Center, New York City.
[Link to Abstract]
NOVEMBER
Cystic Pancreatic Neoplasms: Enucleate or Resect?
Kiely JM, Nakeeb A, Komorowski RA, Wilson SD, Pitt HA.
J Gastrointest Surg. 2003 Nov;7(7):890-7. Medical College of Wisconsin, Milwaukee, Wisconsin.
[Link to Abstract]
Defining the Role of the Epidermal Growth Factor Receptor in Pancreatic Cancer Grown In Vitro.
Durkin AJ, Bloomston PM, Rosemurgy AS, Giarelli N, Cojita D, Yeatman TJ, Zervos EE.
Am J Surg. 2003 Nov;186(5):431-6. H. Lee Moffitt Cancer Center and Research Institute, University of South Florida College of Medicine, Tampa, Florida.
[Link to Abstract]
Intensity Modulated Radiation Therapy and Chemotherapy for Locally Advanced Pancreatic Cancer: Results of Feasibility Study.
Bai YR, Wu GH, Guo WJ, Wu XD, Yao Y, Chen Y, Zhou RH, Lu DQ.
World J Gastroenterol. 2003 Nov;9(11):2561-4. Xinhua Hospital of Shanghai Second Medical University, China.
[Link to Abstract]
A Novel Approach in the Treatment of Neuroendocrine Gastrointestinal Tumours. Targeting the Epidermal Growth Factor Receptor by Gefitinib (ZD1839).
Duffy JP, Hines OJ, Shinchi H, Isacoff WH, Reber HA.
Presentation, Clinical Congress, American College of Surgeons, 89th Annual Meeting, October 21, 2003, Chicago, Illinois. David Geffen School of Medicine, University of California, Los Angeles, California.
[Link to Abstract]
OCTOBER
Chemoradiation Therapy for Stage IV Pancreatic Cancer.
Hopfner M, Sutter AP, Gerst B, Zeitz M, Scherubl H.
Br J Cancer. 2003 Nov 3;89(9):1766-75. University Hospital Benjamin Franklin, Free University of Berlin, Germany.
[Link to Abstract]
Combination Chemotherapy and Surgery Improve Survival of Patients with Unresectable Pancreatic Cancer.
Duffy JP, Hines OJ, Shinchi H, Isacoff WH, Reber HA.
Presentation, Clinical Congress, American College of Surgeons, 89th Annual Meeting, October 21, 2003, Chicago, Illinois. David Geffen School of Medicine, University of California, Los Angeles, California.
[Link to Press Report]
Gemcitabine Infusion Via Splenic Artery for Advanced Pancreatic Cancer.
Baba H, Endo M, Arii S.
Gan To Kagaku Ryoho. 2003 Oct;30(11):1689-92. Tokyo Medical and Dental University, School of Medicine, Japan.
[Link to Abstract]
Intra-Arterial Infusion Chemotherapy with Angiotensin-II for Locally Advanced and Nonresectable Pancreatic Adenocarcinoma: Further Evaluation and Prognostic Implications.
Ohigashi H, Ishikawa O, Yokayama S, Sasaki Y, Yamada T, Imaoka S, Nakaizumi A, Uehara H.
Ann Surg Oncol. 2003 Oct-Nov;10(8):927-34. Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan.
[Link to Abstract]
SEPTEMBER
Mangan-Enhanced MR Imaging for the Detection and Localisation of Small Pancreatic Insulinoma.
Hamoud AK, Khan MF, Aboalmaali N, Usadel KH, Wullstein C, Vogl TJ. Eur Radiol. 2003 Sep 3. University of Frankfurt/Main, Frankfurt/Main, Germany.
[Link to Abstract]
Novel Markers of Pancreatic Adenocarcinoma in Fine-Needle Aspiration: Mesothelin and Prostate Stem Cell Antigen Labeling Increases Accuracy in Cytologically Borderline Cases.
McCarthy DM, Maitra A, Argani P, Rader AE, Faigel DO, Van Heek NT, Hruban RH, Wilentz RE.
Appl Immunohistochem Mol Morphol. 2003 Sep;11(3):238-43. Johns Hopkins Hospital, Baltimore, Maryland.
[Link to Abstract]
Surgical Resection Following Radiation Therapy with Concurrent Gemcitabine in Patients with Previously Unresectable Adenocarcinoma of the Pancreas.
Ammori JB, Colletti LM, Zalupski MM, Eckhauser FE, Greenson JK, Dimick J, Lawrence TS, McGinn CJ.
J Gastrointest Surg. 2003 Sep-Oct;7(6):766-72. University of Michigan Medical School, Ann Arbor, Michigan.
[Link to Abstract]
Thymidylate Synthase Expression Predicts the Response to 5-Fluorouracil-based Adjuvant Therapy in Pancreatic Cancer.
Hu YC, Komorowski RA, Graewin S, Hostetter G, Kallioniemi OP, Pitt HA, Ahrendt SA.
Clin Cancer Res. 2003 Sep 15;9(11):4165-71. University of Rochester, Rochester, New York.
[Link to Abstract]
Utility of Tumor Markers in Determining Resectability of Pancreatic Cancer.
Schlieman MG, Ho HS, Bold RJ.
Arch Surg. 2003 Sep;138(9):951-5; discussion 955-6. University of California at Davis, Sacramento, California.
[Link to Abstract]
AUGUST
Initial Experience Combining Cyclooxygenase-2 Inhibition with Chemoradiation for Locally Advanced Pancreatic Cancer.
Crane CH, Mason K, Janjan NA, Milas L.
IAm J Clin Oncol. 2003 Aug;26(4):S81-4. University of Texas M.D. Anderson Cancer Center, Houston, Texas.
[Link to Abstract]
Morbidity and Mortality of Aggressive Resection in Patients with Advanced Neuroendocrine Tumors.
Norton JA, Kivlen M, Li M, Schneider D, Chuter T, Jensen RT.
Arch Surg. 2003 Aug;138(8):859-66. University of California, San Francisco, California.
[Link to Abstract]
Phase II Study of Gemcitabine, Cisplatin, and Infusional Fluorouracil in Advanced Pancreatic Cancer.
El-Rayes BF, Zalupski MM, Shields AF, Vaishampayan U, Heilbrun LK, Jain V, Adsay V, Day J, Philip PA.
J Clin Oncol. 2003 Aug 1;21(15):2920-5. Karmanos Cancer Institute, Wayne State University, Detroit, Michigan.
[Link to Abstract]
Survival Benefits of Portal Vein Resection for Pancreatic Cancer.
Nakagohri T, Kinoshita T, Konishi M, Inoue K, Takahashi S.
Am J Surg. 2003 Aug;186(2):149-53. National Cancer Center Hospital East, Kashiwanoha, Kashiwa, Japan.
[Link to Abstract]
JULY
Adjuvant Therapy For Pancreatic Adenocarcinoma: What Have We Learned Since 1985?
Abrams RA
Int J Radiat Oncol Biol Phys. 2003;56(4 Suppl):3-9. The Johns Hopkins Medical Institutions, Baltimore, Maryland.
[Link to Abstract]
Gemcitabine Increases Systemic 5-Fluorouracil Exposure in Advanced Cancer Patients.
Correale P, Cerretani D, Marsili S, Pozzessere D, Petrioli R, Messinese S, Sabatino M, Roviello F, Pinto E, Francini G, Giorgi G.
Eur J Cancer. 2003 Jul;39(11):1547-51. Siena University School of Medicine, Siena, Italy.
[Link to Abstract]
Newer Approaches To Gemcitabine-Based Therapy of Pancreatic Cancer: Fixed-Dose-Rate Infusion and Novel Agents.
Hochster HS.
Int J Radiat Oncol Biol Phys. 2003;56(4 Suppl):24-30. New York University School of Medicine, New York City.
[Link to Abstract]
Randomized Phase II Comparison of Dose-Intense Gemcitabine: Thirty-Minute Infusion and Fixed Dose Rate Infusion in Patients With Pancreatic Adenocarcinoma.
Tempero M, Plunkett W, Van Haperen VR, Hainsworth J, Hochster H, Lenzi R, Abbruzzese J.
J Clin Oncol. 2003 Jul 28 (early release published online ahead of print). University of California San Francisco; University of Texas M.D. Anderson Cancer Center; Sarah Cannon Cancer Center, Nashville, Tennessee; New York University Medical Center, New York City; The Hague, Netherlands.
[Link to Abstract]
JUNE
An Experimental Study on the Pharmacokinetics of 5-Fluorouracil Regional Chemotherapy for Pancreatic Cancer.
Mitsutsuji M, Suzuki Y, Iwanaga Y, Fujino Y, Tanioka Y, Kamigaki T, Ku Y, Kuroda Y.
Ann Surg Oncol. 2003 Jun-Jul;10(5):546-50. Kobe University, Kobe, Japan.
[Link to Abstract]
Dietary Meat, Dairy Products, Fat, and Cholesterol and Pancreatic Cancer Risk in a Prospective Study.
Michaud DS, Giovannucci E, Willett WC, Colditz GA, Fuchs CS.
Am J Epidemiol. 2003 Jun 15;157(12):1115-25. National Cancer Institute, Rockville, Maryland.
[Link to Abstract]
Laparoscopic Treatment of Pancreatic Insulinoma.
Goletti O, Celona G, Monzani F, Caraccio N, Zocco G, Lippolis PV, Battini A, Seccia M, Cavina E.
Surg Endosc. 2003 June. University of Pisa, Pisa, Italy.
[Link to Abstract]
MAY
Interferon-Based Adjuvant Chemoradiation Therapy after Pancreaticoduodenectomy for Pancreatic Adenocarcinoma.
Picozzi VJ, Kozarek RA, Traverso LW.
Am J Surg. 2003 May;185(5):476-80. Virginia Mason Medical Center, Seattle, Washington.
[Link to Abstract]
Regression of an Unresectable Pancreatic Tumor Following Nonmyeloablative Allogeneic Peripheral-Blood Stem-Cell Transplantation.
Omuro Y, Matsumoto G, Sasaki T, Tanaka Y, Maeda Y, Sakamaki H, Hiruma K, Tsuruta K, Takahashi T.
Bone Marrow Transplant. 2003 May;31(10):943-5. Tokyo Metropolitan Komagome Hospital, Japan.
[Link to Abstract]
Risk Factors for the Development of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds.
Rulyak SJ, Lowenfels AB, Maisonneuve P, Brentnall TA.
Gastroenterology. 2003 May;124(5):1292-9. University of Washington, Seattle, Washington.
[Link to Abstract]
Transarterial Chemoperfusion of Inoperable Pancreas Carcinoma and Local Recurrence.
Vogl TJ, Heller M, Zangos S, Schwarz W, Eichler K, Mack MG, Berger D, Balzer JO.
Rofo Fortschr Geb Rontgenstr Neuen Bildgeb Verfahr. 2003 May;175(5):695-704. Institut fur Diagnostische und Interventionelle Radiologie, J.W. Goethe-Universitat, Frankfurt, Germany.
[Link to Abstract]
APRIL
Exploration of Global Gene Expression Patterns in Pancreatic Adenocarcinoma Using cDNA Microarrays.
Iacobuzio-Donahue CA, Maitra A, Olsen M, Lowe AW, Van Heek NT, Rosty C, Walter K, Sato N, Parker A, Ashfaq R, Jaffee E, Ryu B, Jones J, Eshleman
JR, Yeo CJ, Cameron JL, Kern SE, Hruban RH, Brown PO, Goggins M.
Am J Pathol 2003 Apr;162(4):1151-62. The Johns Hopkins Medical Institutions, Baltimore, Maryland.
[Link to Abstract]
Gemcitabine and Oxaliplatin for Metastatic Pancreatic Adenocarcinoma: A North Central Cancer Treatment Group Phase II Study.
Alberts SR, Townley PM, Goldberg RM, Cha SS, Sargent DJ, Moore DF, Krook JE, Pitot HC, Fitch TR, Wiesenfeld M, Mailliard JA.
Ann Oncol 2003 Apr;14(4):580-5. Mayo Clinic and Mayo Foundation, Rochester, Minnesota.
[Link to Abstract]
Phase II Trial of the Use of Gemcitabine and 5-Fluorouracil in the Treatment of Advanced Pancreatic and Biliary Tract Cancer.
Murad AM, Guimaraes RC, Aragao BC, Rodrigues VH, Scalabrini-Neto AO, Padua CA, Moore FC.
Am J Clin Oncol 2003 Apr;26(2):151-4. Hospital das Clinicas da Universidade Federal de Minas Gerais, Belo Horizonte, MG, Brazil.
[Link to Abstract]
Prevention of Metastatic Pancreatic Cancer Growth in vivo by Induction of Apoptosis with Genistein, a Naturally Occurring Isoflavonoid.
Buchler P, Gukovskaya AS, Mouria M, Buchler MC, Buchler MW, Friess H, Pandol SJ, Reber HA, Hines OJ.
Pancreas 2003 Apr;26(3):264-273. UCLA School of Medicine and Veterans Affairs Greater Los Angeles Health Care System, Los Angeles, California;
and University of Bern and Insel Hospital, Bern, Switzerland.
[Link to Abstract]
MARCH
In Vivo Induction of Dendritic Cell-Mediated Cytotoxicity Against Allogeneic Pancreatic Carcinoma Cells.
Stift A, Friedl J, Dubsky P, Bachleitner-Hofmann T, Benkoe T, Brostjan C, Jakesz R, Gnant M.
Int J Oncol 2003 Mar;22(3):651-6. Department of Surgery, University of Vienna Medical School, Austria.
[Link to Abstract]
Hyperfractionated Radiotherapy and Paclitaxel for Locally Advanced / Unresectable Pancreatic Cancer.
Ashamalla H, Zaki B, Mokhtar B, Colella F, Selim H, Krishnamurthy M, Ross P.
Int J Radiat Oncol Biol Phys. 2003 Mar 1;55(3):679-87. New York Methodist Hospital, Weill Medical College, Brooklyn, New York.
[Link to Abstract]
Sentinel Lymph Node Navigation Surgery for Pancreatic Head Cancers.
Ohta T, Kitagawa H, Kayahara M, Kinami S, Ninomiya I, Fushida S, Fujimura T, Nishimura G, Shimizu K, Yi S, Miwa K.
Oncol Rep. 2003 Mar-Apr;10(2):315-9. Kanazawa University Hospital, Japan.
[Link to Abstract]
Treatment of Inoperable Pancreatic Carcinoma Using a Cell-Based Local Chemotherapy: Results of a Phase I / II Clinical Trial.
Salmons B, Lohr M, Gunzburg WH.
J Gastroenterol 2003 Mar;38 Suppl 15:78-84. Austrianova GmbH, Vienna, Austria.
[Link to Abstract]
FEBRUARY
BRCA2 Germline Mutations in Familial Pancreatic Carcinoma.
Hahn SA, Greenhalf B, Ellis I, Sina-Frey M, Rieder H, Korte B, Gerdes B, Kress R, Ziegler A, Raeburn JA, Campra D, Grutzmann R, Rehder H, Rothmund M, Schmiegel W, Neoptolemos JP, Bartsch DK.
J Natl Cancer Inst. 2003 Feb 5;95(3):214-21. Knappschaftskrankenhaus University of Bochum, Germany.
[Link to Abstract]
A Case of Advanced Pancreatic Cancer With Multiple Liver Metastasis That Improved Remarkably With Use of Low-Dose Cisplatin And TS-1.
Fujito T, Goda F, Matsuyama J, Hojo S, Yano Y, Endo W, Yamazaki K, Maeura Y.
Gan To Kagaku Ryoho 2003 Feb;30(2):293-6. Shinsenri Hospital, Osaka Health and Medical Foundation, Japan.
[Link to Abstract]
Chemoradiation of Unresectable Pancreatic Carcinoma: Impact of Pretreatment Hemoglobin Level on Patterns of Failure.
Morganti AG, Forni F, Macchia G, Valentini V, Smaniotto D, Trodella L, Balducci M, Cellini N.
Strahlenther Onkol 2003 Feb;179(2):87-92. Universita Cattolica del S. Cuore, Campobasso, Italy.
[Link to Abstract]
Intra-Arterial Chemotherapy Improves Survival in Patients With Pancreatic Cancer.
Pagani M, et al.
14th International Congress on Anti-Cancer Treatment: Meeting Presentation; Paris, France; February 1, 2003. Asola Hospital, Verona, Italy.
[Link to Article]
A Phase I / II Trial of Intratumoral Endoscopic Ultrasound Injection of ONYX-015 With Intravenous Gemcitabine in Unresectable Pancreatic Carcinoma.
Hecht JR, Bedford R, Abbruzzese JL, Lahoti S, Reid TR, Soetikno RM, Kirn DH, Freeman SM.
Clin Cancer Res 2003 Feb;9(2):555-61. Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California.
[Link to Abstract]
JANUARY
Combining Capecitabine and Gemcitabine in Patients With Advanced Pancreatic Carcinoma: A Phase I / II Trial.
Hess V, Salzberg M, Borner M, Morant R, Roth AD, Ludwig C, Herrmann R.
J Clin Oncol. 2003 Jan 1;21(1):66-8. University Hospitals of Basel, Switzerland.
Link to Abstract
Diagnostic Accuracy of Endoscopic Ultrasound-Guided Fine-Needle Aspiration in Patients with Presumed Pancreatic Cancer.
Raut CP, Grau AM, Staerkel GA, Kaw M, Tamm EP, Wolff RA, Vauthey JN, Lee JE, Pisters PW, Evans DB.
J Gastrointest Surg. 2003 Jan;7(1):118-28. Department of Surgical Oncology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas.
Link to Abstract
Pancreatic Cancer in vitro Toxicity Mediated by Chinese Herbs SPES and PC-SPES: Implications for Monotherapy and Combination Treatment.
Schwarz RE, Donohue CA, Sadava D, Kane SE.
Cancer Lett. 2003 Jan 10;189(1):59-68. Department of General Oncologic Surgery, City of Hope National Medical Center, Duarte, California.
Link to Abstract